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SUMMARY 
 
Melanoma arises from the malignant transformation of melanocytes and is one of the most 
aggressive forms of human cancer. In fish of the genus Xiphophorus, melanoma development, 
although very rarely, happens spontaneously in nature and can be induced by interspecific 
crossing. The oncogenic receptor tyrosine kinase, Xmrk, is responsible for melanoma formation 
in these fishes. Since Xiphophorus are live-bearing fishes and therefore not compatible with 
embryonic manipulation and transgenesis, the Xmrk melanoma model was brought to the medaka 
(Oryzias latipes) system. Xmrk expression under the control of the pigment cell specific mitf 
promoter leads to melanoma formation with 100% penetrance in medaka. Xmrk is an orthologue 
of the human epidermal growth factor receptor (EGFR) and activates several downstream 
signaling pathways. Examples of these pathways are the direct phosphorylation of BRAF and 
Stat5, as well as the enhanced transcription of C-myc. BRAF is a serine-threonine kinase which is 
found mutated at high frequencies in malignant melanomas. Stat5 is a transcription factor known 
to be constitutively activated in fish melanoma. C-myc is a transcription factor that is thought to 
regulate the expression of approximately 15% of all human genes and is involved in cancer 
progression of a large number of different tumors.  
 
To gain new in vivo information on candidate factors known to be involved in melanoma 
progression, I identified and analysed BRAF, Stat5 and C-myc in the laboratory fish model 
system medaka. BRAF protein motifs are highly conserved among vertebrates and the results of 
this work indicate that its function in the MAPK signaling is maintained in medaka. Transgenic 
medaka lines carrying a constitutive active version of BRAF (V614E) showed more pigmented 
skin when compared to wild type. Also, some transiently expressing BRAF V614E fishes showed 
a disrupted eye phenotype. In addition, I was able to identify two Stat5 copies in medaka, named 
Stat5ab/a and Stat5ab/b. Sequence analysis revealed a higher similarity between both Stat5 
sequences when compared to either human Stat5a or Stat5b. This suggests that the two Stat5 
copies in medaka arose by an independent duplication processes. I cloned these two Stat5 present 
in medaka, produced constitutive active and dominant negative gene versions and successfully 
established transgenic lines carrying each version under the control of the MITF promoter. These 
lines will help to elucidate questions that are still remaining in Stat5 biology and its function in 
melanoma progression, like the role of Stat5 phosphorylation on tumor invasiveness.  
 
In a third project during my PhD work, I analysed medaka C-myc function and indentified two 
copies of this gene in medaka, named c-myc17 and c-myc20, according to the chromosome where 
they are located. I produced conditional transgenic medaka lines carrying the c-myc17 gene 
coupled to the hormone binding domain of the estrogen receptor to enable specific transgene 
activation at a given time point. Comparable to human C-myc, medaka C-myc17 is able to induce 
proliferation and apoptosis in vivo after induction. Besides that, C-myc17 long-term activation led 
to liver hyperplasia.  
 
In summary, the medaka models generated in this work will be important to bring new in vivo 
information on genes involved in cancer development. Also, the generated transgenic lines can be 
easily crossed to the melanoma developing Xmrk medaka lines, thereby opening up the possibility 
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to investigate their function in melanoma progression. Besides that, the generated medaka fishes 
make it possible to follow the whole development of melanocytes, since the embryos are 
transparent and can be used for high throughput chemical screens. 
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ZUSAMMENFASSUNG 
 
Melanome entstehen durch die krankhafte Transformation von Melanozyten und sind eine der 
aggressivsten Krebsarten beim Menschen. In Fischen der Gattung Xiphophorus können, wenn 
auch sehr selten, spontan Melanome entstehen oder durch spezielle Artenkreuzungen induziert 
werden. Grundlage für das Entstehen der Melanome in diesen Fischen ist die 
Rezeptortyrosinkinase Xmrk. Da alle Xiphophorus-Arten lebendgebärend sind und keine 
Manipulationen an Embryonen vorgenommen werden können, wurde ein Xmrk Melanommodel 
für Medaka (Oryzias latipes) etabliert. Die Expression von Xmrk in Pigmentzellen dieser Fischart 
resultiert mit 100%iger Penetranz in Melanomen. Das Xmrk ist ein Ortholog des menschlichen 
„epidermal growth factor“ (EGFR) und aktiviert verschiedene nachgeschaltete Signalwege. 
Beispiele für diese Aktivierungen sind die Phosphorylierung von BRAF, Stat5 und die erhöhte 
Expression von c-myc. BRAF ist eine Serin-Threoninkinase, welche oft in malignen Melanomen 
mutiert ist. Stat5 ist ein Transkriptionsfaktor, welcher dauerhaft in Fischtumoren aktiviert ist. C-
myc ist ein Transkriptionsfaktor, welcher etwa 15% aller menschlichen Gene sowie die 
Entstehung vieler menschlicher Tumore reguliert.  
 
Um neue Einsichten in die Funktion der Kanidatengene im Prozess der Melanomentstehung in 
vivo zu erlangen, habe ich Orthologe von BRAF, Stat5 und C-myc bei Medaka identifiziert und 
analysiert. Die Domänen des BRAF Proteins sind hoch konserviert in allen Vertebraten. 
Weiterhin deuten die Ergebnisse meiner Arbeit auf eine Beibehaltung der Funktionen im MAPK 
Signalweg hin. Transgene Medakalinien, welche eine dauerhaft aktive Version des BRAF Gens 
(V614E) exprimieren, weisen einerseits eine stärkere Hautpigmentierung auf. Weiterhin treten in 
diesen Fischen Veränderungen der Augen auf. In einem weiteren Projekt meiner Arbeit gelang es 
mir, zwei Kopien des Stat5 Gens im Medaka zu identifizieren, Stat5ab/a und Stat5ab/b. 
Sequenzanalysen zeigten eine höhere Übereinstimmung zwischen den beiden Genkopien, als 
zwischen denen von Medaka und Menschen. Dieses Ergebnis deutet darauf hin, dass die beiden 
Medaka Gene durch eine unabhängige Duplikation entstanden. In meiner Arbeit habe ich beide 
Gene des Medakas kloniert und jeweils eine konstitutiv aktive und eine dominant negative 
Version der Gene hergestellt. Weiterhin konnte ich erfolgreich für jede Genversion eine transgene 
Medakalinie etablieren, welche die verschiedenen Genvarianten unter der Kontrolle des 
pigmentzellspezifischen Promoters des mitf Gens exprimieren. Diese Linien werden in Zukunft 
helfen, den Einfluss von Stat5 Signalen auf den Prozess der Melanomverbreitung und dessen 
Invasivität zu erklären. 
 
In einem dritten Projekt meiner Doktorarbeit untersuchte ich das Vorkommen und die Funktion 
der C-myc Gene des Medakas. Ich konnte zwei Genkopien identifizieren, c-myc17 und c-myc20, 
welche auf unterschiedlichen Chromosomen lokalisiert sind. Ich konnte induzierbare, stabil 
transgene Linien herstellen, welche ein Fusionsprotein aus C-myc17 und der 
Hormonbindungsdomäne des Östrogenrezeptors von Maus exprimiert. Diese Linie ermöglichte 
eine induzierbare Aktivität des Transgens. Vergleichbar zum menschlichen MYC ist C-myc17 
fähig, nach Aktivierung Proliferation und Apoptose in vivo auszulösen. Dauerhafte Aktivierung 
über einen längeren Zeitraum führt in diesen Linien zu Hyperplasie in Leber. 
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Die verschiedenen Fischmodelle, die während dieser Arbeit generiert wurden, werden essentiell 
sein, um neue Einsichten in die Rolle diese Faktoren während der Krebsentwicklung in vivo zu 
erlangen. Weiterhin ermöglichen diese transgenen Linien durch einfaches Auskreuzen auf Xmrk 
Linien, deren Einfluss auf die Verbreitung von Melanomen zu untersuchen. Letztendlich sind mit 
diesen Linien auch Untersuchungen der Entwicklung von Pigmentzellen über Zeit möglich, da die 
Embryonen transparent sind und sich für chemisches Hochdurchsatz-Screening eignen.   
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1. INTRODUCTION 
1.1 Melanoma 
Skin cancer is the third most common human cancer, and its global incidence is rising every year. 
There are an estimated 2-3 million cases of skin cancer in the world every year and although 
melanoma only accounts for 132,000 cases, it is responsible for most skin cancer deaths (World 
Health Organization). If melanoma is diagnosed early it can be cured by surgical procedures. 
However, metastatic malignant melanoma often does not respond to therapies and has a poor 
prognosis (Smalley, 2009).  
 
Melanoma arises from the malignant transformation of melanocytes, specialized pigment cells 
found predominantly in the skin and eyes (White and Zon, 2008). Both genetic and environmental 
factors are believed to contribute to melanoma genesis (Gray-schopfer et al, 2007). Accounting 
for environmental factors, ultraviolet (UV) light exposure has a causal role in melanoma initiation 
(Maddodi and Setaluri, 2008). In response to UV light-induced DNA damage in keratinocytes, 
melanocytes synthesize melanin, which is a protective pigment. Extreme UV exposure (sunburn) 
can lead to massive keratinocyte population death, but melanocytes survive due to their efficient 
DNA damage repair response and therefore have the chance to accumulate mutations (Gilchrest et 
al, 1999). However, the underlying mechanisms that cause a normal melanocyte to become a 
malignant melanoma are only partly understood.  
 
Several types of malignant melanoma can be determined. The most incident is the cutaneous 
melanoma which comprises about 91% of all melanomas (Netscher et al., 2011). Other melanoma 
types like uveal (ocular) and mucosal account for about 5% and 1,5% of the cases, respectively 
(Patrick et al, 2007; Triozzi et al, 2008).  
 
1.1.1 Melanocytes  
Melanocytes are pigment-synthesizing cells of the neural-crest lineage that provide skin tone, hair 
colour and protection from ultraviolet radiation (Thomas and Erickson, 2008). Melanin, the 
principal component of the melanocyte, helps to protect from high levels of reactive oxygen 
species and direct UV radiation that would otherwise damage DNA in skin cells (White and Zon, 
2008). Melanocytes in mammals and birds produce two chemically distinct types of melanin 
pigment: the brown/black eumelanin and the yellow/reddish pheomelanin (Meredith and Sarna, 
2006). Melanin pigments in fishes are essentially eumelanic (Ito and Wakamatsu, 2003). 
 
During normal development, a strict program of subsequent transcription factor activation results 
in normal differentiation of melanocytes from neural crest cells (for a complete description see 
Hirobi et al, 2011). Factors like the microphthalmia-associated transcription factor (Mitf), the 
paired domain and homeodomain containing transcription factor Pax3, and the Sry-related 
transcription factor Sox10 play key roles in the switch from neural crest to melanocyte genesis. 
Loss of any of the three results in failure of melanoblast development (Thomas and Erickson, 
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2008). Although Pax3 and Sox10 are necessary for melanoblast specification, it is Mitf that is 
referred as the master regulator of melanocyte development (Steingrímsson et al, 2004). Loss of 
Mitf function results in almost complete loss of melanocytes in mice and zebrafish (Lister et al, 
1999). Mitf regulates the melanocyte lineage by activating several pigment-producing genes, such 
as dct and tyrosinase (Yasumoto et al, 1994). 
 
1.1.2 The genetics of human melanoma 
Evidence for an increasing number of genetic factors contributing to melanoma genesis was found 
in different studies. Linkage-analysis studies of families with a high incidence of melanoma 
identified two susceptibility genes: CDKN2A and CDK4 (Nobori et al, 1994). Also, a 
pigmentation-associated predisposition to skin cancer has been indicated by the association of the 
melanocortin-1 receptor (MC1R) variation polymorphism leading to red hair, fair skin inability to 
tan and tendency to freckle with skin cancers (Palmer et al., 2000). The MC1R and its ligand, the 
-melanocyte-stimulating hormone (-MSH), comprise key determinants of the pigmentary 
process (Chin, 2003). The result of their signalling cascade activates the protein kinase A (PKA), 
which then translocates to the nucleus where it phosphorylates CREB, a family of transcription 
factors that induce the expression of genes containing CRE sequences in their promoters, like 
mitf. 
 
MITF is considered the master regulator of melanocyte lineage and therefore, not surprisingly, 
plays also a role in melanoma (Levy et al, 2006). Using primary melanoma tissue microarrays, 
MITF was found to be amplified in 10-20% of the cases, with a higher incidence in metastatic 
melanomas (Garraway et al., 2005). Due to its essential role in melanocyte biology, MITF protein 
levels must be under strict control. Gray-Schopfer et al (2007) propose that MITF regulates 
distinct functions in melanocytic cells at different levels of expression. High levels predispose 
cells to cell cycle arrest and differentiation, while low levels lead to cell cycle arrest and 
apoptosis; intermediate levels favour proliferation.  
 
The Ras/Raf/MEK/MAPK pathway, also known as MAPK (mitogen-activated protein kinase) 
pathway, has a key role in the proliferation of most solid tumours, including melanoma (Fecher et 
al, 2008). The most commonly mutated component of the MAPK pathway is BRAF, which is 
mutated in 50 to 70% of all human melanomas (Davies et al., 2002). Another important oncogene 
in melanoma, found mutated in 15% to 30% of melanomas, is NRAS (Gray-Schopfer et al, 2007). 
BRAF and NRAS mutations are mutually exclusive; they are not both found mutated in the same 
cancer (Chin et al, 2006). 
 
Another signalling pathway that is important for melanoma is the PTEN/PI3K/AKT pathway (Wu 
et al, 2003). Activation of the PI3K/AKT pathway in melanoma occurs through either growth 
factors or the loss of expression and/or mutation of negative pathway regulator (Smalley, 2009). 
PTEN encodes a negative regulator of the PI3K pathway, and allelic loss or mutation of PTEN 
has been described in 5-15% of melanoma specimens and metastasis (Guldberget al, 1997).  
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Besides these, several studies have implicated deregulated Notch signalling in patients with 
melanoma (Hoek et al., 2004; Liu et al., 2006; Qin et al., 2004). Mutation in Beta-catenin, the 
central activator of Wnt signalling, is very rare in melanoma (Pollock and Hayward, 2002). 
However, overexpression of Wnt5a, a member of the noncanonical Wnt pathway, might play an 
important role in melanoma invasion and metastasis (Bittner et al., 2000; Dissanayake et al., 
2008). In addition, autocrine activation of HGF/SF-MET signalling pathway has been shown in 
melanoma, stimulating proliferation and motility of human melanocytes in culture (Li et al., 
2001). 
 
In summary, recent investigations identified key signals in melanogenesis and melanoma 
progression, but the detailed interplay between the different pathways in vivo is still unknown.  
 
1.1.3 Melanoma models in mammals  
Exposure to ultraviolet radiation in opossums (Monodelphis domestica) induced melanomas, 
leading to a variety of hyperplastic and neoplastic skin lesions (Kusewitt et al, 1991). Also, 
melanomas have been reported in guinea pigs and hamsters after exposure to chemical 
carcinogens. These tumours metastasize and show similarities in histopathology with human 
melanoma (Bardeesy et al, 2000).  
In mice, several melanoma models have been generated (Becker et al 2010). SV40T antigen 
expressed under the control of the tyrosinase promoter, which targeted the transgene to 
melanocytes led to melanoma formation after UV light exposure, particularly ocular melanoma 
(Bradl et al, 1991). Initiation of melanoma using chemical carcinogens like 7,12-
dimethylbenz(a)anthracene (Berkelhammer et al, 1982) and dimethylbenzanthracene (Kligman 
and Elenitsas, 2001) or combination of chemical and UV radiation (Strickland et al, 2000) have 
also been successfully applied. 
 
In addition, several mouse (Mus musculus) models that spontaneously develop melanoma have 
been established. For example, mice with activated RAS and deletion of both INKA4a cooperate 
to accelerate melanoma development (Chin et al, 1997). Also, mice develop spontaneous 
melanoma after RAS activation in a p53 negative background (Bardeesy et al, 2001). Besides 
these, BRAF V600E cooperates with the loss of the tumour suppressor PTEN to induce metastatic 
melanoma Dankort et al, 2009).  Another model using BRAF to induce melanoma in mice was 
generated by Dhomen et al (2009). In this study the inducible expression of BRAF V600E in 
mouse melanocytes stimulates skin hyperpigmentation, the appearance of senescent nevi, and the 
development of melanoma.  
 
1.1.4 Melanoma models in fish 
As mentioned above with focus on melanoma, mammalian models are widely used in cancer 
research due to their evolutionary relatedness with humans, with comparable cell lineage and 
differentiation pathways (Cheon and Orsulic, 2011). However, fish models that mimic human 
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diseases and cancer are extensively used in the scientific field nowadays (Stoletov and Klemke, 
2008). Advantages of fish models, specially two teleost species – zebrafish (Danio rerio) and 
medaka (Oryzias latipes) - in research include: their high fecundity, their short breeding cycles to 
produce large numbers of progeny, their technically easy exposure to carcinogenesis, and the 
possibility to follow well-defined stages of the disease in vivo over time (Patton et al, 2010). 
Furthermore, in terms of genomic, these teleost dispose of a variety of genetic tools including 
detailed gene map and genome sequence (Flicek et al., 2011) and a large variety of mutants 
(Amsterdam and Hopkins, 2006; Patton and Zon, 2001), including pigmentation mutants (Lynn 
Lamoreux et al, 2005; Parichy, 2006). Also innovative experimental tools, such as morpholinos 
(Nasevicius and Ekker, 2000), efficient transgenic animal production (Kawakami, 2005; Thermes 
et al, 2002), high throughput screening of mutants (Amsterdam and Hopkins, 2006; Furutani-
Seiki et al., 2004; Patton and Zon, 2001), and screening of small molecules (Zon and Peterson, 
2005) are available. Therefore fishes are widely used as disease models or in cancer research 
(Mione and Trede, 2010).  
 
Today, a number of melanoma fish models are available showing similar histopathology with 
human melanoma (Patton et al, 2010). A constantly activated version of the human oncogene 
BRAF (BRAF V600E) driven by the mitfa promoter drives non tumorigenic ectopic melanocytic 
lesions in zebrafish (Patton et al, 2005). However, to develop malignant melanoma, these fishes 
need to carry an additional inactivating mutation in p53, demonstrating that at least one additional 
genetic mutation is required for melanoma formation by overexpression of BRAF V600E. The 
p53 gene is the most frequently mutated gene in human cancer and p53 from zebrafish shares 
strong sequence and functional homology with human (Berghmans et al., 2005). The melanoma 
in these fishes appeared by 16 weeks of age, was highly invasive and showed genomic instability. 
 
In addition, constitutive activation of NRAS under the mitfa promoter in a p53 negative 
background also leads to melanoma formation in zebrafish (Dovey et al, 2009). Melanomas in 
these fishes are variably pigmented and share features with human melanoma. Another melanoma 
model in zebrafish was driven by constitutive expression of HRAS oncogene without the need for 
a second inactivating mutation in tumour suppressors. Fishes carrying human HRASV12 
expressed under the mitfa promoter (Michailidou et al., 2009) develop melanoma after 16 weeks. 
By contrast, expression of HRAS-V12 under the control of another pigment cell specific 
promoter, kita, leads to early onset and highly penetrant melanoma after 4 weeks in zebrafish 
(Santoriello et al., 2010). This difference may be due to the higher levels of HRASV12 
expression driven by the kita and/or to different cell specificity of the kita and mitf promoters. In 
contrast to the BRAF V600E and NRAS-Q61K models, HRAS-V12 show ectopic melanocyte 
patterns during early embryogenesis that can rapidly become melanoma within a few weeks of 
development.  
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1.1.5 The Xmrk melanoma model 
In fish of the genus Xiphophorus, melanoma development happens spontaneously in nature and 
can be induced by interspecific crossing (Meierjohann et al, 2004). The classical crossing 
experiment involves X. maculates which carries a dominant tumour inducing locus (Tu for 
tumour) and a Tu-repressing regulatory locus (R), and X. helleri which lacks both loci (Fig. 1, 
Gordon, 1947). As both loci are located on different chromosomes, it is possible to separate them 
through selective breeding. According to Mendelian inheritance, a cross between these two 
Xiphophorus species produces heterozygous hybrids. Further crosses of these hybrids with X. 
helleri result in 25% of fishes carrying the tumour gene but lacking the repressor (Meierjohann 
and Schartl, 2006). These fishes develop melanoma with 100% of penetrance. 
 
 
Fig. 1. Crossing experiment leading to spontaneous melanoma formation.  Adapted from (Meierjohann and 
Schartl, 2006). Xiphophorus maculatus bears the tumorigenic (Tu) and the repressor (R) loci, while Xiphophorus 
helleri lacks both. An intercross between these two species produces a generation of heterozygous hybrids in both 
loci. A second generation (result from a cross of this heterozygous hybrids and the wild type X. Helleri) produces 
25% of fishes bearing the Tu locus and lacking the repressor resulting in fishes that develop spontaneously 
melanoma. 
 
The receptor tyrosine kinase gene Xmrk (Xiphophorus melanoma receptor kinase) was identified 
by positional cloning as the oncogenic determinant encoded by the Tu locus (Wittbrodt et al, 
1989). Disruption of this gene leads to loss of function with respect to melanoma formation 
(Schartl et al, 1999). Xmrk is apparently restricted to the genus Xiphophorus (Weis and Schartl, 
1998). The Xmrk repressor present in locus R could not be identified up to now. Xmrk is an 
orthologue of the human EGF receptor (Gómez et al, 2004). While the EGF receptor is inactive in 
absence of the respective ligand and signals only after growth factor binding, Xmrk is 
constitutively active independent of ligand activation (Wittbrodt et al, 1992). The oncogenic 
properties of Xmrk derive from two amino acid changes in the extracellular domain in 
comparison to the EGF receptor. These mutations result in the formation of cysteine bridges 
between two receptors monomers, which leads to constitutive activation of Xmrk (Gómez et al, 
2001). 
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Xiphophorus are live-bearing fishes and, therefore, are not compatible with embryo manipulation 
and transgenesis comparable to other laboratory fish species. Hence, the Xmrk melanoma model 
was brought to the medaka system (Schartl et al., 2010). To induce expression of Xmrk in 
pigment cells of medaka, a stable transgenic fish line was generated in which the tumorigenic 
coding sequence of Xmrk is expressed under the control of the medaka mitfa promoter (Fig. 2). 
While in Xiphophorus tumorigenic activation of Xmrk results only in melanoma formation, in 
medaka the expression of Xmrk under the mitfa promoter results in melanoma as well as in 
pigment cell tumours arising from xanthophores and erythrophores (Schartl et al., 2010). 
Conclusively, Xmrk is a powerful and dominant oncogene driving melanoma formation, not only 
necessary but also sufficient for tumour formation.  
 
 
Fig. 2. Mitf:Xmrk transgenic medakas bearing melanoma. (A) Medaka fish bearing exophytic 
xanthoerythrophoromas. (B) Medaka fish bearing invasive extracutaneus melanoma. Pictures were taken by Manfred 
Schartl. 
 
Interestingly, the genetic background seems to play a role in melanoma formation in medaka. The 
Carbio strain developed almost exclusively exophytic xanthoerythrophoromas, and invasiveness 
was only observed at terminal stages (Fig. 2A). In the HB32C strain, almost all tumours were 
invasive extracutaneus melanoma (Fig. 2B). In the albino (i-3) genetic background, transgenic 
fishes showed hyperpigmentation of xanthophores that rarely developed into tumours (Schartl et 
al., 2010).   
 
1.1.6 Medaka as a model organism 
 
Medaka (Oryzias latipes) is a small (2-4 cm long), freshwater teleost fish originating from 
Southeast Asia. They can be easily maintained and bred under laboratory conditions. Males and 
females can be distinguished due to their distinct dorsal and anal fins (Wittbrodt et al, 2001). 
Spawning is under strict control of light, temperature and food availability. Under laboratory 
conditions, fish are kept under a light cycle corresponding to summer conditions (14h light 10h 
dark). Water temperatures between 25 to 28°C are standard under laboratory conditions. Medakas 
are fed with synthetic diets and brine shrimp (Shima and Mitani, 2004).    
 
Medaka fishes have external fertilization similar to zebrafish (Danio rerio), but in contrast to 
these, their eggs are kept attached to the female belly for several hours. Also, medaka fishes have 
a large number of offspring per week, as each female lays between 10-50 eggs per day (Takeda 
and Shimada, 2010). Besides that, the laid eggs have a fast embryonic development when 
compared to mammals. Additionally, embryos have optical clearance allowing close tracing of 
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development (Wittbrodt et al., 2001). Early development is synchronous, and the fully transparent 
embryos are easily staged under the microscope according to a set of morphological criteria 
(Iwamatsu, 2004). All these features made Medaka one of the most famous fish model organism 
in science nowadays.  
 
1.2 Oncogenic signalling of Xmrk 
To be fully tumorigenic, a potential cancer cell must show uncontrolled cell proliferation, anti-
apoptosis signalling, as well as inhibition of differentiation, the ability to migrate and invade other 
tissues and induce vascularisation (Cree, 2011). Normally, the route to a malignant tumour 
involves multiple steps to achieve all the requirements mentioned above. However, the single step 
of Xmrk expression leads to malignant melanoma formation in medaka fishes (Schartl et al., 
2010). Downstream signalling of Xmrk has been well studied in vitro and explains the reason for 
this: Xmrk signalling is involved in many of the tumorigenic events necessary for cancer 
formation and maintenance (Fig. 3, Meierjohann and Schartl, 2006).  
 
 
Fig. 3. Schematic representation of the Xmrk signalling cascade. 
 
As a growth factor receptor, Xmrk is placed at the top of many signal transduction pathways (Fig. 
3). Like other receptor tyrosine kinases, it possesses a carboxy-terminus which contains specific 
substrate binding sites (Meierjohann et al, 2004). Certain phosphorylated tyrosine residues serve 
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as sites for adapter proteins with src homology (Wellbrock and Schartl, 1999). The resulting 
association of these proteins is followed by the induction of the RAS-RAF-MAPK (mitogen-
activated protein kinase, section 1.3) pathway, which affects proliferation, survival and 
differentiation. Accordingly, PSM cells, which are derived from malignant Xiphophorus 
melanoma, exhibit permanently elevated levels of phosphorylated BRAF, MEK and ERK 
(Wellbrock and Schartl, 1999). The src kinase fyn is also associated with the C-terminus of Xmrk 
and enhances the MAPK signalling cascade by inhibiting MKP-1 (Wellbrock et al, 2002). PI3K is 
another protein that binds to phosphorylated tyrosine residues of Xmrk. It becomes activated and 
induces anti-apoptotic signals via its downstream effector Akt (Wellbrock and Schartl, 2000).  
 
The transcription factor Stat5 (signal transducer and activator of transcription 5, section 1.4) is 
activated by Xmrk (Baudler et al, 1999) and promotes both proliferation (Morcinek et al, 2002) 
and, in cooperation with the phosphatidylinositol 3-kinase (PI3-K), anti-apoptotic events (Hassel 
et al, 2008). While other Stat proteins bind to phosphorylated tyrosine residues of the intracellular 
part of receptor tyrosine kinases, an unusual tyrosine-phosphate-independent type of binding of 
Stat5 to Xmrk was found (Morcinek et al, 2002). After this interaction, phosphorylated Stat5 
translocates to the nucleus where it activates specific target genes like the anti-apoptotic protein 
bcl-x. 
 
Recent studies have suggested that c-myc (section 1.5) overexpression correlates with overall 
survival in melanomas (Schlagbauer-Wadl et al., 1999). An unpublished work performed in 
Manfred Schartl’s laboratory detected higher c-myc expression after Xmrk activation in Melan A 
cells (internal communication).  
 
1.3 BRAF 
1.3.1 RAF kinase family  
 
BRAF (also known as proto-oncogene B-Raf or v-Raf murine sarcoma viral oncogene homolog 
B1) is a serine-threonine kinase, and together with ARAF and CRAF, forms the RAF kinase 
family in mammals (reviewed in Chong et al, 2003). The RAF proteins participate in the 
ERK/MAPK signalling cascade, which connects extracellular signals to transcription regulation, 
mediating cell growth, survival and differentiation (Robinson and Cobb, 1997).  
 
RAF proteins share three conserved regions: CR1 (which bears a RAS-binding domain (RBD) 
and a Cystein-rich domain (CRD)) and CR2 are both regulatory and present in the N-terminus. 
Also, CR3 is present in the C-terminus and encompasses the kinase domain. CR3 contains two 
regions important for RAF activation: the activation segment and the negatively charged 
regulatory region (N-region, Fig. 4).  
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Fig. 4. Schematic representation of the human BRAF protein domains. Indicated amino acids represent important 
sites for BRAF activation, regulation and function. CR1, CR2 and CR3 = Conserved region 1, 2 and 3, respectively; 
RDB = Ras binding domain; CRD = cysteine rich domain 
 
RAF proteins carry out non-redundant functions in development as knockout mice for either 
ARAF (Pritchard et al, 1996), BRAF (Wojnowski et al, 1997) and CRAF (Mikula et al., 2001) 
die during embryonic development or shortly after birth. However, these knockout studies 
revealed both overlapping and unique function for RAF isoforms. For example, in CRAF 
knockout mice, BRAF can compensate CRAF loss in the activation of the MAPK pathway 
(Mikula et al., 2001). Besides that, biochemical differences were also found in RAF isoforms. 
ARAF is a much weaker activator of MAPK than the other members of the RAF family. Also, 
ARAF can only activate MEK1, while BRAF and CRAF can activate MEK1 and MEK2 (Wu et 
al, 1996).  
 
1.3.2 Regulation of BRAF kinase activity 
 
Binding of extracellular ligands such as growth factors, cytokines and hormones to the 
corresponding cell surface receptor may lead to activation of RAS and subsequent initiation of 
BRAF activation. RAS proteins are small GTPases that mediate signalling by binding and 
hydrolyzing GTP and subsequent phosphorylation of downstream signalling factors (reviewed in 
Wellbrock et al., 2004). The active, GTP-bound form of RAS binds to BRAF through its RAS 
binding domain (RBD) and cysteine rich domain (CRD) present on CR1, leading to BRAF 
recruitment to the membrane characterizing the initial event in BRAF activation (Chong et al., 
2003). Once activated, BRAF protein phosphorylates and activates MEK1 and 2, which in turn 
phosphorylate ERK1 and 2 (MAPKs, Wellbrock et al, 2004). Other substrates have been 
proposed for CRAF and ARAF, but only MEK1 and MEK2 have been identified as substrates for 
BRAF (Kolch, 2000). 
 
Phosphorylation is an important mechanism by which BRAF activity is regulated. Activation of 
BRAF by RAS requires phosphorylation of T599 and S602 (Michaloglou, 2008). Also, another 
serine, S446, which is necessary for the activation of other RAF members, is constitutively 
phosphorylated in BRAF, while the corresponding serine in ARAF and CRAF is not. Besides 
that, the S446 is located adjacent to two aspartic acids (D448, D449) instead of two tyrosines 
which are present in ARAF and CRAF (Mason et al., 1999). These aspartic acids mimic 
phosphorylated tyrosines. As a result, BRAF has a stronger basal activity and requires fewer 
phosphorylation steps to be active.  
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1.3.3 BRAF mutations in melanoma 
 
BRAF is the only RAF protein to be frequently mutated in cancer. Among human cancers, BRAF 
mutations are most common in melanoma (Michaloglou, 2008). Also, mutations in BRAF are 
found in thyroid cancer in about 45% of sporadic papillary thyroid cancers (Xing, 2005) and in 
colorectal cancer (Sharma and Gulley, 2010). So far, no ARAF mutations have been related to 
cancer (Lee et al., 2005). CRAF mutations are rarely found in human cancers (Emuss et al, 2005). 
 
The highest incidence of BRAF mutations is detected in approximately 66% of all malignant 
melanoma (Davies et al., 2002). The prevalence of BRAF mutations is variable among different 
types of melanoma. They are most common in cutaneous melanoma, are rare in mucosal, acral, 
conjunctival melanoma and are not present in uveal melanoma (reviewed in Michaloglou, 2008).  
 
Also, BRAF mutations were identified in papillary thyroid cancer (Fukushima et al., 2003), 
colorectal cancer (Sharma and Gulley, 2010) and ovarian cancer (Estep et al, 2007) in lower 
frequencies (reviewed in Garnett and Marais, 2004). Over 40 different missense mutations in 
BRAF, involving 24 different sites, have been identified (COSMIC web site: 
www.sanger.ac.uk/genetics/CGP/cosmic/). However, a thymidine to adenosine transversion at 
nucleotide 1796, leading to a valine to glutamic acid conversion (BRAF V600E), predominates in 
most cancer lesions (Davies et al., 2002). This specific mutation accounts for over 90% of BRAF 
mutations in melanoma (Thomas, 2006) and thyroid cancer (Fukushima et al., 2003). In addition, 
clinical data of a specific BRAF V600E inhibitor indicated a significant effect of BRAF function 
on melanoma progression (Bollag et al, 2010). These patients show regressing melanoma after 
BRAF V600E inhibition, but melanomas acquire resistance by RTK or NRAS upregulation 
(Nazarian et al, 2010). 
 
The mutant amino acid V600 is situated between T599 and S602, whose phosphorylation is 
responsible and sufficient for BRAF activity. The V600E mutation is thought to mimic the 
phosphorylation in these sites, giving to BRAF a constitutive activity (Michaloglou, 2008). BRAF 
V600E activity is independent of the presence of a negative charge in the N-region (S446) 
normally required for wild type BRAF activation (Brummer et al., 2006). Besides that, cell lines 
expressing BRAF V600E are capable to signal independent of RAS activation (Davies et al., 
2002). 
 
1.3.4 BRAF V600E model organisms 
 
Several BRAF V600E mouse models have been generated. Mutated BRAF under the control of a 
thyroid follicular cell specific promoter (thyroglobulin promoter) develops papillary thyroid 
carcinoma (PTC) (Knauf et al., 2005). Also, a knock in mutant mouse expressing BRAF V600E 
only after Cre-mediated recombination during development resulted in embryonic lethality 
(Mercer et al., 2005). Additionally, expression of this mutant BRAF in somatic tissues only 
induced proliferation in liver and spleen. Furthermore, these mice developed non-lymphoid 
neoplasia and died after 4 weeks due to bone marrow failure. In a second Cre-recombinase knock 
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in mouse, in which the expression of cre recombinase was driven exclusively in the lung 
epithelium, BRAF V600E mice developed multiple lung adenomas (Dankort et al., 2007). A 
melanoma mouse model was generated with the induction of BRAF V600E combined with the 
PTEN tumour suppressor silencing (Dankort, 2009). In addition, the inducible expression of 
BRAF in mouse melanocytes led to skin hyperpigmentation, appearance of nevi harbouring 
senescent melanocyte and melanoma development (Dhomen et al, 2009). 
 
Fishes have also been used to study the role of BRAF V600E in living organisms. Zebrafish 
expressing mutated human BRAF under the control of the zebrafish mitfa promoter developed 
focal sites of melanocytes hyper proliferation, which did not progress to malignancy (Patton et al, 
2005). However, in a p53 negative background, BRAF V600E fishes developed malignant 
melanoma (Patton et al, 2005). These transgenic zebrafish embryos for human BRAF V600 under 
the control of the mitfa promoter and lacking p53 have been used in another study to identify the 
initiating transcriptional events that occur on activation of human BRAF V600E in the neural 
crest lineage by performing a chemical genetic screen to identify small molecules suppressors of 
the neural crest lineage. (White et al, 2011) One class of compound, DHODH, led to almost 
complete abrogation of neural crest development. When used alone or in combination with a 
specific inhibitor of the BRAF V600E, DHODH led to decrease in melanoma growth in vivo as 
well as in mouse xenograft studies (White et al, 2011). The same zebrafish model has been used 
to test the ability of genes to cooperate with BRAF V600E to accelerate melanoma (Ceol et al, 
2011). In this study, SETDB1, an enzyme that methylates histone H3 on lysine 9 (H3K9), was 
found to accelerate melanoma formation significantly in zebrafish. So far, no fish utilizing a fish 
specific braf or a medaka model bearing BRAF V600E mutation have been generated. 
 
1.4 Stat5 
1.4.1 Stat family 
 
Signal transducers and activators of transcription (Stats), as the name indicates, comprise a family 
of genes that play a role as cytoplasmatic signalling proteins and as nuclear transcription factors, 
that activate a diverse set of genes, including some implied in cancer progression (Lim and Cao, 
2006). Seven members of the Stat family have been identified in mammals: Stat1, Stat2, Stat3, 
Stat4, Stat5a, Stat5b and Stat6 (Santos and Costa-Pereira, 2011).  
 
In general, Stats proteins contain between 750 and 850 amino acids and share 6 structurally and 
functionally divergent domains (Fig. 5, reviewed in Paukku and Silvennoinen, 2004). The N-
terminal domain (N-term) is important for dimerization or tetramerization of Stat monomers as 
well as for nuclear translocation and protein-protein interactions. The coiled-coil domain is 
involved in the interaction with other proteins, like the silencing mediator for retinoic acid 
receptor and thyroid hormone receptor, leading to down regulation of Stat5 activity (Nakajima et 
al, 2001). Also present is a DNA binding domain (DBD), which is able to bind DNA in an 
activated STAT dimer and is involved in nuclear translocation. In close proximity to the DBD lies 
the linker domain (LD), which is involved in transcriptional activation. The most well conserved 
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domain in the structure of Stats is the SH2 domain, which is necessary for receptor association 
and tyrosine phosphodimer formation. The C-terminus incorporates the transactivation domain 
(TAD), which is poorly conserved among Stats and regulates unique transcriptional responses 
(Lim and Cao, 2006). 
 
Fig. 5. Schematic representation of the human Stat5 protein domains. Marked tyrosine (Y) and serine (S) 
residues represent the two amino acids important for Stat5 activation. In human Stat5a and Stat5b the position of this 
tyrosine is 694 and 699 respectively. The serine important for Stat5 activation lays on position 726 in human Stat5a 
and 731 in Stat5b. N-term = N-terminal domain; DBD = DNA binding domain; LD = linker domain; SH2 = SH2 
domain; TAD = transactivation domain.  
 
Stat proteins have central roles in cell differentiation and cell growth (Paukku and Silvennoinen, 
2004). In addition to their central role in normal cell signalling, recent studies have demonstrated 
that diverse oncoproteins can activate specific Stats (specially Stat3 and Stat5) and that 
constitutively activated Stat signalling directly contributes to oncogenesis (Bowman et al, 2000). 
TGF-ß and PI3K/PTEN are controlled by Stat5 action (Ferbeyre and Moriggl, 2011). 
 
The two Stat5 genes present in mammals, Stat5a and Stat5b, are very closely related. They share 
over 90% identity and diverge only at their C-terminus (Paukku and Silvennoinen, 2004). Stat5 
(Stat5a) was first identified as a prolactin-induced mammary gland factor (Gouilleux et al, 1994). 
Soon after, another closely related gene (Stat5b) was identified in mice (Liu et al, 1995). Stat5a is 
the predominant form in mammary gland, while Stat5b is more prominently expressed in liver 
(Paukku and Silvennoinen, 2004). Stat5a knockout mice fail to develop mammary glands due to 
loss of prolactin responsiveness (Liu et al., 1997). By contrast, Stat5b knockout mice have 
sexually dimorphic growth retardation (Udy et al., 1997).  
 
Two Stat5 homologues have been identified in zebrafish by Lewis and Ward in 2004, named 
Stat5.1 and Stat5.2. These authors suggest that the ancestral Stat5 gene has undergone two 
independent gene duplication events to generate a Stat5.2 paralogue in zebrafish and a Stat5a 
paralogue in mammals. However, no functional analysis was done in this work and no study 
focusing on medaka Stat5 genes has been performed so far. 
 
1.4.2 Stat5 activation 
 
Stat5 proteins, like all Stat members, are activated by different cytokines, including interferon and 
interleukin, as well as growth factors and hormones (Bromberg, 2001). Binding of growth factors 
and cytokines to their receptors results in the activation of intrinsic receptor-tyrosine-kinases or of 
receptor-associated kinases, such as the Janus kinase (JAK) or the SRC tyrosine kinase. These 
kinases subsequently phosphorylate the cytoplasmic part of the receptor, which recruits 
monomeric Stat proteins to the receptor. Recruited Stats themselves become subsequently 
activated by phosphorylation, dimerize and translocate to the nucleus, where they can directly 
regulate gene expression (Yu and Jove, 2004).  
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Two constitutively activated versions of mouse Stat5 have been identified. The first mutation 
identified was a Stat5a version bearing two amino acid substitutions: H299R located in the DNA 
binding domain and S711F present in the transactivation domain (Onishi et al, 1998). This mutant 
protein is constitutively phosphorylated at its tyrosine residues and is transcriptionally active even 
in the absence of stimulation. The same mutations in Stat5b have similar effects (Onishi et al, 
1998). In addition, a single point mutation in the SH2 domain, N642H, gives rise to a 
constitutively active Stat5a and Stat5b (Ariyoshi et al., 2000). On the contrary, a deletion of the 
carboxyl-terminal transactivation domain of mouse Stat5a confers the gene a dominant negative 
phenotype (Moriggl et al., 1996). These protein versions sustain the DNA binding activity but fail 
in activation, thus leading to a dominant negative phenotype. In zebrafish, a constitutively active 
form of Stat5.1 was generated based on these previously identified murine Stat5.  Expression of 
zebrafish Stat5.1 N646H and H298R/N714F mutants led to haematological perturbations (Lewis 
et al, 2006). So far, no animal model has been generated bearing any Stat5 constitutive active 
version. 
 
1.4.3 Stat5 in cancer 
 
Whereas Stat5 activation is tightly regulated in normal cells, the constitutive activation of tyrosine 
kinases in cancer causes continuous activation of Stat5, leading to permanent changes in the 
expression of genes that control fundamental cellular processes (Yu and Jove, 2004). It is 
conceivable that multiples factors, such as epigenetic changes, regulation by miRNA, altered 
proteolytic pathways, gene amplification and aberrant growth factor signalling contribute to 
activation of Stat5 proteins in human cancers (Ferbeyr and Moriggl, 2011). Stat5 activation has 
been correlated with initiation and/or progression of breast cancer (Wagner and Rui, 2008) and 
prostate cancer (Tan and Nevalainen, 2008). Also, Stat5 pathway is frequently activated in lung, 
head and neck cancers (Lai and Johnson, 2010).  
 
Correlations of Stat5 with melanoma have been observed in the fish Xiphophorus, where the 
signalling of oncogenic receptor tyrosine kinase, Xmrk, leads to activation of Stat5 (Wellbrock et 
al, 1998). Also, Stat5 phosphorylation in malignant melanoma is important for survival 
(Mirmohammadsadegh et al., 2006) and contributes to anti-apoptosis in melanoma (Hassel et al, 
2008). Besides that, in almost all melanoma cell lines, an abundant level of activated Stat5 protein 
was found (Morcinek et al., 2002). A dominant-negative form of Stat5 leads to apoptosis and 
inhibits melanoma cell growth in vitro (Hassel et al., 2005).  
 
1.5 C-myc 
1.5.1 Myc family 
 
The human myc gene family, comprising c-myc, mycN and mycL, contains a basic helix-loop-
helix leucine zipper (BHLH/LZ) domain (Fig. 6). Myc protein through its BHLH domain can 
bind to DNA while the LZ allows the dimerization with its partner Max, another BHLH 
transcription factor (Eilers and Eisenman, 2008). The basic region motif is the region involved in 
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determining sequence-specific DNA binding (Ryan and Birnie, 1996). Sub cellular localization to 
the nucleus is encoded primarily by the nuclear localization region (Meyer and Penn, 2008). The 
transactivation domain acts as a transcription activator (Ryan and Birnie, 1996). 
 
 
Fig. 6. representation of the human C-myc protein domains. 
 
Genes of the myc family are considered to be proto-oncogenes due to raised activity in a variety 
of human cancers following alterations in their structure or changes in expression. One example is 
Burkitt lymphoma, where the t(8;14)(q24;32) translocation places myc in juxtaposition with 
regulatory elements of the immunoglobulin heavy or light chain genes (Klapproth and Wirth, 
2010). Deregulated expression of c-myc has also been detected in a large variety of other human 
cancers, like breast and colon cancer, small cell lung carcinoma and neuroblastoma (reviewed in 
Nesbit et al, 1999). c-myc overexpression (Ross and Wilson, 1998) and increased copy number 
(Kraehn et al., 2001) have been also described in human melanomas indicating that C-myc plays 
a role in this disease.  
 
1.5.2 c-myc regulation 
 
c-myc expression is strictly controlled, at transcriptional and also at translational level (Meyer and 
Penn, 2008). In non tumorigenic cells, c-myc levels are low and dependent on mitogen signalling 
(Grandori et al, 2000). In most solid human tumours, c-myc expression is deregulated and is 
thought to promote tumour progression (Yokota et al, 1986). C-myc deregulation can be caused 
either by retrovirus integration, insertional mutagenesis, chromosomal translocation, gene 
amplification, increase in c-myc mRNA levels or decrease of C-myc protein stability (for review 
see Meyer and Penn, 2008). Although oncogenic activation of c-myc alone causes uncontrolled 
cell proliferation in vitro, cellular transformation requires additional oncogenic lesions, like Ras 
activation (Jacobs et al., 1999), interaction with the anti-apoptotic activity of Bcl2 and Bcl-x 
(Strasser et al,  1990) or loss of the tumour suppressor p53 (Blyth et al, 1995). 
 
C-myc stability is linked to its phosphorylation status. Ras controls C-myc stability by 
phosphorylating two myc residues, T58 and S62 (Sears et al., 2000). Also, C-myc is 
phosphorylated at S71 by a Rho-dependent kinase (Watnik et at, 2003). Besides that, Myc 
function is controlled post translationally by six lysine residues that are direct substrates for p300-
mediated acetylation (Zhang et al, 2005) and by ubiquitination stimulating proteosomal 
degradation of the protein (Sears, 2004). 
 
1.5.3 C-myc function 
 
The general function of C-myc is to act as a global transcriptional regulator controlling normal 
cell proliferation, growth, survival and differentiation (Meyer and Penn, 2008). Its main function 
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is the activation of gene transcription, which happens through the formation of a heterodimeric 
complex with Max through its C-terminal region where a basic helix-loop-helix and a leucine-
zipper are present (Lüscher and Larsson, 1999). Myc-Max heterodimers bind to genomic E-box 
sequences (CACGTG) with high affinity (Blackwood and Eisenman, 1991). This 
heterodimerization is essential for Myc transformation (Amati et al., 1993). After forming a 
complex with Max, C-myc also recruits cofactors and promotes cell cycle progression (Lüscher, 
2001). Transactivation by C-myc is antagonized by Mad proteins, which heterodimerize with 
Max and bind to the same DNA complexes but recruit repressor complexes to the promoter 
(Wanzel et al, 2003).  
 
Also, C-myc/Max complexes regulate gene activation through chromatin remodelling (Amati et 
al, 2001). C-myc associates with the co-activator TRRAP, a component that bears 
acetyltrasferases (McMahon et al, 1998). After binding to cyclin D2 (CCND2), C-myc recruits 
TRRAP and induces the acetylation of histone H4, which alters the chromatin structure, allowing 
the access and binding of the C-myc/Max complex to target DNA sequences (Bouchard et al., 
2001). Besides that, the induction of gene expression of several other C-myc target genes has 
been correlated with histone H4 acetylation (Frank et al, 2001).  
 
In contrast to its activational role, Myc can also repress gene transcription by different 
mechanisms. First, C-myc is able to repress transcription indirectly by activating the synthesis of 
transcriptional repressor proteins (Wanzel et al, 2003). Also, Myc-Max complex is recruited to 
core promoters through protein-protein interactions with transcription activators that are bound 
directly to DNA, including the nuclear factor Y, NFY (Izumi et al., 2001), SP1 (Gartel et al., 
2001) and the Myc-interacting zinc finger 1, MIZ1 (Peukert et al., 1997). These protein 
complexes are thought to displace co-activators and recruit co-repressors (Wanzel et al, 2003). 
 
1.5.3.1 C-myc promotes cell proliferation 
 
In quiescent cells in vitro, c-myc expression is virtually undetectable, but after mitogenic or serum 
stimulation its mRNA expression and protein production are rapidly induced, and cells enter G1 
phase of the cell cycle (Pelengaris et al, 2002). Myc promotes cell division by activation or 
repression of genes that are involved in cell cycle progression. C-myc induces cyclin-E-CDK2 
activity early in the G1 phase of the cell cycle (Steiner et al., 1995) by activating CCND2 
(Bouchard et al., 1999) and CDK4 (Hermeking et al., 2000) and repressing genes which are 
involved in cell cycle arrest like p15 (Staller et al., 2001) and p21 (Perez-Roger et al, 1999). Myc 
is thought to contribute to tumorigenesis through unrestrained cellular growth and proliferation 
(reviewed in Arvanitis and Felsher, 2006). 
 
1.5.3.2 C-myc induces apoptosis 
 
 Two major pathways by which C-myc induces apoptosis have been uncovered. First, C-myc 
induces expression of the tumour suppressor protein p19 Arf, which activates p53, which in turn 
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activates proapoptotic genes including bax and puma as well as mediators of cell cycle arrest such 
as p21CIP1 (Larsson and Henriksson, 2010). Also, C-myc represses expression of anti-apoptotic 
members of the bcl-2 family including bcl-x and bcl-2 (Eischen et al, 2001). Apoptosis is an 
important cellular mechanism against cancer formation. Thus, the loss of pro-apoptotic genes, 
such as p53, Arf and Bax, or overexpression of anti-apoptotic genes, such as bcl-2 and bcl-x, 
cooperate with c-myc to accelerate tumorigenesis (Eischen, et al, 1999 and 2001). 
 
1.5.4  c-myc model organisms 
 
To better understand C-myc function, model organisms, like transgenic mice, were generated. C-
myc null mice fail to develop normally and die at embryonic day 9.5 – 10.5 with abnormalities of 
the heart, neural tube and pericardium, thereby showing the crucial requirement of C-myc for 
embryonic survival and its role in organ development (Davis et al, 1993). A conditional c-myc 
knockout mouse, using the Cre-loxP technology, provided extra knowledge about c-myc role 
during cell cycle control, organ and body size control (Trumpp et al., 2001).  
 
Different mouse models that enable temporal control of C-myc activation after tamoxifen 
treatment were developed by fusing the c-myc gene to a mutated form of the ligand binding 
domain of the estrogen receptor (ER, Eilers et al, 1989). This mutated ER does not bind to beta 
estradiol, its natural ligand, but instead binds to tamoxifen (Feil et al., 1996).  In the absence of 
tamoxifen, the protein fused to ER is bound to the heat shock protein 90 (Hsp90, Tian et al., 
2006) and is located at the cytoplasm, hence inactive. On administration of tamoxifen, Hsp90 is 
displaced leaving the transcription factor free to translocate to the nucleus and activate target 
genes. 
 
C-mycER activation in the suprabasal epidermis under the control of the involucrin promoter is 
sufficient to induce cell cycle entry of post-mitotic keratinocytes and to block differentiation 
(Pelengaris et al, 1999). In this study, sustained C-myc activation for 21 days resulted in 
epidermal hyperplasia and induction of angiogenesis, but no C-myc induced apoptosis was 
observed. Interestingly, C-mycER activation in pancreatic islet ß-cells under the insulin promoter 
results predominantly in apoptosis (Pelengaris et al, 2002). Another ER model was used to 
investigate the effect of timed C-myc activation in the basal layer of the epidermis under the 
keratin 14 promoter (Arnold and Watt, 2001). In this model, C-myc forces cells out of the stem 
cell niches stimulating epidermal proliferation.  
 
In addition to genetically engineered myc mouse models, zebrafish C-myc models have been 
generated. A T-cell acute lymphoblastic leukemia (T-ALL) model was generated using a human 
C-myc version under the control of the lymphoid cell specific rag2 promoter (Langenau et al., 
2003). This model was later improved by conditioning c-myc expression using Cre/lox (Langenau 
et al, 2005) and heat shock promoter systems (Feng et al, 2007). Recently this zebrafish T-ALL 
model has been extended for a tamoxifen inducible version of myc under the control of the rag2 
promoter (Gutierrez et al, 2011). Although very important for understanding C-myc function in 
vivo, these zebrafish models have been generated using the mouse or human gene instead of 
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utilizing the species-specific orthologue, therefore ignoring possible species-specific functions of 
C-myc. So far, no investigation of medaka c-myc genes has been performed and facilitate the 
possibilities to investigate evolutionary and general functional aspects of Myc. 
 
1.6 Aims 
 
As discussed above, melanoma is one of the most dangerous forms of cancer. Consequently, it is 
essential to investigate the function of genetic factors known to be involved in this malignancy in 
more detail. The first aim of this work was to investigate known downstream signals of Xmrk 
contributing to the tumour phenotype in vivo in the medaka system. To accomplish this, I 
identified, cloned and produced different medaka transgenic lines expressing oncogenic factors in 
pigment cells under the control of the mitf promoter.  
 
The first target was to identify the complete medaka BRAF gene and to clone it. Subsequent 
sequence modifications should result in a constantly activated BRAF version, similar to BRAF 
V600E in humans. BRAF is found mutated in high incidence in human tumours like malignant 
melanoma and thyroid cancer (Davies et al., 2002). I also wanted to produce transgenic lines, 
bearing both medaka BRAF versions under the control of the MITF promoter. These lines should 
bring new insights on how BRAF functions modulate pigment cells in vivo, since for the first time 
a fish BRAF would be analysed.  
 
A second target for investigation was medaka Stat5a and Stat5b. Stat5 is essential for Xmrk 
induced invasive progression of melanoma (Schartl et al., 2010). Identification, cloning and 
production of transgenic medaka lines utilizing both medaka orthologues of these two genes 
should be helpful to understand how Stat5 functions are correlated to melanoma invasiveness in 
vivo and how both versions diverge between each other. Besides that, for the first time a living 
organism carrying constitutive active and dominant negative versions of these genes would be 
produced. These lines will additionally help to bring new insights on how activation or lack of 
Stat5 affects the physiology of a living organism. For example, these fish would allow 
investigation of angiogenesis processes in cancer which are not possible in cell culture.  
 
The integration of medaka genetics with the large tools available to study cancer will provide a 
wider understanding on cancer formation in general. For example, medaka fishes are suitable for 
high-throughput chemical screens. In addition, the lines generated here will constitute promising 
models to test new genes as a cancer therapy agent, since medaka fishes can be easily crossed 
with cancer developing lines, like the melanoma developing Xmrk fishes. Also, medaka fishes can 
be used in genetic screens to detect new tumour suppressors or genetic modifiers in melanoma 
development. 
 
A third aim of this work was to investigate in vivo c-myc, a well known regulator of cell cycle 
progression and potential oncogene. C-myc expression is induced by activation of Xmrk in vitro 
(Svenja Meierjohann, personal communication) and may link Xmrk induced melanoma 
progression and cell cycle regulation. Due to its known harmful developmental effects in vivo 
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after activation, I wanted to create a medaka model utilizing a genetically modified species 
specific C-myc version with strictly controllable activation. Detailed analyses on proliferation and 
apoptosis potentials in individuals of these lines will result in insights into cell fate decisions and 
potential tumour initiation after C-myc deregulation. 
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2. MATERIALS 
2.1 Chemicals and reagents 
Basic chemicals were purchased from MERCK, Sigma-Aldrich and Roth. Specific chemicals are 
listed in the table above. 
 
Compound Supplier 
1 kb DNA ladder Fermentas 
100 bp DNA ladder Fermentas 
4-OHT (4-Hydroxytamoxifen)  Sigma-Aldrich  
Agarose Roth 
Albumin bovine serum PAA 
Aprotinin Sigma-Aldrich  
Bacto® agar A. Hatenstein 
Bacto® tryptone A. Hatenstein 
Bacto® yeast extract A. Hatenstein 
Bradford reagent Sigma-Aldrich  
BrdU (5-bromo-2`-deoxyuridine)  Sigma-Aldrich  
Chelex Bio-Rad 
Chloroform Roth 
Choleratoxin Sigma-Aldrich  
deoxycholate Sigma-Aldrich  
DIG RNA labeling mix Roche 
DMEM Invitrogen 
DMSO  Roth 
DNA oligonucleotides Sigma-Aldrich  
DNTPs (Deoxynucleotides triphosphate) Fermentas 
Ethidium bromide Roth 
EtOH Sigma-Aldrich  
FCS PAA 
FCS gold PAA 
Fetal bovine serum PAA 
Fitc-dextran Sigma-Aldrich  
FLU RNA labeling mix Roche 
FuGENE HD transfection Reagent Roche 
Gel Loading Buffer II”  Ambion 
Glutamine PAA 
Heparin Sigma-Aldrich  
Hoechst Invitrogen 
IPTG (isopropyl-ß-thiogalactopyranosid) Roth 
Leibovitz 15 medium Gibco 
Leupeptin Sigma-Aldrich  
Na3VO4 Sigma-Aldrich  
NaOAC (3M) Roth 
PageRuler™ prestained protein ladder Fermentas 
peqGOLD TriFast Peqlab 
Phenol Roth 
Phenol red  Sigma-Aldrich  
Roti® Histo kit II   Roth 
Roti® Histokit II  Roth 
Rotiphorese® Gel 40 (37.5:1) Roth 
RPM1 medium Gibco 
Sheep serum Sigma-Aldrich  
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Torula-RNA  Sigma-Aldrich  
TPA  PAA 
Tricaine Sigma-Aldrich  
Triton X-100 Roth 
Tween® 20 Roth 
X-gal (5-bromo-4-chloro-3-indolyl-beta-D-
galactopyranoside)  
Sigma-Aldrich  
Xylene Roth 
 
2.2 Antibiotics 
Antibiotic Supplier 
Ampicillin Roth 
Kanamycin Roth 
Streptomycin Invitrogen 
Penicillin Invitrogen 
 
2.3 Enzymes 
Enzyme Supplier 
Ligase  Fermentas 
Meganuclease Fermentas 
Pfu DNA polymerase Fermentas 
Proteinase K Roth 
ReproFast polymerase  Genaxxon 
Restriction endonuclease Invitrogem, NEB, Fermentas 
Sp6 Polymerase Roche 
T7 Polymerase Roche 
 
2.4 Antibodies 
2.4.1 Primary antibodies for western blot (WB) and immunofluorescence (IF) 
 
Antibody anti- Species/isotype Dilution for WB Dilution for IF Supplier 
ER IgG Rabbit     - 1:500 Santa Cruz 
ß-actin IgG Mouse 1:10000 1:10000 Santa Cruz 
BrdU IgG Rat     - 1:250 Serotec 
phospho MAP IgG Rabbit 1:5000    - Cell signalling 
 
2.4.2 Primary antibodies for in situ hybridization 
 
Antibody anti- Species/isotype Dilution Supplier 
fluorescein  Sheep 1:2000 Roche 
digoxigenin Sheep 1:2000 Roche 
2.4.3 Secondary antibodies 
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Antibody anti- Properties  Dilution for WB Dilution for IF Supplier 
Mouse IgG Peroxidase-coupled 1:3000    - Thermo Scientific 
Rabbit IgG Peroxidase-coupled 1:10000    - Bio-Rad 
Rat IgG Alexa 568-coupled    - 1:250 Serotec 
Rabbit  Alexa 488-coupled    - 1:3000 Invitrogen 
 
2.5 Disposables and kits 
Products Supplier 
TOPO TA cloning Kit Invitrogen 
GenElute™ Gel Extraction Kit  Sigma-
Aldrich  
GenElute™ HP Plasmid Miniprep Kit Sigma-
Aldrich  
GenElute™ PCR Clean-Up Kit Sigma-
Aldrich  
GenElute™ HP Plasmid Miniprep Kit RevertAid TM  Fermentas 
First Strand cDNA Synthesis Kit Fermentas 
ApopTag Red In Situ Apoptosis Detection Kit Milipore 
NucleoSpin RNA Clean up Kit QIAGEN 
 
2.6 Laboratory equipments 
Device Model/ Supplier 
Microinjection  
Microinjector FemtoJet and Microinjector 5242, Eppendorf 
Micromanipulator Leitz 
Stereo microscope Stemi SV6 and SV11, Zeiss 
Capillary puller Kopf vertical pipette puller model 720, Bachhofer 
Glass capillaries GC100F-10; Harvard Apparatus 
  
Documentation  
Microscope Axiophot POL, Zeiss 
 
Fujix hc-2000, Fujifilm 
 
Leica CTR 6000 
Stereo microscope SMZ1000, Nikon 
 
CC-12 FW Soft imaging system, Olympus 
Confocal microscope Nikon eclipse Ti, Nikon 
  
 
PCR and Gel electrophoresis 
 
TGradient PCR machine Biometra 
MyiQTM Single-color Real-time PCR Detection 
system  
Bio-Rad 
Gel chambers Department’s workshop 
Power supply EPS 301, Amersham-Pharmacia biotech 
Thermocycler TGradient, Biometra (Goettingen) and DNA 
Engine Dyad 
thermal cycler, Biorad (Hercules, CA) 
Centrifuges  
Tabletop Centrifuge 5415D and Centrifuge 5415R with rotor 
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F45-24-11, 
Eppendorf 
High-speed Sorvall RC-5B with rotor GSA and SLA-1500 
rotor, DuPont 
(Bad Homburg) and MinifugeRF, Heraeus 
  
Lab equipment  
Incubator B5050E, Heraeus 
Water bath Model 1083, GFL 
pH meter pH523, WTW 
Balance BP, Kern and Sohn 
Shaker Reax3, Heidolph 
Spectrophotometer BioPhotometer, Eppendorf 
 UV-visible- Spectrophotometer, Varian 
Thermal block Thermomixer compact, Eppendorf 
UV-sterilizer GS GeneLinker, Biorad 
Vortex  Vortex genie, Scientific industries INC. 
Pipettes Pipetman, Gilson 
Ultra turrax T5 Fu IKA 
 
2.7 Olinonucleotides 
Oligonucleotides were synthesized and purchased from Sigma-Aldrich  in HPLC quality. 
2.7.1 Olinonucleotides for cloning and screening 
 
Primer Sequence (5`-3`) 
Ory_BRAF_ATG_fish_FOR GCTCGAGATGGCGGCGTTGAGC 
BRAF_mdka_R1 TTGACACGAGCAACAAATCC 
BRAF_mdka_F2 TGATGAGGGGACTCATACCC 
BRAF_mdka_R2 GGTGACGTTCAGCATCTTCA 
BRAF_mdka_F3 CAACGTCAAAGTCCCACAGA 
BRAF_v1_mdka_R CCCAAGCTTCTTAAATGCAGAAAACTCCCC 
BrafHindIIIHAFLAGSpeIFOR AGCTTTCACTTGTCATCGTCGTCCTTGTAGTCAGCGTAAT
CTGGAACATCGTATGGGTAG 
BrafHindIIIHAFLAGSpeiREV AGCTCTACCCATACGATGTTCCAGATTACGCTGACTACAA
GGACGACGATGACAAGTGAA 
BRAFV614Efor GGAGACTTTGGCCTGGCGACCGAAAAGAGCCGCTGGAGT
GGCTCC 
BRAFV614Erev GGAGCCACTCCAGCGGCTCTTTTCGGTCGCCAGGCCAAA
GTCTCC 
Stat5ab/a_mdka_left GCTCGAGATGGCCGTGTGGATCCA 
Stat5ab/aR1 TGACCAATGCCGAGATGATA 
Stat5ab/aF1 AAACGATTTGGCAAAACAGG 
Stat5ab/aR2 TGCGGCTTTAGATGCTTTTT 
Stat5ab/aF2 GCCTTTCCTTGTGCCAGATA 
Stat5ab/a_mdka_right GGAATTCGGGACTGCTGGCCCCC 
Stat5ab/b_mdka_left GCTCGAGATGTCCCTGTGGATCCAGG 
Stat5ab/bR1 CTCACACCAGGACTGCAGAA 
Stat5ab/bF1 CTTACCAGAGAGGCCAGCAC 
Stat5ab/bR2 GCGGCTTCAGATGTTTCTTC 
Stat5ab/bF2 AGTTGGGTTTCCACGTCAAG 
Stat5ab/b_mdka_right GGAATTCGTTGCTGGCTGCTCCACT 
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Full length medaka c-myc17 for ATTGCTAAGCTTATGCCACCTGTGTTATC 
Full length medaka c-myc17 rev TTCGTG GATCCCCATGTAAAGTCCTGAGCTGCT 
MF_ef1a1-f02 GCAAGGGCTCCTTCAAGTACGC 
MF_ef1a1-r02 CAGCAGCGACAATCAGCACAG 
Full length medaka c-myc for ATTGCTAAGCTTATGCCACCTGTGTTATC 
Full length medaka c-myc rev TTCGTGGATCCCCATGTAAAGTCCTGAGCTGCT 
Haflag for ATGTACCCATACGATGTTCCAGA 
Stat5ab/a sibling screen rev ACCTCGATGGGAAAATGTTG 
Stat5ab/b sibling screen rev ATAATGCCGCACCTCTATGG 
BRAF sibling screen for TACCACCACCTGCACATCAT 
BRAF sibling screen rev TGGGTAGAGCTTCTTAAATGCAG 
c-myc sibling screen for ATCCTGAGAAAGGCGACAGA 
c-myc sibling screen rev AAGGACAAGGCAGGGCTATT 
MITF_screen_FOR AGGGGAAGCCTGATGTCTTT 
Stat5ab/a_N646H_For GCAGGTGAGCGAATGGTCTGGCATTTAATGCCATACACA
ACCAAA 
Stat5ab/a_N646H_Rev TTTGGTTGTGTATGGCATTAAATGCCAGACCATTCGCTCA
CCTGC 
Stat5ab/b_N647H_For CAAGGGGAAAGACTGGTATGGCACTTATTACCGTACACC
ACCAAA 
Stat5ab/b_N647H_Rev TTTGGTGGTGTACGGTAATAAGTGCCATACCAGTCTTTCC
CCTTG 
Stat5ab/a_neg_Rev TCATGAGGCGCCTTGATCCA 
Stat5ab/b_neg_Rev TCACAGGATGTTGTCACCGACC 
mdk_cmyc20_gap_for CCAAGCTGAAGAAGGTGGTC 
mdk_cmyc20_gap_rev TCCTCTTCCTCCTGGTCCTC 
 
2.7.2 Oligonucleotides used for quantitative real-time PCR 
 
Primer Sequence (5`-3`) ENSEMBL code 
Stat5ab/a_rt_for AGTGTCGGAAGCAACGAACT ENSORLG00000003961 
Stat5ab/a_rt_rev CCGGTAGTCGTCAGGATTGT  
Stat5ab/b_rt_for ACGGGAGTCAGGACAACAAC ENSORLG00000014335 
Stat5ab/b_rt_rev GCGGCTTCAGATGTTTCTTC  
BRAF_rt_for GCCTGGCAACAGTCAAATCT ENSORLG00000009843 
BRAF_rt_rev ACAGTCAGCCATCAGCCTCT  
CDKN2_rt_for ATGATGATGGGGAACTCCAA Primer from Brigitta Wilde  
CDKN2_rt_rev GATGTTCACCGAAGCTCCAT  
ef1a1_rt_for GCCCCTGGACACAGAGACTTCATCA ENSORLG00000007614 
ef1a1_rt_rev AAGGGGGCTCGGTGGAGTCCAT  
ODC1_rt_for TGACAATGCCAAACTGGTGT ENSORLG00000017758 
ODC1_rt_rev CCAGCTCCTCACCCATATCA  
CBX3_rt_for CGTCTCGTCAATGGGAAAGT ENSORLG00000007692 
CBX3_rt_rev TGTCTCTGGCTCATCTGTGG  
CCT5_rt_for GGTAAATCGGGCTGCAGATA ENSORLG00000007700 
CCT5_rt_rev GCTTTTTGGCGATCAGAGTC  
EIF3S8_rt_for GGAGAGGAACGCAGAACAAG ENSORLG00000006318 
EIF3S8_rt_rev GTGATGGAACTGCTTGCTGA  
METTL1_rt_for ACCCAGGGAGTTATGGGAAC ENSORLG00000015181 
METTL1_rt_rev  GTGTACACCAAACCCCCAAC  
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2.8 Plasmids 
2.8.1 Standard vectors 
 
Vector Properties Promoter Reference/Supplier 
pCR® 2.1-TOPO® Amp, Kan T7, T3, Sp6, M13fwd, 
M13rev, Kan 
Invitrogen 
pI-SceI MITF  MITF From Isabell Erhard 
pCDNA3 Amp CMV Invitrogen 
pCSKA Estrogen receptor unknown From Manfred Gessler 
 
2.8.2 Vectors generated in this work 
Plasmid Cloning strategy/reference 
BRAF pCR2.1 Chapter 4.1.1.1 
BRAF V614E pCR2.1 Chapter 4.1.1.2 
BRAF pI-SceI Chapter 4.1.1.3 
BRAF V614E pI-SceI Chapter 4.1.1.3 
BRAF pCDNA3 Chapter 4.1.1.3 
BRAF V614E pCDNA3 Chapter 4.1.1.3 
Stat5ab/a pCR2.1 Chapter 4.2.1.1 
Stat5ab/a N646H pCR2.1 Chapter 4.2.1.3 
Stat5ab/a DN pCR2.1 Chapter 4.2.1.3 
Stat5ab/a pI-SceI Chapter 4.2.1.4 
Stat5ab/a N646H pI-SceI Chapter 4.2.1.4 
Stat5ab/a DN pI-SceI Chapter 4.2.1.4 
Stat5ab/b pCR2.1 Chapter 4.2.1.2 
Stat5ab/b N647H pCR2.1 Chapter 4.2.1.3 
Stat5ab/b DN pCR2.1 Chapter 4.2.1.3 
Stat5ab/b pI-SceI Chapter 4.2.1.4 
Stat5ab/b N647H pI-SceI Chapter 4.2.1.4 
Stat5ab/b DN pI-SceI Chapter 4.2.1.4 
c-myc17-ER pCSKA From Cornelia Schmidt 
c-myc17-ER pI-SceI Chapter 4.3.1 
  
2.9 Bacteria strains 
Strain Properties Supplier 
XL1-
blue 
recA1, lac-, endA1, gyrA96, thi, hsdR17 (rk-, mk+), supE44, relA1, 
λ-, 
[F',proAB, lacIqZ, ∆M15, Tn10 (tetr)] 
NEB 
DH5α supE44 ∆lacU169 (φ80laxZ∆M15) hsdR17 recA1 endA1 gyrA96 
thi-1 relA1 
NEB 
 
2.10 Eukaryotic cell lines 
Strain Souce/Reference 
Melan A Bennett et al, 1987 
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2.11 Hardware 
Microsoft system 
 
2.12 Softwares 
Word-processing Microsoft Word 2007 (Microsoft) 
 Ultraedit-32 (IDM Computer Solutions) 
Graphics CorelDRAW X4 (Corel) 
 ImageJ (NCBI) 
 NIS elements imaging software 
Statistics Microsoft Excel 2007 (Microsoft) 
Vector database Vector NTI advance 10 (Invitrogen) 
Sequence alignment  BioEdit and ClustalW 
Phylogenetic analysis Mega 5.0 
Bibliography Mendeley Desktop (Mendeley Ltd.) 
 
2.13 Internet resources 
ENSEMBL http://www.ensembl.org/index.html 
NBRP medaka http://www.shigen.nig.ac.jp/medaka/ 
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3. METHODS 
 
3.1 Animal maintenance 
Wild type medaka embryos (Oryzias latipes) of the carbio strain (WLC# 2674) were raised as 
described by Kirchen and West (1976) under standard laboratory conditions at 26°C. Embryos 
were staged by morphological characteristics according to Iwamatsu (2004). All procedures 
involving experimental animals were performed in compliance with local animal welfare laws, 
guidelines and policies. 
 
3.2 Microbiological methods 
3.2.1 Sterilization 
 
Solution, media and buffers were sterilized by autoclaving at 121 °C and 138 kPa for 80 min. 
 
3.2.2 Bacterial cultivation and long time storage 
 
For bacteria cultivation, Luria-Bertani (LB) medium was used containing appropriate 
concentrations of antibiotics (60µg/ml ampicillin or 50 µg/ml kanamycin) for colony selection 
according to vector requirements. Cultivation was performed over night at 37°C with permanent 
shaking.  
 
Luria-Bertani-medium (LB) 
10g/l bacto-tryptone 
  5g/l bacto-yeast extract 
10g/l NaCl 
After dilution in dH2O,  a pH 7.4 was adjusted and the solution was autoclaved 
 
 
For long term storage of bacteria, 800µl of a freshly prepared bacteria suspension were mixed 
with 200µl sterile glycerol in a safe lock vial, frozen in liquid nitrogen and stored at -80°C. 
 
3.2.3 Preparation of competent E.coli cells 
 
For production of chemically competent bacteria, a single colony from XL1-Blue or DH5 grew 
overnight in 1ml LB medium. The next day, this 1ml culture was added into 100 mL of LB 
medium and incubated under constant shaking at 37°C until optical density (OD600) reached a 
value between 0.3 and 0.5. After 15 min incubation on ice, the solution was centrifuged for 10 
min at 4°C 600 rpm. The supernatant was discarded and the pellet was resuspended in 20 ml ice-
cold 0.1 M calcium chloride solution. After 30 min incubation on ice, the bacteria solution was 
centrifuged for 10 min at 4°C 600 rpm. Then, the supernatant was discarded again and the 
bacteria pellet was resuspended in 10 ml of ice-cold 0.1 M calcium chloride/20% glycerol 
solution. The competent bacteria were divided into 250 µl aliquots and stored at -80°C.  
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3.2.4 Transformation of competent bacteria 
 
For plasmid transformation into chemically competent bacteria cells, 100 µl competent bacteria 
thawed on ice and 1-10 ng of DNA plasmid were added to it. After 30 min of incubation on ice, a 
heat-shock was performed at 42°C for 90 seconds, followed by another step on ice, this time for 2 
min. Subsequently, 1 ml LB-medium was added and the bacteria were incubated for 1h at 37°C 
under constant shaking. For selection, this solution was platted on LB-agar plate containing the 
appropriate antibiotic (60µg/ml ampicillin or 50 µg/ml kanamycin). For blue-white selection, 40 
µl of 40 mg/ml IPTG and 40 µl 20mg/ml of X-gal were spread 20 min before use on top of the 
plates. Agar plates were incubated ON at 37°C. Plasmid DNA was isolated using gen Elute 
plasmid mini-prep kit (Sigma-Aldrich).  
 
LB agar 
 
15g/liter bacto-agar dissolved in LB medium 
 
After autoclaving and LB agar medium cooled down to 40°C, I added desired antibiotics (60µg/ml 
ampicillin or 50 µg/ml kanamycin). Subsequently liquid LB agar was poured into petri dishes and 
cooled down to RT to polymerize. 
 
3.3 Cloning 
 
Cloning of full length medaka BRAF, Stat5ab/a and Stat5ab/b coding sequence (CDS) were 
performed with Pfu DNA polymerase (5U/µl, Fermentas) using cDNA pool from different 
medaka organs. Before the last amplification step, 0.3µl of dream Taq (5U/µl, Fermentas) was 
added to the reaction to add an adenine overhang for cloning purpose. Each gene was cloned in 
three parts into the plasmid pCR 2.1-TOPO (invitrogen).  
 
Full length CDS medaka c-myc, of the gene copy present on chromosome 17, was PCR amplified 
and further sub-cloned into the vector pCSKA containing the mouse estrogen receptor. This work 
was done by Cornelia Schmidt from Manfred Schartl’s laboratory, who kindly provided me the 
vector to work with.  
 
3.3.1 Sequencing 
 
Each cloned fragment, as well as full length sequences from all genes cloned in this work, was 
confirmed by DNA sequencing carried out by GATC biotech. 
 
3.3.2 Ligation 
 
For ligation reaction, 2 to 5U of T4 DNA Ligase (Fermentas) were incubated with corresponding 
buffer either at RT for 2 hours or ON at 16°C. 
 
 40 
 
3.3.3 Enzymatic DNA digestion 
 
For enzymatic digestion of DNA fragments or plasmids, 2 to 5U of restriction enzymes from 
different companies for 1 µg of DNA were incubated with corresponding buffers at optimal 
temperatures according to manufacturer’s standards for 1 to 10 hours.  
 
3.3.4 Oligo cloning to include HA and Flag tags 
 
Oligos were designed with respective 5’ prime overhang for desired restrictions enzymes. Primers 
were annealed as follows: 5µl of each primer (100µM in ddH2O) were heated up to 95°C for 300 
sec, and then temperature was slowly decreased until 20°C (minus 5°C each 30 sec). Plasmids 
were cut with corresponding restriction enzymes and precipitated as follows: 
  
  15µl of cut plasmid (~1µg)  
1.5µl 3M NaOAC  
 45µl 100% EtOH  
 
This solution was incubated for 1 hour on ice. After 30 min 14000 rpm (in Centrifuge 5415R with 
rotor F45-24-11, Eppendorf) centrifugation, the supernatant was discarded. The next step was to 
wash with 70% EtOH, centrifuge 15 min 14000 rpm and discard supernatant. The DNA pellet 
was air dried and dissolved in annealed oligonucleotides. After that, 5U of ligase (Fermentas) and 
1.2 µl of corresponding ligase buffer were added. The solution was left ON at RT. On the next 
day, 2µl or 5 µl of this ligation were transformed into competent bacteria and plated for screening. 
 
3.3.5 Site directed mutagenesis 
 
To be mutagenized, genes were amplified in two PCR reactions, one amplifying from the ATG 
Start codon until 21 nucleotides downstream the codon to be mutated, which introduces a 
mutation during the first cycle of the reaction by an engineered mis-match. The second PCR was 
performed using primers binding 21 nucleotides upstream the codon to be mutated until the stop 
codon, also introducing the desired mutation. Because PCR employs exponential growth, after a 
sufficient number of cycles the mutated fragment will be amplified sufficiently to jut from the 
original. Both PCR fragments were purified from a TAE gel using GenElute™ Gel Extraction Kit 
(Sigma-Aldrich). Both purified PCR fragments containing the desired mutation were used as 
template for a new PCR reaction to amplify full length gene containing the desired mutation that 
leads to specific amino acid change. 
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An example of the first PCR reactions, where the whole gene is amplified in two different 
fragments to add the mutated nucleotide is listed above: 
 
16.875µl  H2O 
      2.5µl  Buffer (Pfu buffer, Fermentas) 
         1µl  MgSO4 (25mM) 
         1µl DNTP (2.5mM) 
         1µl Primer forward (10pMOL) 
         1µl Primer reverse (10pMOL) 
         1µl cDNA (1µg/20µl) 
      0,5µl DMSO 
  0.125µl Pfu Polymerase (5U/µl) 
 
An example of the second PCR reaction, where the purified PCR products are used as a template 
to amplify the whole gene bearing the mutated nucleotide is listed above.  
 
23.75µl  H2O 
       5µl  Buffer (Pfu buffer, Fermentas) 
       4µl  MgSO4 (25mM) 
       5µl Purified PCR product from ATG to mutagenizing primer 
       5µl Purified PCR product from mutagenizing primer to stop codon 
       2µl Primer forward (10pMol) 
       2µl Primer reverse (10pMol) 
       2µl DNTP (2.5mM) 
       1µl DMSO 
  0.25µl Pfu Polymerase (5U/µl) 
 
A standard program for the PCR thermo cycler for both reactions was: 
 
reaction step temperature time 
pre-heating 95°C 5` 
denaturation 95°C 30s 
primer anealing 50-62°C 30s         40x 
elongation 72°C 180s 
final elongation 72°C 5` 
 
 
Oligonucleotides were engineered for mutagenesis as follows. Each primer was comprised of 45 
nucleotides corresponding to the codon to be mutated and nucleotides corresponding to 7 codons 
downstream and 7 codons upstream of the targeted amino acid to be mutated. The nucleotides 
corresponding to the 5 first and the 5 last amino acids were 100% conserved to the template. The 
nucleotides corresponding to the 5 amino acids in the middle of the primer should be as different 
as possible without changing the codon sequence, except for the amino acid to be mutated. The 
reason for this is to avoid hybridization of the original sequence (without the mutation) in the 
second round of PCR to amplify the full length sequence.  
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3.4 Molecular biology standard methods 
3.4.1 Plasmid DNA amplification and isolation  
 
For plasmid DNA amplification, a single colony was selected from agar plates. Overnight 
bacterial cultures were set up for mini-preparation using GenElute™ HP Plasmid Miniprep Kit 
from Sigma-Aldrich according to manufacturer’s protocol. Purified DNA was dissolved in 50µl 
of deionized water. 
 
3.4.2 DNA purification  
 
For purification from PCR reactions and cleaning of DNA from solution containing proteins, ion 
and other impurities GenElute™ PCR Clean-Up Kit (Sigma-Aldrich) was used according to 
manufacturer’s protocol. 
 
3.4.3 DNA extraction 
 
For genomic DNA extraction from 30-50 medaka embryos of a desired age were collected into 
eppendorf tubes and homogenized in 150µl homogenizing buffer using micropestils. After 
solution was looking homogenous, 350µl of lysis buffer was added and solution was incubated at 
65° for 15 min. After incubation, 250µl of Phenol and 250µl of Chloroform was added and 
solution was left under constant rocking for 10 min. Solution was centrifuged for 10 min at 4000 
RPM in a table top centrifuge and the supernatant was transferred to a new tube. For precipitation, 
350µl of Isopropanol was added and solution was kept for 2 hours on ice. Centrifugation at 4000 
rpm at 4°C for 10 min followed by 45 minutes at 13000 rpm was conducted for gDNA 
precipitation. DNA was washed once with 70% EtOH (in H2O). After the DNA pellet was dry, 
DNA was resuspended in 50µl of dd H2O.    
 
3.4.4 RNA extraction 
 
For RNA extraction from medaka embryos 30-50 eggs of desired age were collected into 
eppendorf tubes and homogenized with solution D using micropestils. 20 µl of 2M sodium acetate 
(pH 4.0) and 200 µl of water saturated phenol and 100 µl Chloroform were added and samples 
were vortexed. Samples were incubated on ice for 20 min and centrifuged at maximum speed (in 
Centrifuge 5415R with rotor F45-24-11, Eppendorf) for 10 min. Supernatant was taken to another 
eppendorf reaction tube, washed with ethanol and ressuspended in 25 µl DEPC H2O. About 1µg 
of RNA was added in DNAse master mix for treatment with DNAse for 30 min at 37°C. 
 
Solution D 23.4g    quanidine thiocyanate 
 1.67ml  750 mM sodium citrate 
   2.5ml  10% sarkosyl 
  27.8ml  ddH2O 
         add 7.2µl/ml Beta-mercaptoethanol just prior to use 
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DNAse Master-Mix   10µl  DNAse buffer (Fermentas) 
 
    5µl  DNAse (1 U/µl, Fermentas) 
 2.5 µl  RNAse inhibitor (Fermentas) 
  add ddH2O to 100µl 
 
For RNA extraction from different tissues, medaka fishes were anesthetized with tricaine 
(100mg/L, MS-222, Sigma) and subsequently killed. Selected organs were homogenized in 100µl 
peqGOLD trifast with the Ultra-Turrax and centrifuged 10 min 12000 rpm at 4°C. Supernatant 
was removed to a new eppendorf tube and 200 µl of chloroform were added. After 30 sec of 
shaking, samples were incubated on ice for 3 minutes followed by 15 min centrifugation 12000 
rpm at 4°C. Supernatant was removed to a new eppendorf tube, precipitated with 500µl 
isopropanol and ressuspended in DEPC H2O.  
 
3.4.5 DNA and RNA concentration determination 
 
The concentration of nucleic acids was determined by measuring the absorption of an aqueous 
solution at a wavelength of 260 nm using a spectrophotometer. The absorption spectrum was 
measured at the range of 240 to 320 nm after having calibrated the photometer with pure water. The 
concentration (c) of the original solution was calculated by the following formula: 
 
DNA c = 50 x A260nm x dilution factor [µg/ml] 
RNA c = 40 x A260nm x dilution factor [µg/ml] 
 
3.4.6 Polimerase chain reaction (PCR) 
3.4.6.1 Standard PCR procedure 
 
PCR was used for amplification of cDNA, plasmid or genomic DNA templates. PCR reactions 
were performed using either Dream Taq polymerase (Fermentas), PFU polymerase (Fermentas) 
or ReproFast polymerase (Genaxxon). Primers used for PCR reaction are listed in the section 
2.7.1 in materials.  
      2.5µl buffer (Fermentas) 
0.5-1.5µl ethylene glycol or DMSO 
   0.5-1µl DNTP (each nucleotide at 2.5mM) 
0.5-1.5µl MgCl2 (50mM) 
 0.75-1µl primer forward (10pMol) 
 0.75-1µl primer reverse (10pMol) 
 0.25-1µl cDNA/gDNA 
  To 25µl H2O 
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A standard program for the PCR thermo cycler was: 
 
reaction step temperature time 
pre-heating 95°C 5` 
denaturation 95°C 30s 
primer anealing 50-62°C 30s               30-40x 
elongation 72°C 25-300s 
final elongation 72°C 5` 
  
A template for PCR reaction is listed above. The amount of ethylene glycol, DMSO, MgCl2, 
primers and DNA used as well as the temperature were optimized for each PCR reaction.  
 
3.4.6.2 Agarose gel electrophoresis 
 
Electrophoretic separation of RNA and DNA was performed in 1% up to 2% (w/v) agarose gels. 
Samples containing DNA were mixed with 10 x DNA sample buffer and loaded into the gel. Gel 
run was carried out at 80 to 200 V in an electrophoresis chamber containing 1x TAE-buffer. RNA 
samples were mixed with “Gel Loading Buffer II” (Ambion) and denatured at 70°C for 10 min 
before loading to gel. After separation, DNA and RNA were bathed for 5 to 15 min in EtBr for 
visualization on an UV-transilluminator at a wavelength of 254 nm. 
 
(10x) DNA loading buffer 25mg  bromphenol blue 
 25mg  xylene cyanol 
    3ml glycerol 
    2ml 0,5M EDTA 
    1ml 10% SDS 
  Add ddH2O to achieve final concentration of 10ml 
   
(50x) TAE buffer  242g tris base 
 57.1ml acetic acid 
  100ml 0,5M EDTA 
  Add ddH2O to achieve final concentration of 1 litre  
 
3.4.6.3 Gel extraction of DNA fragments 
 
To purify DNA fragments separated by gel electrophoresis, the desired band was cut out of the 
gel and extracted with GenElute™ Gel Extraction Kit (Sigma-Aldrich). Purified DNA was 
dissolved in 10 to 20 µl ddH2O. 
 
3.4.6.4 cDNA synthesis 
 
Single stranded cDNA was synthesized using 1µg of RNA using RevertAid TM First Strand cDNA 
Synthesis Kit (Fermentas) using oligo dT primers according to supplier’s protocol. 
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3.4.6.5 Quantitative Real Time PCR (qPCR) 
 
For qPCR detection primers were developed flanking the fusion point of exon/intron boundaries. 
cT values were relatively calculated to the house keeping gene ef1a1 (ENSORLG00000007614). 
All qPCR experiments were performed in MyiQTM Single-color Real-time PCR Detection system 
(Bio-Rad). Primers used in qPCRs are listed in the section 2.7.2 in materials. 
 
A standard qPCR mix consisted of: 
 
17,75µl H2O 
1 µl MgCl2 (50mM) 
0,7 µl DNTPs (10mM each) 
0,75 µl SYBR green (1:2000 in DMSO) 
0,25 µl Fitc (1:2000 in DMSO) 
2.5 µl 10X PCR buffer (Fermentas) 
0,3 µl Dream Taq-Polymerase (Fermentas) 
0,75 µl Primer fwd 
0,75 µl Primer rev 
0,25 µl Template 
 
A standard program for the qPCR thermo cycler was: 
 
95°C 3 min 
95°C 10s         40 
60°C 30s       cycles 
with subsequent melting curve analyses 
 
The different amount of target, normalized to the endogenous reference (ef1a1) and relative to a 
calibrator, is given by: 2-∆∆Ct. Where: ∆∆Ct = ∆Ct sample – ∆Ct reference control.  
 
3.4.6.6 Genotyping from fin biopsies 
To genotype adult fishes, gDNA was extracted from sectioned tail fin tissue. Therefore, fishes 
were anesthetized with tricaine (100mg/L, MS-222, Sigma -Aldrich ) and the posterior part of the 
pectoral fin was cut using scissors. Tissue was digested in digestion solution (5% chelex (w/v; 
Bio-Rad) in H2O; just before use, 10µg/µl proteinase K was added). Fins were kept for 1h at 
55°C, followed by 10 min at 95°C. For PCR reaction 1µl supernatant of this digested solution was 
used as DNA template.  
 
A standard mix for PCR for genotyping consisted of: 
      2.5µl buffer (Fermentas) 
0.5-1.5µl ethylene glycol or DMSO 
   0.5-1µl DNTP (each nucleotide at 2.5mM) 
0.5-1.5µl MgCl2 (50mM) 
 0.75-1µl primer forward (10pMol) 
 0.75-1µl primer reverse (10pMol) 
 0.25-1µl cDNA/gDNA 
  To 25µl H2O 
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3.4.7 Synthesis of labelled RNA probes for in situ hybridization 
Plasmids containing the 600 to 900 base pairs of genes of interest were linerized for antisense 
probes at 5`end and for control sense probes at the 3`end. After checking of digestion efficiency 
on agarose gel, linerized plasmids were extracted by phenol-chloroform. DNA was precipitated 
with 3M NaOAc and again checked on agarose gel. Reverse transcription was performed as 
follows: 
 
       2µg  template 
       2µl  Dig/Flu RNA labeling mix (Roche) 
    0.5µl  RNAse Inhibitor (Roche) 
       2µl  10x transcription buffer (Roche) 
       1µl  T7/Sp6 polymerase (5U/µl, Roche) 
To 20µl  H2O 
  
After 2h at 37°C 1µl of DNAse was added and the solution was kept for 30 min at 37°C. 
Ripobrobes were purified with the NucleoSpin RNA clean up kit and eluted in 50µl H2O. After 
checking correct RNA synthesis on an agarose gel, riboprobes were filled up to 100µl with 
Hybmix and stored at -20°C. 
 
Hybmix  50% (w/v) formamid  
 5% (w/v)   1x SSC 
 0,1% (w/v) Tween 20 
   5mg/ml Heparin 
 150µg/ml   Torula-RNA  
 
3.4.8 Whole mount in situ hybridization (ISH) 
One color RNA in situ hybridization was performed according to protocol described by 
Hauptmann and Gerster (1994) with RNA probes digoxigenin-UTP (DIG-UTP) or fluorerscein-
UTP (FLU-UTP) to visualize gene expression. Embryos were fixed at desired time point of 
development with 4% paraformaldehyde (PFA) in phosphate buffered saline (PBS) solution at 
4°C over night. Chorions were removed and PFA was replaced by MetOH for long time storage. 
Embryos were rehydrated and were digested with proteinase K at RT. Hybridization was 
performed ON at 65°C. In the next day, washes in 50% Formamid in 2x SSCT, 2x SSCT and 0,2x 
SSCT were performed also at 65°C.  
 
Embryos were incubated 1h in blocking solution, and afterwards, with first AB (sheep anti- 
fluorescein or anti-digoxigenin, dilution 1:2000, Roche) at 4°C ON. Then, embryos were washed 
six times in PBST for 20 min each and two times in staining buffer. For staining, embryos were 
incubated in the dark with staining solution up to 48 hours. 
 
10x PBS (1 liter) 1M NaCl (58.44g) 
 19.5mM KCl (1.45g) 
 59mM Na2HPO4 (10.5g) 
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20x SSC (1 liter) 175.3g NaCl 
 88.2g sodium citrate 
  
1x SSCT 10ml 20x SSC 
 190ml ddH2O 
 0,1% (w/v) tween 20 
  
1x PBST (1 liter) 100ml 10x PBS 
 5mL 20% Tween20 
  
75%, 50%, 25% Methanol in PBST  
  
50% Formamid in 2x SSCT (100mL) 10ml 20x SSCT 
 500µl 20% Tween 20 
  
Proteinase K 5µl Proteinase K (10mg/mL) in 1 ml 1x PBST 
  
4% PFA 3ml 16% PFA (80g to 500mL H2O) in 9ml PBST 
  
1x glycine 1M glycine in PBST 
  
blocking solution 1:20 dilution of sheep serum (Sigma-Aldrich ) in 
PBST 
  
staining buffer     1ml 5M sodium chloride 
 2,5ml 1M Magnesium chloride  
    5ml 1M Tris-Cl pH 9.5  
 0,1% Tween 20 
 Add H2O to 50ml 
  
staining solution  20µl NBT/BCIP (Roche) in 1mL staining buffer 
   
3.4.9 Cell culture 
3.4.9.1 Primary cell culture 
 
Anal medaka fins were cut from anesthetized fishes from both c-myc17 lines and wild type and 
immersed in PBS containing 0.4% Sodium hypochlorite for 30 seconds. Tissues were rinsed three 
times in PBS and minced into small fragments. PBS was replaced by Leibovitz L-15 medium 
(Invitrogen). Tissues fragments were cultivated in a gelatin-coated µ-slide 8 well (IBIDI) 
containing 300µL of the culture medium. The culture was incubated at 28°C for five days and 
fixed with 2% Formaldehyde. 
 
Leibovitz L-15 medium To 200mL 
 176mL L-15 medium 
     2mL glutamin 
     2mL Pen-Strep (100u/mL-100µg/mL, Invitrogen) 
   20mL FCS gold (20%, PAA) 
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3.4.9.2 Mouse melanocyte cell culture 
 
Melan A cells were originally derived from C57BL/6 J (black a/a) mice, originating from Prof. 
Dorothy C. Bennett lab (St, George`s Hospital, London, UK). Melan A cells were cultivated in 
DMEM medium. To passage Melan A cell line, cells were washed with PBS, treated with trypsin-
EDTA for 3-5 min and splited. Cultures were kept in an incubator at 37°C in a humidified 
atmosphere with 5% CO2. Prior to cell harvesting to check constitutively activity of BRAF 
V614E cells were cultivated in starving medium for 2 hours. 
 
DMEM medium To 500 ml 
     440,5ml DMEM 
          50ml FCS (10%) 
           5 ml 10x  Pen/Strep (1x) 
        2,5 ml TPA from 40 µM stock solution (200nM) 
        2,0 ml Choleratoxin from 25 µg/ml stock solution (0,1 µg/ml) 
  
Starving medium DMEM 
 2,5% dialysed FCS 
 
3.4.9.3 Mouse melanocyte cell transfection  
 
Plasmids BRAF pCDNA3 and BRAF V614E pCDNA3 (2µg of each) were transfected to Melan 
A cells using FuGENE HD transfection reagent (Roche) in 6 well plates containing 1x105 cells 
according to supplier`s protocol. 
 
3.4.10 Western Blot  
 
Total protein was prepared from hatched medaka embryos or from cell pellets. Embryos were 
kept for 2 hours in lysis buffer in ice for lysis. Protein concentration was measured by adding 1µl 
of protein lysate in ml of Brafford reagent (Sigma) and measured at the spectrophotomer. Before 
loading protein samples were kept with 1x Laemmli buffer at 95°C for 10 minutes. A total of 
50µg of protein lysate was separated by 10% SDS/PAGE gel for 3 to 4 hours at 25mA. After the 
run proteins were transferred to a nitrocellulose membrane according to standard western blotting 
protocols (Sambrook et al, 1989). For testing constitutively activity of BRAF V614E anti-
phospho MAP kinase was used. For checking if c-myc transgenic lines are producing the fused 
protein an anti-ER antibody (1:500, santa cruz) was used. For both experiments, anti-beta-Actin 
(1:10000, Santa Cruz) was used as positive control. Peroxidase-coupled anti-mouse (1:3000, 
Thermo Scientific) and anti-rabbit (1:10000, Bio-Rad) were used as secondary antibodies. 
   
Nonidet-P40 (NP40) 20mM HEPES pH 7.9 
 500mM  NaCl 
 5mM MgCl2 
 5mM KCl 
 1% Nonidet-P40 
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Lysis buffer 0,5% (NP40) 
 0.1% deoxycholate 
 10µg/ml  Aprotinin  
 10µg/ml  Leupeptin  
  200µM  Na3VO4 
     1mM  PMSF 
 100mM  NaF 
   
10x TBS 100mM Tris pH 7.9 
 1,5M NaCl 
   
10% polyacrylamide gel 4152µl H2O 
 2125µl 1,5M TrisHCl pH 8.8 
 2138µl Acrylamid 40 (37,5:1) 
     85µl 10% SDS 
  42,5µl 10% APS 
   8,5 µl TEMED 
   
4% Stacking gel 1408µl H2O 
   550µl 0,5M TrisHCl pH 6.8 
   220µl Acrylamid 40% (37,5:1) 
     22µl 10% SDS 
     11µl 10% APS 
    2,2µl TEMED 
   
SDS gel loading buffer (2x) 100mM Tris-Cl (pH 6.8) 
 200mM Dithiothereitol 
 4% SDS 
 0,2% Bromophenol blue 
 20%  glycerol 
   
   
5x Blotting buffer  125mM Tris 
 960mM Glycine 
   
5x SDS running buffer 250mM Tris 
 192mM Glycine 
 0,5% SDS 
 
   
Transfer buffer 39mM Glycine 
 48mM Tris base 
 0,037% SDS 
 20%  methanol 
   
5x Laemmli buffer 312,5mM Tris pH 6.8 
 50% Glycerin 
 10% SDS 
 0.005% bromophenol blue 
 Add H2O to 75ml  
 25% ß-mercapthoethanol 
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3.4.11 4-OHT treatment for C-myc induction 
 
4-Hydroxytamoxifen (4-OHT; H7904; Sigma-Aldrich) was dissolved in ethanol at a final stock 
concentration of 10mM and kept in dark at 4°C. To induce the estrogen receptor coupled C-
myc17 activity, transgenic adult fishes were kept continuously in tap water (pH 7) containing 
1µM of 4-OHT in the dark for forty eight hours. To validate the effect of long C-myc17 
activation, fishes were kept for four weeks in water containing 1µM of 4-OHT, with medium 
changes after 3 days. To induce c-myc17 activity in primary cell culture, L-15 medium was mixed 
with 1µM of 4-OHT for twenty four hours. 
 
3.4.12 Paraffin embedding  
Adult fishes were anesthetized, killed and fixed ON in 4% PFA. Fixed fishes were kept in 
decalcification solution (10% Formic acid, 10% Formalin, 80% H2O) for 24 hours followed by 2 
times 10 minutes washes with PBS and 1 time 10 minutes at 0,9% NaCl in room temperature. For 
dehydration fishes were transferred every 2 hours in solutions containing different proportions of 
isopropanol (30%, 50%, 70%, 85%, 95% and 100% of isopropanol in H2O, respectively, 2 hours 
each) in room temperature. Dehydrated fishes were transferred to a 1:1 (v/v) 
isopropanol/chloroform solution followed by chloroform for 2 hours each in room temperature. 
The next step was to transfer the fishes to a 1:1 (v/v) chloroform/paraffin solution at 60°C. The 
last step was to transfer fishes to paraffin and let it cool until room temperature. Paraffin 
embedded fishes were kept in 4°C until myotome sectioning, where 6µm thick sections were 
produced.  
 
3.4.13 Hematoxylin and eosin (HE) staining 
 
For histological analysis of paraffin sections, fishes were stained with haematoxylin and eosin 
(HE). Slides were kept for 30 min at 68°C to melt the paraffin. After 2 times 5 min bath in xylene, 
slides were transferred to a glass coplin jar containing 100%, 95%, 80% EtOH in H2O for 2 min 
each, respectively. Slides were stained in haematoxylin for 2 to 5 min and bathed in warm water 
for 10 min. After that, slides were stained with eosin for 3 to 5 min and dehydrated with a fast 
rinse in H2O, 30%, 50%, 70%, 85%, 95% and 100% of EtOH in H2O, respectively. Glass slides 
were mounted with Roti® Histokit II (Roth). Hematoxylin and eosin solutions were kindly 
prepared by Robin Wacker, Biozentrum, University of Würzburg. 
 
Hematoxylin 50g potassium 
 1g haematoxylin 
 0.2g sodium iodate  
 1g citric acid 
 To 1000 ddH2O 
   
Eosin 10g Eosin y 
 200ml ddH2O 
 800ml 95% EtOH inH2O 
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3.4.14 Proliferation and apoptosis assays 
 
For the in vivo analysis of BrdU incorporation and apoptosis detection liver and gills from adult 
fishes were fixed for two hours in 10% neutral buffered formalin (RT or 4°C). For in vivo and 
primary cell apoptosis detection TUNEL assay was performed using ApopTag Red In Situ 
Apoptosis Detection Kit (Milipore) according to manufacturer’s protocol. For detection of 
proliferating cells, adult fishes were bathed in a solution of 1g/L BrdU (Sigma-Aldrich) in 
aquarium water for five hours before dissection of organs. BrdU assays were performed using 
anti-BrdU antibody (1:250, serotec) and anti-rat 458 secondary antibody (1:250, serotec).  
 
3.4.15 Nuclear translocation assay 
 
Primary cell culture from medaka anal fins were cultured with 4-OHT (1mM, soluted in L-15 
medium) for 2 hours and fixed with 2% formaldehyde. Nuclear translocation assays were 
performed using anti anti-ER antibody (Santa Cruz). Nuclei were counter-stained with Hoechst 
33342 fluorescent stain (Invitrogen). Imaging was done with Nikon eclipse Ti confocal 
microscope and NIS elements imaging software. Translocation ratio was calculated by the 
following formula: FInucleus – FIcytoplasm. FI indicates fluorescence intensity. 
 
3.5 Generation of transgenic lines  
To obtain freshly fertilized eggs male and female fishes were separated in different tanks the 
evening before injection. At the next day, 2 males were put together in tanks containing 3 to 5 
females. 30 to 45 min later each female laid eggs, which were kept attached to the belly of the 
females. Freshly laid eggs were transferred into Petri dishes with fresh 0,3x Danieau`s medium. 
The injection dish was freshly made from 2% agarose in 0,3x Danieau`s medium.  
 
Medaka transgenics were generated using the Meganuclease (I-SceI) technology (Thermes et al, 
2002). One-cell-stage eggs were injected with the following solution: 10 ng/µl of plasmid, 1x 
Tango buffer (Fermentas), 0.35 U/µl of I-SceI (Fermentas). Injection solution was incubated for 
30 min at 37°C. Before injection 0.1% phenol red for visualization and 0.2% Fitc-dextran (Sigma-
Aldrich) for screening of positive injected were added to the solution. Approximately 500pl of 
DNA solution was directly injected through the chorion into the cytoplasm of the first cell.  
 
Injected embryos were transferred to a new Petri dish with fresh 0,3x Danieau`s medium and 
incubated at 28°C. After injection, embryos were controlled for positive injection, by fluorescence 
of Fitc-dextran. Positive injected embryos were sorted under the fluorescent microscope and 
raised for further investigations and breeding. Visual control of dead or mal-formed embryos was 
performed every day. Embryos were raised to sexual maturity followed by sibling screening for 
transgene integration by fin clipping as described in section 3.4.6.6. 
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1x Danieau`s  58 mM  sodium chloride 
 0,7 mM potassium chloride 
 0,4 mM magnesium sulfate 
 0.6 mM calcium nitrate 
 0.5 mM HEPES 
 0,1% methylen blue 
   
0,3x Danieau`s 30%  Danieau`s in H2O 
 
3.6 Phylogenetic methods and alignments 
 
Sequence alignments were generated applying BioEdit (Hall, 1999) and ClustalW (Thompson et 
al, 1994). Maximum likelihood analysis was performed using Mega 5.0 software according to a 
JTT model of amino acid substitutions. Confidence of each node was confirmed by 100 bootstrap 
replicates. Analysis of c-myc gene synteny was performed utilizing the ENSEMBL database and 
the synteny database (Catchen et al., 2009). 
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4. RESULTS 
4.1 BRAF  
BRAF is a serine threonine kinase found mutated in high incidence in human tumours like 
malignant melanoma and thyroid cancer (Garnett and Marais, 2004). A deeper understanding of 
BRAF biology will help to elucidate its function in cancer initiation and progression and will 
open up the possibility to further investigate BRAF as a possible target for cancer therapy. To 
gain new knowledge on BRAF function I have identified and cloned for the first time the medaka 
braf gene. 
 
4.1.1 braf cloning and sequence analysis 
4.1.1.1. Full length Medaka braf cloning 
 
Initial investigations of published database sequence information showed that Medaka BRAF 
sequence in ENSENBL database (ENSORLG00000009843) is not complete. Based on 
comparison with orthologues of fugu (Takifugus rubripes), zebrafish (Danio rerio), tetraodon 
(Tetradon nigroviridis) and stickleback (Gasterosteus aculeatus), I noticed that the first 156 
nucleotides are missing. As the first 20 nucleotides from these species are 100% conserved, I used 
a degenerated forward primer (OrybrafATGfish) for cloning full length medaka BRAF based on 
their sequences. The newly annotated sequence not present in the database is marked in purple in 
Figure 7. After cloning of the full length BRAF sequence, a tandem sequence for Ha (Field et al., 
1988) and Flag tags (Thomas et al, 1988) were added to the C-terminal region of the protein and 
are marked in red and green, respectively, in Figure 7. 
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Fig 7. Protein sequence of the translated full length medaka BRAF coding sequence. Marked in purple is the 
sequence lacking in ENSEMBL database but cloned in this work based on homology to other fish sequences. Ha 
(marked in red) and Flag (marked in green) tags were added in the N-terminal region of the protein after the last 
BRAF amino acid before the stop codon. 
 
The strategy used to clone BRAF was to amplify the full length gene in three, partly overlapping 
parts and clone these into the pCR2.1 vector (Invitrogen, Fig. 8). The first comprised from the 
first ATG until nucleotide 915 (using primers Ory BRAF ATG fish FOR and BRAF R1), the 
second from nucleotide 596 until 1506 (using primers BRAF F2 and BRAF R2) and the third part 
comprising nucleotide 1275 until the last nucleotide before the stop codon (2343, using primers 
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BRAF F3 and BRAF_v1_mdka_R). The next step was to combine each of the overlapping 
fragments together to obtain full length BRAF sequence. 
 
Part one was cut from the vector using XbaI and AccI, and the vector was further digested in a 
way that after purification the only fragment with overlapping ends to the desired receiving vector 
was the BRAF segment (Fig. 8). This way, without the need of gel purification, I was able to fuse 
part one and part two, previously cut with the same enzymes. After control digestions to confirm 
the acquisition of the sequence corresponding to the beginning of BRAF in the vector containing 
the middle sequence, part one and two, now together in the same vector, were cut using XbaI and 
BsEI and added in vector containing the C-terminal part in a similar way as described for the first 
sub-cloning step. Ha and Flag tags were added at the full length gene by oligo cloning as 
described in section 3.3.4. 
 
 
Fig. 8. Schematic representation of full length braf cloning strategy. (A) The braf coding sequence was cloned in 
three parts, each with overlapping sequences containing restriction endonuclease sites. Those restriction sites were 
used for sub-cloning all parts together in the same vector. (B) After full length braf sequence was generated, Ha and 
flag tags were added by oligo cloning. 
 
4.1.1.2 Generation of constitutively activated BRAF 
 
After production of full length BRAF containing the HA and FLAG tags, I developed a 
constitutive active version of BRAF by site directed mutagenesis as described in section 3.3.5. It 
is known that a single point mutation in braf sequence leading to a valine to glutamic acid 
substitution at the position 600 of the corresponding protein results in a constitutively active 
version in humans (Davies et al., 2002; Wellbrock and Hurlstone, 2010). Figure 9A shows the 
wild type amino acid (big letters) and nucleotide (small letters) sequence of the region flanking 
the corresponding valine in medaka. Figure 9B shows the amino acid (big letters) and nucleotide 
(small letters) sequence of the same region after mutagenesis. Figure 9C shows the alignment of 
human and medaka BRAF protein sequences confirming that the valine in position 600 in human 
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is conserved in medaka (present in position 614).  After production of this mutation the region 
containing medaka valine 614 was sequenced to confirm success of mutagenesis (Figure 9D).  
 
 
 
Fig. 9. Mutagenized BRAF sequence in medaka. (A) Wild type BRAF amino acid (big letters) and nucleotide 
(small letters) sequence. In red is the amino acid to be mutagenized. (B) Mutagenized BRAF amino acid (big letters) 
and nucleotide (small letters) sequence. In red is the amino acid that was mutagenized. (C) Alignment sequence of 
human and medaka BRAF showing conservation in both species of human V600. (D) Alignment of cloned medaka 
wild type and mutagenized BRAF sequences showing the successful mutagenesis of a valine to glutamic acid.   
 
 
BRAF sequence was amplified in two parts with primers inserting desired mutation 
(Ory_BRAF_ATG_fish_FOR and mdkaV614Erev for the first PCR and mdkaV614Efor and 
BRAF_v1_mdka_R for the second PCR) as described in Figure 10A. After gel purification (Fig. 
10B), both fragments were used as a template for a new PCR reaction to amplify the sequence 
containing the mutation (Fig. 10C).  
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Fig. 10. Schematic representation of site directed mutagenesis. (A) Medaka BRAF was PCR amplified in two 
parts using primers including desired mutation. (B) Both PCR products were gel purified (C) Purified PCR products 
were used as a template for a new PCR that amplified full length gene bearing the desired mutation. 
 
4.1.1.3 Sub-cloning of BRAF gene sequences into expression plasmids 
 
Full length BRAF and BRAF V600E bearing Ha and Flag tags in the C-terminal sequence, were 
sub-cloned into I-SceI MITF - polyA plasmid (received from Isabell Erhard) using XbaI and SpeI 
restriction enzymes. This plasmid contains the pigment cell specific medaka mitf promoter 
(Schartl et al., 2010), a SV40 poly A site and two meganuclease (I-SceI) sites flanking the 
construct. The plasmids containing the desired coding sequences were used for microinjection 
into one-cell stage medaka embryos to produce transgenic lines (Grabher and Wittbrodt, 2007). 
 
Full length BRAF and BRAF V600E bearing Ha and Flag tags in the C-terminal sequence were 
also sub-cloned into the mammalian expression plasmid pCDNA3 (Invitrogen) using XbaI and 
HindIII restriction endonucleases. This plasmid contains the ubiquitously expressed ß-actin 
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promoter and a SV40 poly A site. This plasmid was used for transfecting Melan A cells (Bennett 
et al, 1987) to test BRAF constitutive activity (chapter 4.1.3). Correct construct assembly was 
controlled by restriction endonuclease digestion and sequencing. 
 
4.1.2 BRAF evolution  
 
By comparing the full length amino acid sequences of medaka, fugu, tetraodon, stickleback, 
zebrafish, xenopus (Xenopus tropicalis), mouse and human, I observed a high degree of similarity 
in the known BRAF domains CR1, which contains the Ras-binding domain (RBD) and the 
cystein-rich domain (CRD), CR2 and CR3, which is also known as the kinase domain (Fig. 11). 
The CR1 domain from medaka is 99% identical to human. The CR2 domain is 100% identical 
between these two species, while the kinase domain is 96% similar. 
 59 
 
 
 60 
 
 
Fig 11. Protein alignment of full length BRAF from medaka, fugu, tetraodon, stickleback, zebrafish, xenopus, 
mouse and human. Conserved domains are marked in purple base on human sequence. RBD = Ras-binding domain; 
CRD = cystein-rich domain; RBD and CRD together constitute the conserved region 1, CR1; CR2 = conserved 
region 2; the kinase domain is the conserved region 3 (CR3). 
 
Although human and medaka BRAF protein sequences are very conserved, synteny analysis 
comparing human BRAF locus on chromosome 7 and the corresponding medaka locus on 
chromosome 23 revealed no conservation between these species (Table 1). 
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Human BRAF  
up genes 
Medaka BRAF 
up genes 
Human BRAF 
down. genes 
Medaka BRAF 
down. genes 
C7orf5 PIK3CG BRAF BRAF 
LUC7L2 HBP1 (2 of 2) CCT4P1 LARGE 
KLRG2 PTPRZ1 (1 of 3) MRPS33 BICD1 (2 of 2) 
CLEC2L ARNTL2 (2 of 2) AGK TMPO (2 of 2) 
HIPK2 STK38L KIAA1147 STRAP 
TBXAS1 MED21 WEE2 SLC25A3 
PARP12 FGFR1OP2 SSBP1 LDHB (1 of 2) 
JHDM1D TM7SF3 TAS2R3 CNTN1 (2 of 2) 
RAB19 GAS2L3 TAS2R4 CNTN1 (2 of 2) 
SLC37A3 ARID2 TAS2R5 THAP5 
MKRN1 SLC38A4 MGAM PNPLA8 (2 of 2) 
DENND2A FAM55C (3 of 3) OR9A4 DNAJB9 
ADCK2 FAM55C (2 of 3) CLEC5A AKR1B1* 
BRAF BRAF TAS2R38  AKR1E2* 
Table 1. Analysis of human and medaka braf gene synteny. First column shows genes present upstream human 
braf, second column shows genes present upstream medaka braf, third column shows genes present downstream 
human braf gene and fourth column shows genes present upstream medaka braf. No gene present on the human 
chromosome in the region where braf is present was found in the surround region of medaka braf. Genes marked 
with one asterisk (*) are not annotated gene versions of medaka. 
 
4.1.3 Functionality of BRAF constructs 
 
In order to test the wild type and mutagenized braf coding sequences for their ability to produce 
functional proteins, I transfected mouse Melan A cells with either full length medaka braf or with 
the constitutively activated medaka brafV614E in the plasmid pCDNA3 under the control of the 
ß-actin promoter. As shown in Figure 12B, both proteins are produced, as they could be detected 
by Western Blot with an antibody targeting the human BRAF protein. Preliminary experiments to 
detect Braf proteins via their Ha or Flag tag were not successful.  I also tested, whether BRAF 
V614E is constructively active. Therefore, I cultivated transfected cells in starving medium in 
order to lose the external stimulation on BRAF. Non stimulated BRAF is not able to activate 
MEK, which in turn is not able to phosphorylate MAP-kinase (reviewed in Michaloglou, 2008, 
Fig. 12A). BRAF V614E does not need stimulation to be active and therefore is able to 
phosphorylate MAP kinase even in starving medium (Fig. 12B). This enabled me to conclude that 
the constitutively activated version of BRAF works as expected. 
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Fig. 12. Test of BRAF constructs functionality. (A) Wild type BRAF needs external signalization to become active 
and phosphorylate MEK. In a starving medium, no external signal is present, so BRAF is not active. In contrast, 
BRAF V614E is constitutively active, and therefore it is expected that even without stimulus, it phosphorylates MEK. 
(B) Western Blot showing the presence of BRAF in Melan A cells transfected with full length BRAF and BRAF 
V614E but only low amounts in cells transfected with empty vector. In starving medium, only BRAF V614E is able 
to phosphorylate MAP. 
 
4.1.4 BRAF expression pattern  
 
Using whole mount RNA in situ hybridization, I analysed BRAF expression during the early 
stages of development. RNA expression of BRAF was not detected at medaka development stage 
20 (Fig. 13A) by in situ hybridization. At stage 28 (Fig. 13B) and 32 (Fig. 13C), a ubiquitous 
expression of braf was observed with raised expression in the otic vesicle (ot), mesencephalon 
(me) and prosencephalon (pe). As other tissues also show weaker staining, ubiquitous expression 
is possible. No expression or light blue background coloration was detected in the negative sense 
control (Fig. 13D-F). 
 
 
Fig. 13. In situ hybridization of medaka embryos using BRAF probes. (A-C) braf expression. (D-F) sense 
control. In stage 28 (B) and 32 (C), expression can be observed in the lens (l), otic vesicle (ot), mesencephalon (me) 
and prosencephalon (pe). 
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Braf expression was detected by Real Time PCR (qPCR) in wild type fishes in skin, brain, 
kidney, liver, testis and muscle. In brain the highest expression level was observed, it was 4 fold 
higher compared to skin (Fig. 14). No expression was found in eyes and gills. 
 
Fig. 14. braf  expression in different organs from adult medaka fishes. braf expression was normalized against 
skin. The results shown here were calculated by the mean value of a triplicate assay. The expression of medaka ef1a1 
was used as internal cDNA control and standardization.  
 
4.1.5 Generation of BRAF transgenic lines 
 
One of the goals of my thesis was to investigate the effects of deregulated BRAF in vivo. 
Therefore I generated transgenic medaka lines carrying the medaka BRAF full length sequence 
and a constitutively activated BRAF version under the control of the pigment cell specific MITF 
promoter. These constructs were used to inject one cell stage medaka embryos to produce 
transgenic lines. Successfully injected fishes were raised, and progeny of sibling crossings were 
screened for transmission of transgene via genotyping PCR (section 3.4.6.6). For mitf:braf, four 
different lines transmitted the transgene to the next generation (named BRAF line 1, 2, 3 and 4), 
for mitf:braf V614E, three lines were screened positive (named BRAF V614 line A, B and C). An 
example of PCR result from generation 1 genotyping can be seen in Figure 15. 
 
 
Fig. 15. F0 screen for transgene transmission to siblings. After crossing injected fishes, gDNA of the siblings was 
extracted. From 1-8, each line corresponds to a pool of hatchlings from fishes injected with wild type BRAF. 8-16 
correspond to siblings of fishes injected with BRAF V614E construct. 3, 5 and 11 are positive. Neg = water negative 
control; pos = plasmid positive control  
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4.1.6 Analysis of BRAF transgenic lines 
 
Phenotypic investigations of the established lines revealed that all BRAF V614E lines show a 
more pigmented skin when compared to lines bearing full length BRAF (Fig. 16). BRAF line 3 
bearing the full BRAF sequence was used as control (Fig. 16 A-D). Higher pigmentation could be 
observed in all three BRAF V614E lines produced in this work (Fig. 16 E-P). Constitutive activity 
of BRAF leads to a stronger pigmentation in the skin of the trunk as well as in the fins, probably 
due to higher number of melanocytes.  
 
 
Fig. 16. Phenotypic comparison between BRAF V614E lines show differences in pigmentation. Pictures of trunk 
(first and second column) and fin (third and fourth column) from adult medakas from BRAF or BRAF V614E F1 
lines showing different pigment patterns. 
 
In transiently expressing Braf V614E F0 fishes from line A, a disrupted eye development was 
observed. To investigate this phenotype, histology on paraffin section was done. In Figure 17 one 
can easily observe the bigger right lens (indicated with red arrows in Fig. 17A and B) compared 
to the normal left lens in a Braf V614E specimen. This phenotype is also indicated by a red arrow 
in the adult fish (Fig. 17C). In another fish a melanin containing tumour like structure was 
observed (indicated with red arrows in Fig. 17D and E and in the adult fish in 17F). The structure 
was observed only in the right eye. No disrupted eye phenotype was observed in the wild type 
control (Fig. 17G-I). 
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Fig. 17. Disrupted eye phenotype observed in braf V614E transient expressing fishes. HE staining of braf V614E 
(A-B) and fish (C) showing phenotype at the lens and HE staining of braf V614E (D-E) and fish (F) showing a 
tumour like lesion in the eye. HE staining of wild type (G-H) and wild fish (I) were used as control. Red arrows point 
to abnormal lens (A and B) and pigmented tumour like structure (C and D) observed in the transgenic fishes. 
 
In summary, I was able to identify and clone medaka braf and produce transgenic lines bearing 
either wild type or a constitutively active BRAF under the control of the pigment cell specific mitf 
promoter. My results also indicate that constitutive activation of BRAF leads to a disrupted eye 
development and to hyperpigmented skin.  
 
4.2  Stat5   
The signal transducer and activator of transcription 5 (Stat5) is constitutively activated in many 
human cancers affecting gene expression, controlling cell proliferation and cell survival (Ferbeyre 
and Moriggl, 2011). Understanding Stat5 function in more detail and its role during tumorigenesis 
will bring new insights into the biology of cancer cells. To gain new knowledge on Stat5 function 
in vivo, I have identified and cloned for the first time both medaka Stat5 genes. As Stat5 ab/a and 
Stat5ab/b are not homologues of human Stat5A and Stat5B (see section 4.2.2), they were so 
named to avoid false correlation with human copies.  
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4.2.1 Stat5 cloning  
4.2.1.1 Medaka full length Stat5ab/a  
 
Medaka Stat5ab/a sequence was cloned from cDNA pool from different organs of adult fishes. 
Protein sequence of full length Stat5ab/a is shown in Figure 18 in comparison with the protein 
sequence available in ENSEMBL database (ENSORLP00000004950). As mentioned below, the 
sequence cloned in this work lacks 5 amino acids corresponding to positions 693 to 697 (orange 
box in Figure 18) of the sequence available in the database. The 2421 nucleotides from Stat5ab/a 
gene were amplified from the initial ATG with primer Stat5ab/a _mdka_left that includes an XhoI 
site and primer Stat5ab/a R1 to nucleotide 985. The second part, from nucleotide 851 till 1763, 
was amplified using primers Stat5ab/a F1 and Stat5ab/a R2. The third part was amplified from 
nucleotide 1482 until the stop codon with primers Stat5ab/a F2 and Stat5ab/a _mdka_right that 
includes an EcoRI site.  
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Fig 18. Protein sequence alignment of full length medaka Stat5ab/a gene. Ha (marked in red) and flag (marked in 
green) tags were added in the C-terminal region of the protein. Orange square marks the difference between the 
sequence present in ENSEMBL database and the sequence cloned from cDNA clones. 
 
To validate that the cloned cDNA really lack these nucleotides, I aligned 4 independently cloned 
sequences and noticed that all of them lacked a 15 nucleotide sequence that was present in 
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ENSEMBL database (ENSORLG00000003961) in between nucleotides 2074 and 2090 (Fig. 19). 
The sequence used in this work for all analyses was based on the initially cloned Stat5ab/a gene.  
 
Fig. 19. Sequence alignment of different Stat5ab/a clones with ENSEMBL database. All 4 sequenced clones 
lacked 15 nucleotides corresponding to nucleotides 2074 to 2090 of the ENSEMBL database Stat5a gene. The raw 
data was used to build this graphic. Sequence variation is due to sequencing error. Every variation was checked, and 
two picks in the Abi file were detected, always corresponding to amino. 
For full length Stat5ab/a cloning as schematized in Fig. 20, part one was cut from the 
corresponding pCRII vector using XbaI and NsiI and the vector was further digested in a way that 
after purification the only fragment with overlapping ends to the desired receiving vector was the 
Stat5 segment. This way, without the need of gel purification, I was able to sub-clone part one 
into part two previously cut with the same enzymes. After control digestions to confirm the 
acquisition of the sequence corresponding to the beginning of Stat5ab/a in the vector containing 
the middle sequence, part one and two, now together in the same vector, were cut using XbaI and 
SacII and added in vector containing the C-terminal part in a similar way as described for the first 
sub-cloning step (Fig. 20). Ha and Flag tags were added at the full length gene by oligo cloning as 
described in section 3.3.4. For Stat5ab/a constitutive active form, oligos XbaIHAFLAGXhoIFOR 
and XbaIHAFLAGXhoIREV were designed with respective 5’prime overhang for XbaI and 
XhoI. Correct construct assembly was controlled by restriction endonuclease digestion and 
sequencing. 
 
 
Fig. 20. Schematic representation of Stat5ab/a cloning strategy. (A) Medaka stat5ab/a coding sequence was 
cloned in three parts, each with overlapping sequences containing restriction endonuclease sites. Those restriction 
sites were used for sub-cloning all parts together in the same vector. (B) After full length Stat5ab/a sequence was 
generated, Ha and flag tags were added by oligo cloning. 
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4.2.1.2 Medaka full length Stat5ab/b cloning  
 
Corresponding to the stat5ab/a cloning strategy, the 2358 nucleotides from medaka Stat5ab/b 
sequence (ENSORLG00000014335) were cloned from cDNA pool from different organs of adult 
fishes as described in section 3.3. Protein sequence of full length Stat5ab/b is shown in Figure 21 
in comparison with the protein sequence available in ENSEMBL database 
(ENSORLP00000004950).  As shown in closer detail in Fig. 22, the sequence cloned in this work 
has 4 amino acids that are not present in the sequence available in the database between 635 and 
636. Also the arginine residue present in ENSEMBLs sequence in position 636 was not found in 
our cDNA clones, which have instead a glycine (blue box in Fig. 21). In addition, the cloned 
Stat5ab/b sequence lacked 6 amino acids corresponding to amino acids 688 to 693 of the available 
Stat5ab/b sequence online (Fig. 21, purple box).  
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Fig 21. Protein sequence of full length medaka Stat5ab/b gene. Ha (marked in red) and flag (marked in green) tags 
were added in the C-terminal region of the protein. Blue and purple squares mark the difference between the 
sequence present in ENSEMBL database and the sequence cloned from my cDNA clones. 
 
To validate the changes in the sequences, I aligned 5 independently sequenced clones of Stat5ab/b 
and noticed that all of them included 12 nucleotides between nucleotides 1909 and 1910 which 
are not present in the sequence in ENSEMBL’s database (Fig. 22A). Also, all sequenced clones 
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lacked the 12 nucleotide sequence that was present in ENSEMBL database 
(ENSORLG00000003961) in between nucleotides 2074 and 2090 (Fig. 22B). The sequence used 
in this work for all analyses was based on cloned Stat5ab/a gene.  
 
 
Fig. 22. Sequence alignment of different Stat5ab/b clones with ENSEMBL database sequence. (A) All 5 clones 
sequenced bore 12 nucleotides between nucleotides 2458 and 2459 of the ENSEMBL database Stat5b sequences. 
Besides that, all five clones had a guanine at position 2460 instead of a cytosine present in the ENSEMBL database 
sequence. This modification is responsible for the glycine present in position 661 which differs from the arginine 
present at the same position in the ENSEMBL data base sequence. (B) Also, cloned Stat5ab/b lacked 12 nucleotides 
corresponding to nucleotides 2624 and 2628 to 2638 ENSEMBL database Stat5ab/b coding sequence. 
Stat5ab/b was amplified from the initial ATG with primer Stat5ab/b_mdka_left that includes an 
XhoI site and primer Stat5ab/bR1 to nucleotide 843. The second part was amplified from 
nucleotide 646 until 1765 using primers Stat5ab/bF1 and Stat5ab/bR2. The third part was 
amplified from nucleotide 1364 until the stop codon with primers Stat5ab/bF2 and 
Stat5ab/b_mdka_right that includes an EcoRI site.  
 
For full length Stat5ab/b cloning, the first part was cut from the vector using XbaI and EcoNI, and 
the vector was further digested in a way that after purification the only fragment with overlapping 
ends to the desired receiving vector was the Stat5ab/b segment. This way, without the need of gel 
purification, I was able to sub-clone part one into part two previously cut with the same enzymes. 
After control digestions to confirm the acquisition of the sequence corresponding to the beginning 
of Stat5ab/b in the vector containing the middle sequence, part one and two, now together in the 
same vector, were cut using XbaI and HindIII and added in vector containing the C-terminal part 
in a similar way as described for the first sub-cloning step. Ha and Flag tags were added at the full 
length gene by oligo cloning as described in section 3.3.4 (Fig. 23). For Stat5ab/b, oligos 
XhoIHAFLAGNdeIfor and XhoIHAFLAGNdeIrev were designed with respective 5’prime 
overhang for XhoI and NdeI. Correct construct assembly was controlled by restriction 
endonuclease digestion and sequencing. 
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Fig. 23. Schematic representation of Stat5ab/b cloning strategy. (A) Stat5ab/b coding sequence was cloned in 
three parts, each with overlapping sequences containing restriction endonuclease sites. Those restriction sites were 
used for sub-cloning all parts together in the same vector. (B) After full length Stat5ab/b sequence was generated, Ha 
and flag tags were added by oligo cloning. 
 
4.2.1.3 Generation of constitutively activated and dominant negative Stat5ab/a and Stat5ab/b 
 
After full length Stat5ab/a and Stat5ab/b with Ha and Flag tags were generated, a constitutive 
active version of each was produced as described in section 3.3.5. It is known that a single point 
mutation in the SH2 domain of human Stat5A (Ariyoshi et al., 2000), leading to an aspargine to 
histidine substitution at the position 642, is constitutively activated. As aspargine in position 642 
in human is conserved in medaka (present in position 646 in Stat5ab/a and 647 in Stat5ab/b), I 
produced the same mutation by site directed mutagenesis (Fig. 24). Site directed mutagenesis was 
performed as described in section 4.1.1.2 with braf gene. For Stat5ab/a Stat5ab/a_N646H_For 
and Stat5ab/a_N646H_Rev primers were used. For Statab/b Stat5ab/b_N646H_For and 
Stat5ab/b_N646H_Rev primers were used.  
 
Figure 24A shows the wild type amino acid (big letters) and nucleotide sequences (small letters) 
of the region flanking this aspargine in medaka Stat5ab/a. Figure 24B shows the amino acid (big 
letters) and nucleotide (small letters) sequence of the same region after mutagenesis. Figure 24C 
shows the wild type amino acid (big letters) and nucleotide (small letters) of the region flanking 
this aspargine in medaka Stat5ab/b. Figure 24D shows the amino acid (big letters) and nucleotide 
(small letters) sequence of the same region after mutagenesis. Also, an alignment of human 
Stat5A and Stat5B with both medaka Stat5 sequences (Fig. 24E) confirms that the aspargine 642 
in humans is conserved in both medaka sequences. The result of the sequencing after mutagenesis 
of Stat5ab/a (Fig. 24F) and Stat5 ab/b (Fig. 24G) confirms that the mutagenesis successfully 
added the desired mutation in medaka sequences.  
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Fig. 24. Comparison of mutagenized stat5ab/a and stat5ab/b sequences. (A) Wild type Stat5ab/a or (B) Stat5ab/b 
amino acid (big letters) and nucleotide (small letters) sequence. In red is the amino acid that will be mutagenized. (C) 
Sequence alignment of human and medaka Stat5ab/a and Stat5ab/b genes showing conservation of human N642 in 
both species.  (D) Alignment of cloned medaka wild type and mutagenized Stat5ab/a and (E) Stat5ab/b sequences 
showing the successful mutagenesis of an aspargine to histidine.   
 
Deletion of the carboxyl-terminal region of mouse Stat5A leads to sustained DNA-binding and 
dominant negative phenotype (Moriggl et al., 1996). Therefore, dominant negative Stat5 
constructs were generated by deletion of the carboxyl-terminal transactivation domain from 
medaka Stat5ab/a and Stat5ab/b. The deletion was done by adding a stop codon in the same 
region as done in mouse Stat5a by PCR and subsequently cloned into pCR2.1 topo (Fig. 25, 
marked with green arrow). Figure 25 shows an alignment of both mice Stat5 sequences with 
cloned full length and dominant negative Stat5ab/a (Fig. 25A) and Stat5ab/b (Fig. 25B). 
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Fig. 25. Alignment of dominant negative versions of medaka Stat5 coding sequences. (A) Stat5ab/a and (B) 
Stat5ab/b alignment with its respective full length sequence showing the lack of the N-terminal region. 
 
4.2.1.4 Sub-cloning of Stat5 genes sequences into pI-SceI plasmid 
 
To produce stable transgenic medaka fish lines, both full length Stat5ab/a and Stat5ab/b bearing 
HA and Flag tags in the N-terminal region were sub-cloned into an I-SceI plasmid that has a 
medaka mitf promoter and a SV40 poly A site using XbaI and SpeI restriction endonucleases. 
(Vector maps can be found in appendix section 7.2) 
 
4.2.2 Stat5 sequence analysis  
 
By comparing amino acids sequences of medaka Stat5ab/a and Stat5ab/b, I observed a high 
degree of similarities in known conserved Stat5 domains like coiled-coil (83%), DNA binding 
(92%) and the SH2 domain (92%). As expected, the domain with lower degree of homology is the 
transactivation domain. Medaka Stat5ab/a have similar levels of homology with both human 
Stat5A and Stat5B sequences (Table 2). 
 
 
 medaka Stat5ab/b human Stat5A human Stat5B 
medaka Stat5ab/a N-term 74% 79% 80% 
medaka Stat5ab/a CC 83% 80% 80% 
medaka Stat5ab/a DBD 92% 95% 97% 
medaka Stat5ab/a LD 78% 74% 76% 
medaka Stat5ab/a SH2 92% 75% 72% 
medaka Stat5ab/a TA 51% 60% 59% 
Table 2. Comparison of Stat5 conserved domains. Conservation of medaka Stat5ab/a and Stat5ab/b and human 
Stat5A and Stat5B protein sequences. N-term indicates the N-terminal domain. CC indicates the coiled-coil domain. 
DBD indicates the DNA binding domain. LD indicates the linker domain. SH2 indicates the SH2 domain. TA 
indicates the transactivation domain. 
 
Figure 26 shows a protein alignment between human Stat5A and Stat5B and medaka Stat5ab/a 
and Stat5ab/b. Their conserved domains are highlighted based on the known human sequences. 
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Fig. 26. Protein alignment of full length Stat5A and Stat5B from human and Stat5ab/a and Stat5ab/b from 
medaka. Conserved domains are marked in purple based on human sequence.  
 
The whole protein sequence of medaka Stat5ab/a is about 80% similar to medaka Stat5ab/b, as 
well as to both human sequences. Medaka Stat5ab/b sequence is approximately 75% similar with 
both human sequences. Human Stat5 sequences, when compared to each other are 94% conserved 
(Table 3).  
 
 Medaka Stat5ab/a Medaka Stat5ab/b Human Stat5A 
Medaka Stat5ab/b 79% --- --- 
Human Stat5A 79% 74% --- 
Human Stat5B 80% 75% 94% 
 
Table 3. Comparison of medaka and human Stat5 full length protein sequences. Conserved amino acids of full 
medaka Stat5ab/a and Stat5ab/b and human Stat5A and Stat5B.  
 
To further analyse the evolutionary relationship of Stat5 genes, I created a phylogenetic tree using 
medaka Stat5ab/a (ENSORLG00000003961), medaka Stat5ab/b (ENSORLG00000014335), 
human Stat5a (ENSG00000126561), human Stat5b (ENSG00000173757), mouse Stat5a 
(ENSMUSG00000004043), mouse Stat5b (ENSMUSG00000020919), zebrafish Stat5.1 
(ENSDARG00000019392), zebrafish Stat5.2 (ENSDARG00000055588), stickleback Stat5a 
(ENSGACG00000008634) and stickleback Stat5b (ENSGACG00000015405) protein sequences 
(Fig. 27). This analysis revealed that Stat5a and Stat5b from mammals are more related to each 
other than both fish Stat5 proteins. This indicates that the two Stat5 copies arose through different 
duplication processes in mammals and in fishes.  
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Fig. 27. Phylogenetic tree of vertebrate Stat5 genes. Amino acid sequences were aligned by maximum likelihood 
method. Human Stat3 sequence was used as out group. Numbers on nodes are bootstrap values out of 100 iterations. 
The scale bar indicates evolutionary distance.  
 
 
To further analyse the possibility that human Stat5a and Stat5b arose from a different duplication 
process than medaka Stat5 genes, additional synteny analyses of the comprising medaka genome 
regions to the human chromosome 17 where both Stat5 copies are present was performed (Table 
4). This analysis showed that medaka Stat5ab/a copy shares a high number of syntenic genes, 
which is not observed in medaka Stat5ab/b. 
 
Human Stat5A  
up/down. genes 
Medaka Stat5ab/a 
up/down. genes 
Medaka Stat5ab/b 
up/down. genes 
KLHL10 ADAM11 (1 of 2) USH1G (2 of 2) 
KLHL11 FKBP10 (1 of 2) C17orf28 (2 of 2) 
ACLY NT5C3L (1 of 2) PLAU 
CNP KLHL11 (1 of 2) HO ENDOD1 
DNAJC7 ACLY* FMNL1 (2 of 2) 
NKIRAS2 CNP SRCIN1 (2 of 2) 
ZNF385C DNAJC7 (1 of 2) GRB7 
DHX58 NKIRAS2 MAP3K14 (2 of 2) 
KAT2A ZNF385C (1 of 2) GRN (2 of 2) 
HSPB9 DHX58 RACGAP1* 
RAB5C KAT2A JAKMIP3 
KCNH4 RAB5C MTR 
HCRT KCNH4 (2 of 2) TFAM 
GHDC HCRT IPMK 
Stat5B PLCL2* NAGLU 
Stat5A Stat5ab/a Stat5ab/b  
STAT3 STAT3 PTRF (1 of 2) 
PTRF PTRF (2 of 2) ATP6V0A1 (1 of 2) 
ATP6V0A1 ATP6V0A1 (2 of 2) RFNG 
HSD17B1P1 STK17B* EXOC6 (2 of 2) 
NAGLU HSD17B1 EXOC6 (1 of 2) 
HSD17B1 COQ10B* CYP26A1* 
 medaka Stat5ab/a
 tetradon Stat5a 
 stickelback Stat5a
 zebrafish Stat5.1
 zebrafish Stat5.2
 medaka Stat5ab/b
 stickelback Stat5b
 human Stat5a
 mouse Stat5a 
 human Stat5b
 mouse Stat5b 
 human Stat3
100
95
100 
89
87
88
43
66
0.2
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COASY L1TD1* REEP3 
MLX MYLK* NRBF2 
PSMC3IP FZD2 NHLRC3 
FAM134C CCDC43 EGR2* 
TUBG1 C1QL1 (1 of 2) ADO 
TUBG2 RAMP2 BMS1 
PLEKHH3 EZH1 MBTD1 
CCR1 CNTNAP1 NME1* 
CNTNAP1 MYO16* MRPL27 
Table 4. Analysis of human and medaka Stat5 gene synteny. Human Stat5A and Stat5B genes lay adjacent to each 
other on the same chromosome. The first column shows genes present upstream and downstream of human Stat5 
genes.  The second column shows genes present downstream and upstream of medaka Stat5ab/a gene on 
chromosome 8. The third column shows genes present downstream and upstream of medaka Stat5ab/b gene on 
chromosome 19. Genes marked with one asterisk (*) are not annotated gene versions of medaka. Genes marked in 
pink represent genes found in the surrounding of human Stat5 genes and medaka Stat5ab/a. The gene marked in green 
was the only found surrounding human Stat5 genes and medaka Stat5ab/b. Genes marked in blue are genes found in 
the surrounding of human Stat5 genes and both medaka Stat5 genes. 
 
Synteny analysis of the medaka genome region where Stat5ab/a copy is present with the region 
from zebrafish containing Stat5.1 gene and the region from stickleback, tetraodon and fugu where 
Stat5a is present was performed (Table 5).  This analysis showed that medaka Stat5ab/a copy 
shares a high number of syntenic genes with the other fish species analysed. 
 
Medaka 
Stat5ab/a 
up/down. genes 
Zebrafish 
Stat5.1 
up/down. genes 
Stickleback 
Stat5a    
up/down. genes 
Tetraodon 
Stat5a 
up/down. genes 
Fugu         
Stat5a  
up/down. genes         
ADAM11 (1 of 2) EFTUD2 TUBG2 FAM134C TUBG2 
FKBP10 (1 of 2) EPS8L1 PLEKHH3 TUBG2 PLEKHH3 
NT5C3L (1 of 2) KCNJ12 (2 of 2) CNTNAP1 PLEKHH3 CNTNAP1 
KLHL11 (1 of 2) MPRIP EZH1 CNTNAP1 EZH1 
ACLY SLC6A16 (1 of 2) RAMP2 EZH1 RAMP2 (2 of 2) 
CNP SLC17A7 C1QL1 (1 of 2) C1QL1 (1 of 2) C1QL1 (1 of 2) 
DNAJC7 (1 of 2) HRAS CCDC43 CCDC43 CCDC43 
NKIRAS2 GYS1 FZD2 FZD2 FZD2 
ZNF385C (1 of 2) ASPDH MYLK MYLK MYLK 
DHX58 TMEM86B COQ10A COQ10A COQ10A 
KAT2A LRRC3C (2 of 2) HSD17B1P1 HSD17B1P1 HSD17B1P1 
RAB5C STK17B STK17B STK17B STK17B 
KCNH4 (2 of 2) ATP6V0A1A ATP6V0A1 (2 of 2) ATP6V0A1 (2 of 2) ATP6V0A1 (2 of 2) 
HCRT PTRFA PTRF (2 of 2) PTRF (1 of 2) PTRF (1 of 2) 
PLCL2 STAT3 STAT3 STAT3 STAT3 
Stat5a/b a Stat5.1 Stat5a Stat5a Stat5a 
STAT3 PLCL2 PLCL2 (2 of 2) PLCL2 PLCL2 
PTRF (2 of 2) HCRT KCNH4 (2 of 2) HCRT HCRT 
ATP6V0A1 (2 of 2) RAB5C RAB5C (2 of 2) KCNH4 (2 of 2) KCNH4 (2 of 2) 
STK17B KAT2A KAT2A RAB5C (1 of 2) RAB5C (1 of 2) 
HSD17B1 DHX58 DHX58 KAT2A KAT2A 
 COQ10B CNP (2 of 2) ZNF385C (1 of 3) DHX58 DHX58 
L1TD1 DNAJC7 (1 of 2) NKIRAS2 ZNF385C ZNF385C (1 of 2) 
MYLK ZNF385C DNAJC7 (1 of 2) STAC2 (2 of 2) NKIRAS2 
FZD2 NKIRAS2 CNP FBXL20 DNAJC7 (1 of 2) 
CCDC43 DNAJC7 (2 of 2) ACLY (2 of 2) CDK12 CNP 
C1QL1 (1 of 2) TTC25 KLHL11 NEUROD2 ACLY (1 of 2) 
RAMP2 CNP (1 of 2) NT5C3L (1 of 2) PPP1R1B KLHL11 
EZH1 ACLYA FKBP10 (1 of 2) STARD3 NT5C3L (1 of 2) 
CNTNAP1 COQ10A LEPREL4 (1 of 2) MREG FKBP10 (1 of 2) 
MYO16 HSD17B1 ADAM11 (2 of 2) TCAP LEPREL4 (1 of 2) 
Table 5. Analysis of medaka, zebrafish, stickleback, tetraodon and fugu Stat5a gene synteny. The first column 
shows genes present upstream and downstream of medaka Stat5ab/a gene.  The second column shows genes present 
downstream and upstream of zebrafish Stat5.1 gene. The third column shows genes present downstream and 
upstream of stickleback Stat5a gene. The fourth column shows genes present downstream and upstream of tetraodon 
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Stat5a gene. The fifth column shows genes present downstream and upstream of fugu Stat5a gene. Genes marked 
with the same colour represent genes found in the surrounding of medaka Stat5ab/a gene that was also found in the 
surrounding of Stat5a of the other fish species analysed.  
 
Besides that, synteny analyses of the region containing the medaka Stat5ab/b gene, the region in 
zebrafish that contains Stat5.2 gene and from stickleback that contains Stat5b gene was performed 
(Table 6). This analysis showed that medaka Stat5ab/b copy shares a high number of syntenic 
genes with stickleback region where Stat5b is present but not with zebrafish region where Stat5.2 
is located. The synteny analyses of the region containing Stat5 genes in different fishes will help 
to hypothesize whether the different Stat5 copies present in fishes arose from the fish specific 
genomic duplication. 
 
Medaka Stat5ab/b 
up/down. genes 
Zebrafish Stat5.2 
up/down. genes 
Stickleback Stat5b    
up/down. genes 
USH1G (2 of 2) GRID1 (1 of 2) EGR2 (1 of 2) 
C17orf28 (2 of 2) FAM190B (2 of 2) NHLRC3 
PLAU PATL2 NRBF2 
ENDOD1 CMN REEP3 
FMNL1 (2 of 2) PAQR4 (2 of 2) JMJD1C 
SRCIN1 (2 of 2) PELO CYP26A1 
GRB7 PPP1CAB EXOC6 
MAP3K14 (2 of 2) IRF9 HHEX 
GRN (2 of 2) ATP2A1L TRUB1 
RACGAP1 FAM158A LRRC45 
JAKMIP3 PSME2 RAC3 
MTR LSM5 DCXR 
TFAM RNASEN RFNG 
IPMK KCNH4 ATP6V0A1 (1 of 2) 
NAGLU GHDCL PTRF (1 of 2) 
Stat5a/b b Stat5.2 Stat5b 
PTRF (1 of 2) OPLAH NAGLU 
ATP6V0A1 (1 of 2) FOXH1 IPMK 
RFNG PPP1R16A UBE2D1 (1 of 2) 
EXOC6 (2 of 2) ADAM11 TFAM 
EXOC6 (1 of 2) DBF4B  POLR3D 
CYP26A1 FKBP10 - 
REEP3 KLHL11 - 
NRBF2 ACLY (2 of 2) - 
NHLRC3 GPT (2 of 2) - 
EGR2 KBTBD2 - 
ADO AVL9 - 
BMS1 MTO1 - 
MBTD1 BECN1 - 
NME1 NEUROD2 - 
MRPL27 PKMYT1 - 
 
Table 6. Analysis of medaka, zebrafish and stickleback Stat5b gene synteny. The first column shows genes 
present upstream and downstream of medaka Stat5ab/b gene.  The second column shows genes present downstream 
and upstream of zebrafish Stat5.2 gene. The third column shows genes present downstream and upstream of 
stickleback Stat5b gene until the end of the scaffold. Genes marked with the same colour represent genes found in the 
surrounding of medaka Stat5ab/b gene that was also found in the surrounding of Stat5b of the other fish species 
analysed.  
 
4.2.3 Expression pattern  
 
Using whole mount RNA in situ hybridization, I analysed Stat5ab/a and Stat5ab/b expression 
during the early stages of medaka embryonic development. RNA expression of Stat5ab/a was 
detected at medaka development stages 20, 28 and 32 (Fig. 28 A-C). In all stages analysed, 
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Stat5ab/a expression was detected in the prosencephalon (pe), mesencephalon (me) and otic 
vesicle (ot). No expression was detected using the sense probe as negative control (Fig. 28 D-F). 
Stat5ab/b expression was detected in all stages analysed, but the expression was restricted to brain 
vesicles and otic vesicles at stages later than 28 (Fig. 28 G-I). Both genes show a rather 
ubiquitous expression pattern at stage 20 (Fig. 28 A and G). No expression was detected using 
Stat5ab/b sense probe as negative control (Fig. 28 J-L).  
 
 
Fig. 28. In situ hybridization of medaka embryos using Stat5a/a and Stat5a/b probes. All pictures show dorsal 
views of the head region. Anterior is orientated to the left side. Arrows indicate regions of expression in the 
prosencephalon (pe), mesencephalon (me) and otic vesicle (ot). 
 
Additionally Stat5ab/a and Stat5ab/b expression was investigated by qPCR in skin, brain, kidney 
and liver of wild type fishes. No expression was observed in eyes, gills, testis and muscle. Both 
genes had a raised expression in brain. The expression pattern of both genes was very similar to 
each other (Fig. 29). 
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Fig. 29. Real time PCR of different organs from adult medaka fishes. Stat5ab/a and Stat5ab/b expressions were 
normalized against skin. The results shown here were calculated by the mean value of a triplicate assay. The 
expression of medaka ef1a1 was used as internal control. 
 
4.2.4 Generation of Stat5ab/a and Stat5ab/b transgenic lines 
 
To gain new insights on Stat5 function, I generated transgenic medaka lines carrying the medaka 
Stat5ab/a and Stat5ab/b full length sequence under the control of the pigment cell specific mitf 
promoter (Schartl et al, 2010). Also, to investigate the consequences of constitutive activation or 
the lack of Stat5 signalling on cancer progression in vivo, I established a constitutively activated 
version and a dominant negative version of each gene under the control of the same pigment cell 
specific promoter. Therefore, after cloning full length medaka Stat5ab/a and Stat5ab/b, producing 
Stat5ab/a N646H and Stat5ab/b N647H through site directed mutagenesis and producing 
Stat5ab/a dominant negative and Stat5ab/b dominant negative through PCR adding a premature 
stop codon, I sub-cloned all sequences into the pISce-I containing a mitf promoter and a poly A. 
These constructs were used to inject one cell staged medaka embryos to produce transgenic lines. 
Positive injected fishes were raised and siblings were screened by genotyping PCR for 
transmission of transgene; 14 different lines were positive screened (Table 7).  
 
Gene version Feature Number of lines Names 
Stat5ab/a Full length 3 Stat5ab/a 5, 6 and 7 
Stat5ab/b Full length 2 Stat5ab/b 8 and 9 
Stat5ab/a N646H Constitutive active 2 Stat5ab/a N646H D and E 
Stat5ab/b N647H Constitutive active 2 Stat5ab/b N647H F and G 
Stat5ab/a neg Dominant negative 3 Statab/a neg ,ß and γ 
Stat5ab/b neg Dominant negative 2 Statab/b neg δ and ε 
Table 7. Different Stat5 transgenic medaka lines established in this work. Gene variant, feature, number of lines 
and name of each line are listed. 
 
In summary I was able to identify and clone medaka Stat5ab/a and Stat5ab/b and produce 
transgenic lines bearing either wild type, a constitutively active and a dominant negative version 
of each medaka Stat5 gene under the control of the pigment cell specific mitf promoter. These 
lines will help to gain new knowledge on Stat5 function in the normal development and in cancer.  
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4.3 c-myc 
c-myc expression is deregulated in a wide range of human cancers and is often associated with 
aggressive tumours (Larsson and Henriksson, 2010). Detailed knowledge of C-myc biology is a 
key premise to understanding its role in cancer initiation, progression and to target it for cancer 
therapy. To obtain new information on C-myc function, the identification and cloning of one of 
the medaka c-myc genes was performed.  
 
4.3.1 Identification and cloning of a novel c-myc gene  
 
By searching available medaka databases I identified two c-myc genes, positioned on 
chromosomes 17 (c-myc17, ENSEMBL database identifier: ENSORLT00000008816) and on 
chromosome 20 (c-myc20, chromosome location 20:19323350-19324300). The sequence of c-
myc17 (which was cloned by Cornelia Schmidt) differs from the one found in the ENSEMBL 
database. Marked with a green square in Figure 30 is an exon, which is present in the database, 
but was not found in our cDNA clones. According to the c-myc sequences from tetraodon, 
zebrafish, stickleback and fugu present in the same database, these other fish species also lack this 
extra sequence. Also, the last amino acids (marked in red in Figure 30) differ between our 
sequence and the database. All the results shown in this work refer to experiments obtained with 
the sequence from our cDNA clones.  
 
Fig. 30. Protein sequence alignment of full length medaka c-myc17 gene. Green and red squares mark the 
differences between the sequence present in ENSEMBL database and the cDNA clones sequences. 
 
Medaka c-myc20 was not annotated in the ENSEMBL database. By blasting the human c-myc 
gene in NBRP cDNA database (http://www.shigen.nig.ac.jp/medaka/) two different orthologues 
were found. And by blasting this second copy in ENSEMBL lastetgp database, I found out that it 
lays on medaka chromosome 20. After alignment with c-myc sequence from different fish species, 
I observed that 120 amino acids were missing (marked in purple in Fig. 31). Using primers 
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flanking this gap (mdk_cmyc20_gap_for and mdk_cmyc20_gap_rev) I was able to obtain full 
length c-myc20 sequence (Fig. 31). Newly identified medaka c-myc17 and c-myc20 coding 
sequences have been submitted to Genebank (c-myc17: GeneBank-nr. JN542547; c-myc20: 
GeneBank-nr. JN634762). 
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Fig. 31. Nucleotide alignment of c-myc20 sequences. The consensus sequences were obtained from NBRP cDNA 
database. The sequence missing was obtained by direct sequencing using a PCR product of a reaction using primers 
flanking the gap. This way the full length c-myc20 coding sequence was obtained. 
 
Medaka c-myc17 sequence was PCR amplified from pooled medaka organ cDNA using 
ReproFast polymerase (Genaxxon) with primers inserting HindIII restriction site downstream and 
BamHI site upstream the gene. To compare homology among different vertebrates, C-myc protein 
sequences from human, mouse, fugu and both medaka copies were aligned (Fig. 32). The DNA 
binding domain, the helix-loop-helix domain and the leucine-zipper domain share an overall high 
rate of conservation throughout all investigated vertebrates (purple lines in Fig. 32). 
 
Fig. 32 Alignment of C-myc protein sequences. Human, mouse and fugu C-myc protein sequences were aligned 
with medaka C-myc17 and medaka C-myc20. Black boxes highlight conserved amino acid residues (more than 75% 
conservation in all sequences). Yellow arrows indicate known amino acid sites for posttranslational modifications in 
the human Myc protein, e.g. phosphoserine and N6-acetyllysine modifications, as stated in the UniProt database.  
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Table 8A lists the degree of similarity between both medaka C-myc protein sequences and 
human, fugu and the three zebrafish protein sequences. Human C-myc basic-helix-loop-helix 
(BHLH) domain is 78% similar to C-myc20 and 55% similar to C-myc17 (Table 8B). The DNA 
binding domain is 100% equal to C-myc20 and 92% similar C-myc17. Interestingly, the leucine-
zipper, which is responsible for the interaction with MAX, is only 50% similar to C-myc20 but 
68% similar to C-myc17. 
 
   A                                                                       B 
 c-myc17  c-myc20    c-myc17  c-myc20  
c-myc17 --- 47%  Human c-myc HLH 55% 78% 
Human c-myc 46% 55%  Human DBD 92% 100% 
Fugu c-myc 51% 84%  Human LZ 68% 50% 
Zebrafish c-myca 49% 70%  c-myc17 HLH --- 68% 
Zebrafish c-mycb 48% 69%  c-myc17 LZ --- 61% 
Zebrafish c-mych 31% 43%  c-myc17 DBD --- 93% 
Table 8. Comparison of medaka C-myc sequences. (A) Conserved amino acids of full human, fugu and zebrafish 
C-myc sequences in comparison with medaka C-myc17 and 20. (B) Conservation of C-myc17 and 20 motifs 
compared between themselves and with human sequences. HLH indicates helix-loop-helix domain; DBD indicates 
DNA binding domain; LZ indicates Leucine-zipper domain. 
 
Furthermore the alignment in Figure 32 shows that known C-myc phosphorylation sites for the 
human protein (Adhikary and Eilers, 2005), like T58, targeted by glycogen synthase GSK3, and 
S62, targeted by MAP kinase, are conserved in both medaka orthologues. Apparently differences 
between the two medaka Myc proteins could be determined. S71, targeted by Rho-dependent 
kinase and related with transcriptional repression by Myc, is only conserved in C-myc17 but not 
in C-myc20. Apart from the phosphorylation sites, there are six lysine residues on human C-Myc 
that are direct substrates for acetylation by p300 (Zhang et al., 2005). Two of these are conserved 
in both medaka c-myc genes: K143 within Myc homology box 1 and K323 within the nuclear 
localization signal. Three lysine modification sites are only present in C-myc20: K157 located 
next to the Myc homology box 2, K275 not linked to functionally important Myc domains and 
K371 within the BHLH domain. One site is not present in both medaka copies K317 next to the 
nuclear localization signal. These results indicate that essential functional domains and amino 
acid residues of C-Myc have been conserved in both Medaka genes, but some changes in 
posttranslational regulatory amino acid motifs, especially those of N-6 acetyllysine modification 
sites in C-myc17, may have resulted in functional divergence of these orthologues. 
 
4.3.2 Syntenic and phylogenetic analysis of c-myc orthologues in medaka 
 
To further analyse the relation between both medaka C-myc orthologues and the human C-myc, I 
performed syntenic analyses of C-myc corresponding genome regions on medaka chromosome 17 
and 20 and the human chromosome 8 (Tables 9 and 10). Most of the genes present upstream 
human C-myc are present either on medaka chromosome 11 or 16. Homologues of genes 
downstream human C-myc are present either on chromosome 11, 16 or 17. Interestingly, no 
homologue present on medaka chromosome 20 was found (Table 9). 
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human myc   
up. genes 
medaka 
chromosome 
human myc 
down. genes 
medaka 
chromosome 
POU5F1B 12 GSDMC not present 
FAM84B 11 and 16 FAM49B 17 
TRIB1 11 ASAP1 not present 
NSMCE2 not present ADCY8 17 
TMEM65 11 and 16 EFR3A not present 
NDUFB9 11 OC90 not present 
KLHL38 11 and 16 HHLA1 not present 
FAM91A1 11 KCNQ3 17 
MTSS1 11 and 16 LRRC6 17 
TRMT12 10 TMEM71 not present 
RNF139  not present NDRG1 11 and 16 
TATDN1 not present PHF20L1 not present 
ZNF572 not present ZFAT 16 
SQLE 16 KHDRBS3 11 
KIAA0196 16 COL22A1 11 
FER1L6 21 KCNK9 11 
WDR67 16 PTK2 16 
C8orf76 16 SLC45A4 16 
ZHX1 11 CHRAC1 11 
ATAD2 16 TRAPPC9 11 
Table 9. Analysis of c-myc gene synteny between human and medaka genomes. First column shows genes present 
upstream human c-myc locus, while the second column indicates the position of the corresponding gene orthologue 
on the medaka chromosomes. Third column shows genes present downstream of the human c-myc and fourth column 
the chromosome in which they are found in medaka.  
 
The synteny analysis of medaka chromosome 17 and 20 in comparison with human C-myc locus 
(Fig. 33) confirms that more genes are conserved between human chromosome 8 and medaka 
chromosome 17 than 20 (blue lines, Fig. 33A). Figure 33B shows a magnified picture illustrating 
the corresponding chromosome regions around human and medaka c-myc. Medaka C-myc20 is 
not present in the analysis because it is not annotated in the used databases. 
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Fig. 33. Synteny analysis of the medaka cmyc in comparison to human. Analysis of c-myc gene synteny was 
performed utilizing the ENSEMBL database and the Synteny database. (A) Blue lines show conserved loci between 
human chromosome 8 and medaka chromosome 17. Red lines show conserved loci between human chromosome 8 
and medaka chromosome 20. The asterisk (*) indicates c-myc genes on human and medaka chromosomes. The 
human cmyc locus, 10MB around the human c-myc gene, is indicated. (B) shows on the x-axis the complete human 
chromosome 8, while the y-axis represents all medaka chromosomes. Red dots indicate syntenic regions between 
species. Blue rings mark the position of human c-myc at 8q24 and potential regions of c-myc homologues in the 
medaka. The magnified picture illustrates the corresponding chromosome regions, containing neighbouring genes on 
the human and the medaka loci. Medaka c-myc20 is not present in the analysis because it is not annotated in the used 
databases. 
 
Additional syntenic analyses of the comprising medaka genome regions to another fish species, 
the fugu, showed that c-myc17 and c-myc20 lie in regions of high evolutionary conservation 
(Table 10), hinting to a common origin by the fish specific genome duplication.  
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Table 10. Analysis of medaka c-myc17 and c-myc20 gene synteny. First column shows genes present upstream and 
downstream c-myc17, second column shows genes present upstream and downstream c-myc20, third column shows 
genes present upstream and downstream fugu c-myc gene and fourth column shows in which chromosome from 
medaka the orthologue in fugu is present. Genes marked with one asterisk (*) are genes present on medaka 
chromosome 17 that are duplicate in the medaka genome and where its corresponding copy is present on 
chromosome 20. Genes marked with two asterisks (**) are genes present on medaka chromosome 20 that are 
duplicated in the medaka genome and where its corresponding copy is present on chromosome 17. Black lines 
indicate corresponding gene orthologues between the different genomic regions. 
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To assess the evolutionary relation of the c-myc genes of medaka in more detail, phylogenetic 
comparison of human, mouse, xenopus, tetraodon, stickleback, fugu and zebrafish myc genes with 
both medaka sequences was performed (Fig. 34).  
 
 
Fig. 34. Unrooted phylogenetic tree of myc family genes. Amino acid sequences were aligned by maximum 
likelihood method. Numbers on nodes are bootstrap values out of 100 iterations.  
 
These analyses revealed that the medaka c-myc genes cluster together with the vertebrate C-myc 
family and not with mycN or mycL (Fig. 34). Moreover the phylogenetic tree revealed that the 
copy present on medaka chromosome 20 clusters closely with sequences from other vertebrates, 
while the copy on medaka chromosome 17 seems to be unique as it branches off relatively early 
(black box in Figure 34). This unexpected result indicates that c-myc17 of medaka is a highly 
divergent or an aberrant gene version.  
 
In summary, these results strongly suggest that medaka c-myc17 is an evolutionary modified myc 
gene version apart of all vertebrate c-myc genes, harbouring possible different functions.    
 90 
 
4.3.3 Production of transgenic lines and expression pattern 
 
To exclude that c-myc17 is a non functional, not expressed pseudogene, expression studies of 
both medaka c-myc genes were performed by RT-PCR (Fig. 35). Expression of both genes was 
detected in all analysed developmental stages (10, 18, 21, 24, 30, 34 and 38; Fig. 35A). In adult 
tissues (Fig. 35B), expression of both medaka c-myc genes was detected in all analysed tissues. 
Expression was lower in gills and liver when compared to brain, eyes, muscle, skin and testis. 
This result shows that the c-myc copy present on medaka chromosome 17 had a similar 
expression pattern to c-myc20 during development. 
 
 
Fig. 35. Reverse transcript PCR of both c-myc copies present in Medaka (A) in different developmental stages 
and (B) in different adult organs. PCR reaction was performed using as template cDNA from different medaka stages 
of development.  
 
To analyse in detail functions of this novel c-myc17 gene and to compare these to the human C-
myc gene, I established a novel inducible in vivo model in medaka. The coding region of c-myc17 
lacking the stop codon was fused to the hormone-binding domain of the mouse estrogen receptor 
(from vector pWZLneoG525R, a gift from Martin Eilers and performed by Cornelia Schmidt), 
which enables induction of the transcription factor at a chosen time point by addition of 
tamoxifen. For ubiquitous expression of the construct, the cytoskeletal-actin promoter of Xenopus 
borealis was utilized (Lakin et al., 1993). The c-myc17-ER construct was then sub-cloned into the 
pI-SceI vector, containing the cytoskeletal-actin promoter and a SV40-poly A, and named c-
myc17-ER I-SceI plasmid. This construct was injected into one cell stage medaka embryos. 
Integration of the construct into the genome resulted in two independent transgenic lines, named 
c-myc line 1 and 2.  
 
Transgene expression in both lines was determined by qPCR. The transgenic medaka line 1 
showed a 7 fold higher expression of the transgene only in the gills when compared to the other 
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organs examined (Fig. 36A). In line 2, brain, eyes, gills and muscle have at least 6 fold increased 
expression when normalized to liver. Direct comparison of both lines indicates that line 2 has an 
overall higher c-myc RNA expression than line 1. To additionally test whether the protein is 
produced in both lines, western blot analyses were conducted. In both lines the fusion protein 
could be detected by using an antibody directed against the mouse ER (Fig. 36B). 
 
 
Fig. 36. Expression of c-mycER transgene in established medaka transgenic lines. (A) Real time PCR analysis of 
c-mycER transgene from liver, brain, eyes, gills and muscle from adult fishes. Levels from the transgene were 
normalized against ef1a1 in each tissue. Histograms with T-bars indicate the mean standard deviation based on 
triplicate assays. (B) Western blot analysis of the c-mycER protein fusion. Protein samples extracted from wild type 
(WT) and two transgenic fishes immuno-stained with anti-ER antibody. Protein extract containing human c-mycER 
was used as control (crtl).  
 
4.3.4 In vitro induction of c-myc in medaka primary cells 
 
To test whether the inducible c-myc17ER system works in the established transgenic medaka 
lines, dissociated fibroblast cells from tail fins were cultured for five days followed by 24h 
treatment with 4-hydroxytamoxifen (4-OHT). Immunofluorescence of these cells using an anti-
ER antibody shows nuclear translocation only in the presence of 4-OHT, confirming the 
functionality of the inducible c-mycER system in medaka (Fig. 37A). Differences of nuclear to 
cytoplasm fluorescence intensity enabled me to quantify nuclear translocation (Fig. 37B) and  
demonstrate that in line 1 a 10 fold higher rate of nuclear myc-ER was detected after 4-OHT 
treatment, while in line 2 the ratio was only 2,7 fold increased.  
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Fig. 37. Functionality tests of c-mycER transgenic lines. (A) Immunofluorescence of c-mycER line 2 in medaka 
fin primary cell culture in the presence or absence of 4-OHT using anti-ER antibody and nuclear counterstaining with 
Hoechst. Scale bar: 10µM. (B) Quantification of mean intensity differences (n=7 cells per treatment). Each cell was 
measured at two independent regions in the nucleus and the cytoplasm. Mean values were subtracted to calculate 
cytoplasmic to nuclear difference. (C) Direct c-myc target gene expression, ODC1, CBX3, CCT5, EIF3S8 and 
MTLL1, in different organs via qPCR analysis after 4OHT treatment.  Relative fold change levels for each gene were 
normalized against ef1a1 in each tissue separately. Histograms with T-bars indicate the mean standard deviation 
based on duplicate assays. 
 
In addition, I was able to quantify the expression of five target genes that are up-regulated by 
human c-myc (Dang et al., 2006; Mao et al., 2003; Wagner et al, 1993; Zeller et al, 2003): 
ornithine decarboxylase 1(ODC1), chromobox homolog 3 (CBX3), chaperonin containing TCP1, 
subunit 5 (CCT5), translation initiation factor 3, subunit 8 (EIF3S8) and methyltransferase-like 1 
(METLL1). Expression of the Medaka orthologues genes was determined in different adult 
tissues from c-myc17ER lines after 4-OHT treatment. This analysis revealed induced expression 
in almost all investigated tissues compared to control samples (Fig. 37C). Differences between the 
two established lines are obvious, as tissue samples of line 2 always show a stronger 
transcriptional induction of all five genes compared to line 1. Nuclear translocation of the C-
myc17ER and induction of target gene expression after 4-OHT treatment show functionality of 
the transgene. 
 
4.3.5 Function of novel C-myc17 
 
By initially investigating the medaka c-myc gene copy present on chromosome 17, I could 
observe that this less conserved copy is expressed (Fig. 35 and 36) and that it is able to translocate 
to the nucleus (Fig. 37 A and B). In addition, I could notice that this protein is also able to induce 
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expression of known C-myc target genes (Fig. 37C). To further understand its function, I 
performed proliferation and apoptosis assays and looked for its possible role in cancer initiation. 
 
4.3.5.1 Proliferation  
 
I investigated whether ectopic expression of c-myc17ER leads to increased cell proliferation in 
vivo, one hallmark function of human C-myc. Distinct higher BrdU incorporation was detected in 
4-OHT treated individuals of both transgenic lines in comparison to EtOH treated control fish 
(Fig. 38A). Quantification of BrdU incorporation after C-myc17 induction (Fig. 38B) revealed 
that line 1, which has a lower transgene expression level, has a higher rate of proliferation than 
line 2. For example in liver, line 1 has 3.1% of BrdU positive cells when treated with tamoxifen 
and 0.49% in the EtOH control. 4-OHT treated line 1 has 2.04% of proliferative cells while EtOH 
treated cells have 0.58%. In gills, tamoxifen treated fishes present 6.55% (line 1) and 4.07% (line 
2) of BrdU positive cells. Control of line 1 and line 2 show 3.13% and 2.88% of proliferating 
cells.   
 
 
Fig. 38. Cell proliferation after c-myc activation in vivo. (A) BrdU staining on sections of liver (upper panel) and 
gills (lower panel) in the presence or absence of 4-OHT. Scale bar: 10 µM. (B) Quantification of BrdU positive cells 
in liver (left graphic) and gills (right graphic) in both c-mycER lines. Histograms with T-bars indicate the mean 
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percentage of BrdU positive cells of two independent experiments with their corresponding standard deviation. C N 
indicates average cell number counted from 5 different sections. 
 
4.3.5.2 Apoptosis  
 
In contrast to the proliferational potential, line 2 had a higher in vitro apoptosis rate after 4-OHT 
treatment when compared to line 1 in primary cells (Fig. 39A and B) and in vivo in liver and gills 
(Fig. 40 A and B). In primary cell culture from medaka fins, 4-OHT and EtOH treated cells from 
line 1 showed 7.27% and 2.61% apoptosis rate, respectively. Line 2 presented11.49% and 1.8%, 
respectively, in treated versus non treated cells.  
 
 
Fig. 39. Effects of C-myc activation on cell death in vitro. (A) Detection of apoptosis in primary cell culture 
(arrows indicate TUNEL positive cells). Cells were treated for five hours with 4-OHT before fixation. Nuclei were 
counterstained with Hoechst. Scale bar: 100 µM. (B) Quantification of apoptotic cells in primary cultures derived of 
both C-mycER lines and wild type fishes in presence or absence of 4-OHT in the media. C N indicates total cell 
number for each assay. 
 
A similar observation was made when looking at adult tissues from transgenic fishes (Fig. 40). 
For example, livers from fishes from line 2 had 11.61% TUNEL positive cells after treatment 
with tamoxifen, while EtOH treated control fish had only 2.52%. In gills, the amount of apoptotic 
cells was 21.39% of 4-OHT treated cells. In contrast, the amount of TUNEL positive cells in non 
treated gills was 1.58%. In summary, our functional experiments show that in both transgenic 
lines C-myc17 can induce proliferation and apoptosis. Additionally, I could confirm differences 
in potency of both lines to induce these effects. Line 1 shows a higher rate of proliferative cells, 
while line 2 is more potent to drive cells into apoptosis.  
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Fig. 40. Induction of apoptosis after C-myc activation in vivo. (A) Detection of apoptosis by TUNEL assays in 
liver and gills sections from adult fishes. Fishes were treated for 24 hours with 4-OHT to induce y-myc17 function.. 
DNA fragmentation is visible as red spots colocalizing with nuclei, which are stained with Hoechst. Scale bar: 10µM. 
(B) Quantification of apoptotic cells in liver (left panel) and gills (right panel) of both C-mycER lines fishes in 
presence or absence of 4-OHT. C N indicates total cell number for each assay. 
 
4.3.5.3 Hyperplasia 
 
I conducted long time C-myc activation experiments of several individuals of both c-myc17 lines 
to investigate potential pathological changes. Figures 41 A and B show liver histology from both 
transgenic lines after 4 weeks of treatment with tamoxifen. I observed hyperplasia, a raised 
number of cells,  in the liver from c-myc line 1 and 2 when compared to either wild type fishes 
treated or non treated with 4-OHT (Fig. 41 C and D). I counted an average of 890 and 794 cells 
per section in C-mycER fishes after 4-OHT treatment. Wild type fishes had an average of 354 and 
397 cells per section in fishes treated and non treated with tamoxifen (Fig. 41 E). Cell nuclei of C-
mycER fishes after 4-OHT treatment were smaller (average 2 µm) when compared to cell nucleus 
of treated and non treated wild type fishes (average 3.8 µm). All visible cells on a picture were 
counted. Three not overlapping tissue parts, each with an area of approximately 87410µm2, were 
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used for counting. This result indicates that long time activation of Cmyc17 does lead to tissue 
hyperplasia in vivo. Interestingly, no differences in both lines were detectable.  
 
 
Fig. 41. Constant c-myc activation triggers liver cell hyperplasia in vivo. Images show haematoxylin and eosin 
stained sections of liver from adult transgenic fishes from line 1 (A), line 2 (B) and wild type (C) treated for four 
weeks with tamoxifen or non treated wild type (D). Scale bar: 20µM. (E) Cell number per section in both C-mycER 
lines and in wild type fishes treated or not treated with tamoxifen.  
 
In summary, I generated a tamoxifen inducible in vivo model for the medaka c-myc gene present 
on chromosome 17. Using this model I showed that C-myc17 leads, when activated, to increased 
proliferation and to apoptosis in a dose dependent manner, similar to human Myc. It also triggers 
hyperplasia in adult liver after long-term activation.  
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5. DISCUSSION 
 
5.1 BRAF 
 
5.1.1 Identification and sequence analysis of medaka BRAF hint to evolutionary conservation   
 
BRAF is a serine threonine kinase found mutated at high incidence in human tumours like 
malignant melanoma, thyroid cancer, colorectal carcinoma and ovarian cancer, and in low 
incidence in tumours like colon cancer, lung adenocarcinoma, breast cancer and lymphoma  
(Garnett and Marais, 2004). Analysis of the medaka braf gene is expected to bring new 
information on BRAF structure and conserved domains that can reflect its different or similar 
function between different organisms. In this work, I have identified and cloned the medaka braf 
gene for the first time. To analyse the similarities between different fish species, including 
medaka and other higher vertebrates, I aligned the amino acid sequences of the medaka BRAF, 
cloned in this work, and the ones from fugu, tetraodon, stickleback, zebrafish, xenopus, mouse 
and human, which are available in online databases (Figure 11). BRAF protein domains are 
highly conserved among vertebrates. The high similarity between all BRAF domains suggests the 
maintenance of function between different organisms. Although human and medaka BRAF 
protein sequences are highly conserved, synteny analysis (Table 1) comparing human BRAF 
locus on chromosome 7 and the corresponding medaka locus on chromosome 23 revealed no 
syntenic conservation between these species. One evolutionary reason for this observation might 
be a regional translocation in the corresponding medaka region where, during evolution, BRAF 
jumped out from the chromosome region where it belonged and was inserted in a totally new area.  
 
5.1.2 Medaka BRAF has similar expression pattern as mouse 
 
Analysis of murine braf mRNA expression by RT-PCR in different organs revealed a high 
expression of braf in brain and testis and a low expression in eye and liver (Barnier et al, 1995). 
In the same work, no expression was observed in kidney. This result is in accordance with the 
high braf expression in medaka brain found in this work in adult tissues by qPCR (Fig. 14). I also 
observed expression in the mesencephalon and prosencephalon by in situ hybridization during 
larval development (Fig. 13). Through these experiments, I also detected expression in the eye 
and liver in adult fishes (Fig. 14). However, I found a moderate expression in kidney, which 
disagrees with the results from Barnier et al. The mouse braf gene encodes multiple protein 
isoforms with tissue specific expression (Barnier et al, 1995). So far, no study to identify different 
BRAF isoforms in medaka has been performed.  
 
5.1.3 Medaka transgenic lines support known BRAF functions 
  
BRAF phosphorylates and thereby activates MEK, which subsequently phosphorylates and 
activates MAPK, which in turn phosphorylates several cytoplasmatic and nuclear targets 
(Wellbrock et al, 2004). BRAF mutations were found in approximately 66% of human 
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melanomas, and the most common is a T-A transversion leading to a valine to glutamic acid 
substitution, BRAF V600E (Michaloglou, 2008). This mutation results in a constitutive active 
BRAF and therefore induces constitutive MEK/MAPK signalling, resulting in enhanced 
proliferation (Fecher et al., 2008). To obtain more information of BRAF function in vivo in 
medaka and to take advantage of laboratory fish models to answer some of the remaining open 
questions of BRAF function, I established a medaka transgenic model carrying the medaka braf 
gene. To accomplish this, I produced transgenic lines carrying the wild type medaka gene and a 
constitutive active form. The constitutive active medaka BRAF showed to be able to transduce the 
MAPK signalling, since I was able to detect phosphorylated MAPK even without stimulus. This 
experiment also proved that medaka BRAF has the same function as mammalian BRAF in the 
propagation of signals through the MAPK pathway. Moreover, this experiment showed that the 
BRAF carrying the valine to glutamic acid mutation in the fish homologue of the human V600E 
(position 614, in medaka) is constitutively active. These results show that the medaka homologue 
of braf is able to fulfil similar functions to mammalian proteins, and that a fish specific mutation 
V614E can resemble a known human property. 
 
5.1.4 BRAF plays a role in skin pigmentation 
 
I observed disrupted pigmentation phenotype in transgenic BRAF V614E medaka fishes, as 
individuals of these lines show darker body pigmentation (Fig. 16). This phenotype was expected 
since a role of BRAF in pigmentation has been elucidated in zebrafish, where constitutively 
activated BRAF also plays a role in melanocyte development (Patton et al, 2005). In this work, 
transgenic zebrafishes showed focal sites of melanocyte proliferation, and BRAF activation was 
sufficient to promote nevus formation. However, although dramatic changes in zebrafish pigment 
pattern were observed, no tissue invasion was apparent. In conclusion, expression of BRAF 
V600E can cause the expansion of melanocytes, but additional mutations are required for 
melanoma formation. In accordance to this study, no tumour formation was observed in my 
BRAF V614E medaka fishes. In the same study, Patton et al (2005) observed that in a 
background without the function of the tumour suppressor p53, activated BRAF can lead to 
melanoma formation. In medaka, a p53 negative background or the loss of another tumour 
suppressor like cdkn2 would probably also lead to melanoma formation, but this remains to be 
elucidated. Although results from fish models may not necessarily be directly extrapolated to the 
human situation, they will still be very informative to determine the effect of BRAF V600E in 
melanocytes also in the context of other cancer-predisposing lesions. In addition, medaka fishes 
have the advantage to enable close visualization of pigmentation during every stage of 
development and the possibility to screen for chemical compounds. It is important to notice that 
no correlation between braf overexpression and skin pigmentation in mammals has been drawn so 
far, which could constitute a specific fish BRAF function. In addition, it is known that BRAF not 
only stimulates melanocyte proliferation but also induces senescence in human melanocytes in 
vitro (Michaloglou et al, 2005) and in mice melanocyte in vivo (Dhomen et al, 2009). It remains 
to be elucidated whether the hyperpigentation spots present in medaka BRAF V614E lines are 
made up of senescent melanocytes. 
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5.1.5 Role of BRAF in the eye development? 
  
Tissue specific in vivo manipulation of gene expression from a new species that was never 
analysed before will bring new insights into the genes’s function. Unexpectedly, I observed a 
disrupted eye development in some fishes transiently expressing the constitutively active 
brafV614E gene under the control of the mitf promoter (Fig. 17). The vertebrate eye is formed by 
cells of the ectoderm origin, which gives rise to the retina, the epithelium of the iris and the lens 
(Chow and Lang, 2001). A number of genes that play a role in retina and lens development have 
been identified (reviewed in Cvekl and Mitton, 2010). Among these, the pigment cell master 
regulator MITF is known to play a role in retinal development (Hallsson et al., 2004). Also, Pax6 
function is essential for normal eye development (Ashery-Padan and Gruss, 2001) and it is 
phosphorylated by MAPK, enhancing its transcriptional activity (Lang, 2004; Mikkola et al, 
1999). Additionally, MAPK induces degradation of Mitf protein and thereby represses 
differentiation (Delfgaauw, 2003). As BRAF phosphorylates MEK, which in turn phosphorylates 
MAPK, I hypothesize that through constant activation of this pathway by BRAF V600E normal 
eye development is deregulated. Further studies will confirm or reject this theory by investigating 
pax6 phosphorylation and mitf stability. Besides that, braf mutations were observed in 14-40% of 
conjunctiva melanoma (Gear et al, 2004), showing a relation of BRAF with ocular melanoma. 
However, braf mutations are absent in uveal melanoma (Rimoldi et al., 2003). 
 
5.1.6 Importance of BRAF animal models 
 
Temporal and spatial control on BRAF expression and activity, in particular uncontrolled levels 
of oncogene expression and function, promote different effects in cell behaviour, like quiescence, 
proliferation or senescence (Woods et al., 1997; Zhu et al, 1998). BRAF regulates not only 
melanoma initiation and progression, but also general tumour progression (Hoeflich et al., 2006), 
which favours BRAF as a therapeutic target for the treatment of melanoma. Both proto-oncogenes 
activation and tumour-suppressor inactivation are implied in cellular transformation and tumour 
progression in melanoma (Polsky and Cordon-Cardo, 2003). Inhibitors of MEK in a background 
expressing mutant BRAF, like U0126 (Calipel et al., 2003) or CI 1040 (Solit et al., 2006), reduce 
phosphorylated MAPK and inhibit proliferation and oncogenic transformation, which can be 
easily explained since BRAF V600E signal via MEK and MAPK. Another BRAF inhibitor, 
sorafenib, inhibits BRAF and BRAF V600E as well as other protein kinases and retards the 
growth of human melanoma cells and complete inhibits MEK phosphorylation (Karasarides et al., 
2004). However sorafenib is not efficient in preventing lung metastasis in a mouse model 
(Sharma et al, 2006). Recently a new drug, which is still investigated by a clinical trial, has been 
developed. PLX-4032, an inhibitor designed to target specifically BRAF V600E, is highly 
selective for this mutated form, demonstrating a 10 fold greater potency for the mutated BRAF 
than for the wild type in kinase assays and more than 100 fold in cell proliferation assays (Tsai et 
al., 2008). In several tumour xerograph models of BRAF V600E expressing melanoma, PLX-
4032 treatment caused partial or complete tumour regression in a dose dependent manner (Yang 
et al, 2010). Phase 1 clinical study in melanoma patients showed that PLX-4032 treatment led to 
tumour regression in cancer patients. However, tumour re-growth occurs in many of the patients 
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and the cancer is then resistant to PLX-4032 treatment (Bollag et al, 2010). Clearly, inhibition of 
BRAF has a prominent role in melanoma therapy. The medaka BRAF V614E model generated in 
this work could be very helpful for drug selection and new BRAF target genes search, due to the 
fact that fish can be more easily screened when compared to mouse models. Also, the medaka 
model established here can be used to investigate the melanoma resistance (Nazarian et al, 2010) 
after treatment with PLX-4032. 
 
To further understand BRAF function, other BRAF V600E models have been generated in 
different species. The BRAF V600E zebrafish model (Patton et al, 2005) was the first described 
model organism used to study constitutive BRAF activation. Although this group worked with a 
fish species, transgenic zebrafishes were carrying the human BRAF gene. Besides the zebrafish 
models, several BRAF V600E models have been generated in other species. A transgenic mouse 
expressing BRAF V600E under the control of the bovine thyroglobulin promoter, which drives 
the expression of the transgene in thyroid cells, shows increased MAPK signalling and an 
enlarged thyroid as well as poorly differentiated carcinomas (Knauf et al., 2005). This result 
indicates that BRAF V614E can serve as a tumour initiator and promote progression to 
carcinomas. 
 
In addition, two Cre recombinase inducible BRAF V600E knock in mice have been generated. In 
one model, the constitutive activation of BRAF during embryonic development resulted in 
embryonic lethality due to bone marrow failure (Mercer et al., 2005). This model indicated that in 
some primary mouse cells, constitutive activation of BRAF is able to induce several hallmarks of 
transformation, like morphologic transformation, hyperproliferation and loss of contact inhibition, 
without the involvement of a second cooperating oncogene.  However, for the development of 
cancer in vivo, the situation is more complex, since BRAF V600E mutations are frequently found 
in nevi which remain senescent and do not progress to tumour formation (Pollock et al., 2003). 
Although BRAF is the most prominent oncogene in melanoma and the acquisition of an 
activation mutation in BRAF creates an advantage in the proliferation of melanocytes, the 
constant signalling from BRAF itself is not sufficient to fully transform normal melanocytes. In 
the second model, BRAF V600E is expressed in the lung epithelium and leads to lung adenomas 
(Dankort et al., 2007). In that work, lesions appear to be dependent on MEK/MAPK signalling, 
since pharmacological inhibition of MEK prevents adenoma formation. But without 
pharmacological inhibition, adenomas grow rapidly for about 8 weeks followed by a reduction in 
proliferative activity and senescence. In this model adenomas rarely progress to adenocarcinomas 
unless either p53 or CDKN2 is deleted. The model that I established now opens up the possibility 
to resolve the cell fate decision of braf overexpressing cells by investigation of pigment cell 
development over the full life time of an individual fish. In addition, the medaka mitf:BRAF can 
be crossed to the melanoma developing Xmrk line to understand in details the role of BRAF in 
melanoma initiation and progression. Also, BRAF V614E fishes can be used in screens for 
melanoma-suppressing or enhancing genes as well as for testing novel melanoma therapeutics.  
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5.2 Stat5 
5.2.1 Evolution of Stat5 genes 
The signal transducer and activator of transcription 5 works as a cytoplasmatic signal transducer 
and a nuclear transcription factor. It has been linked with myeloid cell transformation, breast, 
prostate, lung, neck, head and liver cancers and melanoma (Ferbeyre and Moriggl, 2011). 
Understanding of Stat5 biology in detail helps to elucidate its function in cancer initiation and 
progression and comprises the possibility of its usage as a target for cancer therapy. To further 
investigate Stat5 function in vertebrates I have identified and cloned the medaka Stat5ab/a 
(ENSORLG00000003961) and Stat5ab/b (ENSORLG00000014335) genes. It has been proposed 
that all members from the Stat5 family have arisen from a series of gene duplications, the most 
recent of which generated the two Stat5 genes (Copeland et al., 1995). The human Stat5A 
(ENST00000345506) and Stat5B (ENST00000293328) genes show high sequence identity (Fig. 
26 and Table 3) and lie adjacent to each other in close proximity to Stat3 gene (position: 
17:40350565-40540000) on chromosome 17. The two medaka Stat5 proteins showed higher rates 
of homology to each other than to human Stat5A and Stat5B, suggesting that they do not 
represent human Stat5A and Stat5B equivalents but have arisen independently. The same is 
observed with the two Stat5 genes from zebrafish (Lewis and Ward, 2004) and stickleback 
(ENSEMBL database) indicating that this represents a fish specific duplication. However, other 
fish species like fugu (Lewis and Ward, 2004) and tetraodon (Sung et al., 2003) only have one 
Stat5 copy. Synteny analysis of the comprising medaka genome regions to the human 
chromosome 17 where both Stat5 copies are present (Table 4) revealed that Stat5ab/a copy shares 
a high number of syntenic genes with human, which is not observed in medaka Stat5ab/b. This 
also suggests that the second copy from medaka Stat5 gene arose from a different duplication 
process than the human. Also, further syntenic analysis of Stat5 genes from different fish species 
(Tables 5 and 6) suggests that the second copy of medaka Stat5 gene arises from the fish specific 
duplication event due to the high number of syntenic genes between zebrafish, stickleback, 
tetraodon, fugu and medaka Stat5 genes. 
 
5.2.2 Conservation of functional motifs of medaka Stat5 genes 
 
To further analyse medaka Stat5 genes and their possible correlation with human Stat5 function, I 
analysed the level of similarities between known Stat5 conserved domains. The Stat5 family of 
proteins contains six conserved domains: the N-terminal domain, a transactivation domain, a 
DNA binding domain, a linker domain, a Src homology 2 (SH2) domain and the coiled-coil 
domain (Lim and Cao, 2006). Stat5 proteins show evolutionary conservation from Drosophila to 
mammals (Miyoshi et al., 2001). Comparison of amino acid sequences of medaka Stat5ab/a and 
Stat5ab/b revealed a high degree of similarity between the two medaka Stat5 in the DNA binding 
domain and in the SH2 domain. Also, the N-terminal domain, the coiled-coil domain and the 
linker domain showed moderate levels of similarity (Table 2). Since the transactivation domain is 
known to be the least conserved domain of  the whole Stat5 family (Paukku and Silvennoinen, 
2004), it was no surprise that this domain was the least conserved among both medaka Stat5 
genes sharing only 51% of equal amino acid. Comparison of medaka Stat5ab/a and Stat5ab/b 
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protein sequences with human Stat5A (Figure 26 and Table 3) revealed highest homology in the 
DNA binding domain: 95% and 90% respectively. Besides the ability to bind to DNA, this 
domain is also involved in nuclear translocation (Lim and Cao, 2006). Further work remains to be 
performed to test whether both medaka Stat5 proteins are able to translocate to the nucleus and act 
as a transcription factor, but the high similarity indicates that this is the case. As expected, the 
transactivation domain from both medaka proteins is also the least conserved in their amino acid 
sequences when compared to human Stat5A. Medaka Stat5ab/a and Stat5ab/b are 60% and 51% 
similar to the human Stat5A protein sequence, respectively.  
 
5.2.3 Medaka Stat5 genes have similar expression pattern to other vertebrates 
 
Additional characterization of gene expression also brings new information that can be useful for 
understanding the function of a given gene. Stat5a and Stat5b were found at similar levels in 6 
week old mice by reverse transcription PCR in heart, kidney, liver, lung, ovary and spleen (Liu et 
al., 1995). In the same study, only Stat5b was found to be expressed in brain and muscle. During 
my work, I observed similar expression patterns of both medaka Stat5 genes in all tissues 
analysed, including brain and muscle (Fig. 29). The reason for this can be the different origins of 
mammal and medaka Stat5 genes. Both medaka Stat5 genes could have arisen from the 
duplication of one of the human/mouse Stat5, which would explain the similar expression pattern 
observed among both Stat5 copies in medaka. The expression of the single Stat5 gene found in 
Tetraodon fluviatilis was detected in all analysed organs including gills, heart, liver, intestine, 
kidney and testis by reverse transcription PCR (Sung et al., 2003). In situ hybridization of the 
single Stat5 gene found in Xenopus laevis revealed Stat5 expression in the evaginating eye 
(Pascal et al, 2001). In the same study, Stat5 expression was observed on the ventral part of the 
embryo at Xenopus stage 28. The expression pattern observed by these authors in Xenopus 
greatly differs from the expression pattern I observed in medaka embryos by in situ hybridization 
(Fig. 28) where expression was detected in the otic vesicle, prosencephalon and mesencephalon. 
However, the developmental stages in medaka and the ones in xenopus are too different to make a 
clear statement about the differences. 
 
5.2.4 Stat5 function during melanoma development 
 
Xmrk signalling leads to Stat5 activation in Xiphophorus melanoma (Wellbrock et al., 1998). 
Melanoma developing medaka fishes carrying the Xmrk under the mitf promoter show a 
correlation of Stat5 activation and MITF and BCL-X levels with more aggressive stages of the 
malignancy (Schartl et al., 2010). Stat5 has been shown to contribute to anti-apoptosis signalling 
through up-regulation of BCL-X and to trigger proliferation also in human melanoma cell lines 
(Morcinek et al., 2002). All investigations studying phosphorylated Stat5 were based on the 
phosphorylation on Tyr694 of the human protein, which is conserved between both human and 
medaka Stat5 proteins. This means that no difference between different copies of Stat5 was found 
in this study. To obtain more information on Stat5 function in vivo in medaka and to investigate 
the different roles of each gene copy, I established medaka lines carrying the full length medaka 
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Stat5ab/a and Stat5ab/b gene (Table 7). In addition to these lines, lines carrying constitutive 
active and dominant negative versions of each gene were generated. The established lines in this 
work will be important to test whether both medaka Stat5 copies play a role in melanoma and to 
investigate different function of each gene in a whole organism.  
 
5.2.5 Importance of Stat5 animal models 
 
Stat5a was first identified as a prolactin-induced mammary gland factor (Gouilleux et al., 1994). 
Subsequent studies identified a closely related gene, Stat5b that shares more than 90% similarity, 
diverging only in their carboxy-terminal region (Azam et al., 1995). To further decipher their 
functions in vivo, Stat5a and Stat5b single knockout mice were generated. Stat5a knockout mice 
are normal in appearance, size, weight and fertility but they have impaired mammary gland 
development and females fail to lactate due to loss of prolactin responsiveness (Liu et al., 1997). 
Stat5b knockout mice revealed that this protein is required to maintain sexual dimorphism of 
body growth rates and liver gene expression due to defects in growth hormone signalling (Udy et 
al., 1997). A study on combined Stat5a -/- and Stat5b -/- mice during fetal development revealed 
that embryos were severely anemic (Socolovsky et al, 1999). Also, double knockouts for both 
Stat5 genes have severe alterations in different bone marrow progenitor populations (Snow et al., 
2003).  
 
Due to the severe defects observed in the established mouse models, investigations of Stat5 
function during processes like cancer in vivo are still elusive. In this work, Stat5 transgenic fishes 
were generated for the first time. The different generated medaka Stat5 lines will help in the 
future to determine if any specific functional division of medaka Stat5 proteins has occurred. The 
constitutively active Stat5ab/a and Stat5ab/b constitute the first animal models to bear gain of 
developmental function of Stat5 proteins. Also, the dominant negative lines of both medaka Stat5 
genes will help to gain new insight on fish Stat5 function as well as serve for  comparison with 
higher vertebrate models. 
 
5.2.6 Stat5: possible target for gene therapy? 
 
To be an ideal target for cancer therapy, a transcription factor needs to fulfil four main criteria. 
First, it must be overactive in a large percentage of cells in different tumour types. Second, this 
activity should determine gene expression patterns that not only promote cancer cell survival and 
proliferation, but also promote other malignant properties such as tumour angiogenesis and 
immune evasion. Third, good therapeutic targets must also be susceptible to specific inhibition by 
small molecule drugs. And fourth, tumour cells should be more dependent on activity of the target 
than normal cells (Yu and Jove, 2004). Stat5 has been correlated in vitro with all of these 
categories. However, no studies involving a living organism have been reported. The Stat5 lines 
generated here constitute a nice model to test Stat5 as a cancer therapy agent since medaka fishes 
can be easily crossed with cancer developing lines, like the melanoma developing Xmrk fishes, to 
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produce a double transgenic bearing the different Stat5 versions. A double mutant for both stat5 
versions in one individual would be useful to study the role of Stat5 in cancer progression.   
 
5.3 C-myc 
5.3.1 Evolution of c-myc genes in medaka 
 
In my PhD work, I have identified two medaka C-myc genes, named C-myc17 (Fig. 30) and C-
myc20 (Fig. 31). In addition, I have further cloned and characterized the c-myc17 gene. The 
amino acid sequence alignments indicated that the two medaka c-myc genes are orthologues of the 
human C-myc (Fig. 32). Analyses of the available sequenced teleost genomes revealed that just 
the zebrafish genome has kept two c-myc copies besides medaka (Schreiber-Agus, et al,1993). 
Their evolutionary origin from the fish specific genome duplication (Meyer and Schartl, 1999) 
was clearly established from synteny analysis comparing C-myc17 and 20 with the human myc 
locus at chromosome 8q24 and the corresponding fugu locus, which revealed a high degree of 
conservation between these species (Table 9). The phylogenetic analysis revealed also that both 
medaka c-myc genes are bona-fide members of the c-myc gene family (Fig. 34). However, c-my17 
differs significantly from other vertebrate c-myc genes as it branches off very basal in the 
phylogenetic tree (box in Fig. 34), while both zebrafish genes come out closely together within 
the teleost branch. This indicated a high degree of diversification of this gene copy. Unless the 
presence of an extra gene product is advantageous, two genes with identical functions are unlikely 
to be stably maintained in the genome (Nowak et al, 1997). Duplicated genes can be maintained 
when they differ in some aspects of their functions, which can, for example, occur by 
subfunctionalization. During this process, each gene copy adopts parts of the functions of their 
parental genes (Zhang, 2003). Another (non-exclusive) possibility is that one of the two versions 
adopts a novel function. Our studies of C-myc17 indicate that after the duplication process of the 
locus, the structure, and to a minor extent the expression of the medaka myc genes, changed. 
However, the essential Myc functions even after significant structural and amino acid changes are 
maintained. Further experiments will reveal whether the two medaka c-myc genes have 
compensating or overlapping functions or might differ in more subtle aspects of their overall 
function.   
 
5.3.2 Conservation of functional motifs of medaka C-myc genes 
 
By comparing amino acid sequences of the human DNA binding domain with C-myc17 and C-
myc20, I observed 92% and 100% similarities, suggesting that both copies retained the ability to 
bind to DNA. Moreover, the leucine-zipper, which is responsible for interaction with Max, is only 
50% similar to C-myc20 and 68% similar to C-myc17 (Table 8B). Since medaka has two Max 
copies (ENSORLG00000019517 and ENSORLG00000016817), it is likely that each medaka C-
myc copy binds to a specific Max for activation of gene transcription. This hypothesis remains to 
be elucidated. In addition, C-myc function in inducing gene transcription has been shown to be 
conserved in medaka C-myc17 (Fig. 37C). As in humans, medaka homologues of odc1, cbx3, 
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cct5, eif3s8 and metll1, were up regulated after C-myc activation by 4-OHT treatment in the 
established C-mycER17 fishes. Thereby, these results show transcriptional activity of C-myc17.    
 
Additionally, the protein alignment indicated the loss or change of essential residues in Cmyc17 
responsible for posttranslational regulation of C-myc function and stability (indicated as yellow 
arrows in Fig. 32). These changes did not ablate the transcriptional function of C-myc17 in vivo, 
but may result in altered potential of Myc function during cell transformation by influencing 
Myc’s life time (Spencer and Groudine, 1991). In human cancers, stabilized versions of Myc act 
as main reasons for malignant transformation and cancer progression (Junttila and Westermarck, 
2008). Phosphorylation (Westermarck, 2010) and ubiquitination (Gregory and Hann, 2000) are 
key regulators of Myc turnover. Besides these modifications, acetylation of Myc by histone 
acetyltransferases, like p300/CBP, Tip60 and GN5, (Vervoorts et al, 2003; Patel et al, 2004) is 
critical for protein stabilization. My analysis indicates that C-myc17 lost a number of these 
conserved modification sites hinting to a reduction of stability by reduced acetylation and a faster 
turnover rate. Interestingly, C-myc20 displays a higher rate of residue conservation, pointing to 
differences in posttranscriptional regulation and subsequent different protein stability rates 
between the two medaka orthologues.   
 
A correlation to known tumour related human SNP changes in MYC indicated that a number of 
conserved residues, for example P57 and P59 residues, found mutated in Burkitt Lymphoma 
(Bhatia, 1993) are unchanged in medaka. Other human regulatory residues are not conserved, like 
E39 and N86, in both versions of C-myc in medaka. Functional consequences of these changed 
residues in fish are not observed, but can be investigated by future mutational analyses.    
 
5.3.3 C-myc17 plays a role in apoptosis and proliferation 
 
It is known from higher vertebrates that activation of C-myc leads to cell proliferation through its 
ability to activate expression of genes involved in cell cycle progression (Steiner et al., 1995), in 
repression of CDK inhibitors (Staller et al., 2001) and also in chromatin remodelling (Amati et 
al., 2001). Deregulated C-myc activation may also lead to cell growth arrest and subsequent 
apoptosis under certain conditions (Evan et al., 1992). To test the ability of C-myc17 to perform 
established C-myc functions, I generated two transgenic medaka lines expressing a mouse 
estrogen receptor coupled version of the gene under the ubiquitously expressed beta-actin 
promoter. In the absence of a ligand, C-mycER fusion protein is bound to the heat-shock protein 
Hsp90 and therefore located in the cytoplasm, hence inactive. 4OHT has higher affinity to the 
estrogen receptor than Hsp90, and therefore after its administration, 4OHT binds to ER instead 
(Tian et al, 2006). C-myc ER is then free to translocate to the nucleus and act as a transcription 
factor. The two C-myc lines generated in this work showed to be efficiently activable on 4OHT 
administration since C-myc nuclear translocation (Fig. 37A and B) and activation of known C-
myc target genes (Fig. 37C) were only observed after 4-OHT treatment.  
 
Interestingly, the two independently generated medaka lines displayed differences in the amount 
of transgene expression (Fig. 36A) and showed clearly distinguishable functional differences after 
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activation. Line 1, which had a lower c-myc17ER transgene expression, showed a raised 
proliferative rate when compared to line 2 (Fig. 38). Vice versa, line 2 had a higher transgene 
expression level and appeared to induce higher apoptosis rates than line 1 (Fig. 39 and 40). A 
comparable observation was obtained by Murphy et al (2008) in mice, where the activation of C-
myc under the weak Rosa26 promoter triggered proliferation, while the more powerful rat insulin 
promoter, when driving C-myc expression, led to apoptosis. This indicated that cellular fate 
decisions are obviously taken depending on different threshold levels of C-myc. My work 
supports this view since the ability to induce higher proliferation or higher apoptosis rates was 
related to the differences in the level of transgene expression in the two medaka lines, which were 
otherwise genetically identical. What is not clear is how different levels of Myc trigger such 
different biological outputs. Murphy et al suggest two possibilities. First, it is possible that Myc 
induced proliferation and apoptosis are mediated by a distinct set of target genes. Low and high 
levels of Myc might engage proliferative and proapoptotic target genes, respectively. This might 
be due to changed affinity to promoter elements. So, with low levels of Myc, only proliferation 
target genes achieve the threshold that leads to cell proliferation. On the other hand, high levels of 
Myc would make the target genes involved in apoptosis cross the threshold and trigger cell death. 
A second explanation would be that proliferation and apoptosis themselves have a different 
threshold. Low levels of Myc would lead to low levels of both sets of target genes (proliferative 
and pro apoptotic), which would achieve only the proliferation execution threshold. By contrast, 
high levels of Myc regulate the same genes but in a greater extend, achieving the higher apoptosis 
execution threshold. It seems that the level of Myc required to trigger apoptosis is not fixed, but 
depends on each cell’s microenvironment. The two C-myc lines established in my PhD work will 
be helpful in further studies aiming to understand how the mechanisms of Myc triggering 
proliferation and/or apoptosis work.  
 
5.3.4 A possible role for C-myc17 in tumorigenesis   
 
Although a link between C-myc and cancer is well established, the molecular and cellular 
mechanisms of C-myc mediated transformation are not yet fully understood (Wang et al, 2011). 
C-myc is thought to contribute to tumorigenesis by deregulating gene expression and abrogating 
cell cycle checkpoints, thereby driving uncontrolled cellular growth and promoting cell 
proliferation. Additional effects on cellular adhesion, angiogenesis, metabolism and genomic 
instability have been described and are key elements of tumour progression (Lutz et al, 2002). 
Nevertheless, Myc induced cellular alterations can lead to apoptosis and senescence as a 
mechanism to protect the organism from proliferation of damaged and abnormal cells that could 
be progenitors of cancer cells (Evan et al., 1992). In an oncogenic background, with additional 
mutations that activate anti-apoptotic signals, Myc can lead to neoplasms and subsequently to 
malignant transformation (Nilsson and Cleveland, 2003). To give one example, C-myc was 
shown to collaborate with loss of p53 (Blyth et al., 2000) or Arf (Jacobs et al., 1999) in mouse 
lymphoma genesis.  
 
To further decipher Myc functions and cell fate decisions, genetic models utilizing inducible 
protein versions have been established in higher vertebrates and recently in zebrafish. Two 
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examples from transgenic mice are an activable C-myc version in mouse epidermis (Pelengaris et 
al., 1999) and in adult mouse pancreatic ß-cells (Pelengaris et al., 2002). Both mouse models 
greatly differ in the potential of inducing apoptosis, proliferation and their dependence on 
additional mutations. Although laboratory fish systems offer several experimental advantages in 
comparison to mice, such as the possibility to perform large scale screens and in vivo 
visualization of tumour progression, a similar inducible myc-ER system, like the one presented in 
this work, has been established only recently for lymphomas (Gutierrez et al., 2011). Prior to this 
study, mouse or human C-myc was used in zebrafish to induce T-cell acute lymphoblastic 
leukemia (T-ALL, Langenau et al., 2003). The examination of molecular pathways activated in 
response to C-myc overexpression closely resembled the most common subclass of human 
leukemia and thereby indicates great overlap in the underlying signals between humans and fishes 
(Langenau et al., 2004). Lymphoid malignancy in zebrafish also requires additional events of 
transformation, such as tal1 and lmo2 deregulation. Gutierrez et al. (2011) show that ablation of 
Myc activation results in regressions of T-ALL and tumour regression depending on Akt/Pten 
singling. In contrast to these published zebrafish models, my work presents a more general 
tumorgenesis model to induce Myc function in other organs than blood in an evolutionary 
divergent laboratory fish species by using a species specific c-myc orthologue.     
 
As a first indication of cellular transformation caused by C-myc activation, hyperplasia, but not 
tumour formation, was observed in livers of c-myc17-ER transgenic medaka individuals after 4-
OHT treatment. Interestingly, no difference in the degree of liver hyperplasia between line 1 and 
line 2 was observed. Based on the studies mentioned above, I can hypothesize that Cmyc17 would 
need an additional anti-apoptotic event to function as a viable tumour model. In accordance with 
our findings in medaka, sustained overexpression of c-myc in the liver of transgenic mice led to 
cancer only after 12 months (Santoni-Rugiu et al., 1996). In zebrafish, constantly expressed 
oncogenic Kras, an upstream factor of C-myc in the Map-kinase-signalling pathway (Gupta and 
Davis, 1994; Jin et al, 2004), was sufficient to drive liver tumorigenesis (Nguyen et al., 2011). 
These fishes exhibit a similar histological phenotype as observed in our C-myc medaka.  
 
Data from animal models support the idea that the liver is more susceptible to neoplastic 
transformation during stages of liver growth and regeneration (Heindryckx et al, 2009). Using a 
tetracycline regulated conditional mouse model it was postulated that C-myc’s ability to induce 
mitotic division and tumorigenesis in the liver is developmentally regulated (Beer et al., 2004). In 
an embryonic or neonatal liver, in which hepatocytes are actively undergoing cellular division, c-
myc overexpression further increases mitosis and results in liver tumorigenesis. In contrast, when 
c-myc is overexpressed in adult murine hepatocytes, cellular growth but no tumour formation was 
observed.  
 
In summary, the medaka model established here, utilizing a teleost c-myc, opens up the possibility 
to decipher transition from hyperplasia to liver cancer. Medaka can be easily manipulated to 
produce double transgenic individuals lacking anti-apoptotic factors, for example p53 mutants 
(Taniguchi et al., 2006) to induce tumor growth. Additionally, this model is suitable for large 
scale genetic and chemical compound screens to screen anticancer agents. It also facilitates the 
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investigation of cell fate decision and their consequences during early steps of tumorigenesis and 
development in closer detail. 
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7. APPENDIX 
7.1 Abbreviation 
Terms 
 
 
4-OHT 4-Hydroxytamoxifen  
BrdU 5-bromo-2`-deoxyuridine  
ddH2O Deionized water 
DN Dominant negative 
DNA Deoxyribonucleic acid 
DNTPs Deoxynucleotides triphosphate  
Fig. Figure 
IF Immunefluorescence 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
I-SceI meganuclease 
NaCl sodium chloride 
ON overnight 
PFA paraformaldehyde 
RNA Ribonucleic acid 
rpm  Rotations per min 
RT Room temperature 
SDS sodium dodecyl sulfate 
UV ultraviolet 
WB Western blot 
X-gal 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside 
 
Units 
 
 
°C degrees Celscius 
bp base pairs 
h hour 
kb kilobase 
l liter 
M molar 
µ micro 
m mili 
min min 
ml mililiters 
mM milimolar 
rpm revolutions per minute 
s seconds 
U unit 
vol volume 
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7.2 Vectors 
7.2.1 BRAF pCR2.1 vector map 
 
This vector contains full length medaka braf cloned by the strategy described in section 4.1.1.1 
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7.2.2 BRAF pSceI MITF vector map 
 
This vector contains full length medaka braf sub-cloned by the strategy described in section 
4.1.1.3 
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7.2.3 BRAF pCDNA3 vector map 
 
This vector contains full length medaka braf sub-cloned by the strategy described in section 
4.1.1.3 
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7.2.4 Stat5ab/a pCR2.1 vector map 
 
This vector contains full length medaka Stat5ab/a cloned by the strategy described in section 
4.2.1.1 
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7.2.5 Stat5ab/a pSceI MITF vector map 
 
This vector contains full length medaka Stat5ab/a sub-cloned by the strategy described in section 
4.2.1.4 
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7.2.6 Stat5ab/b pCR2.1 vector map 
 
This vector contains full length medaka Stat5ab/a cloned by the strategy described in section 
4.2.1.2 
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7.2.7 Stat5ab/b pSceI MITF vector map 
 
This vector contains full length medaka Stat5ab/a cloned by the strategy described in section 
4.2.1.4 
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